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PREFACE 
The present PhD thesis represents the current knowledge within foetal programming of type 2 
diabetes and the research activities performed in the present PhD project to gain novel insights into 
this area. 
The PhD project comprises three plasma metabolome studies in a population of young, healthy, low 
and normal birth weight men that have been exposed to a short-term high-fat overfeeding 
intervention. The overall aim of the studies was to investigate metabolic mechanisms behind the 
type 2 diabetes susceptible phenotype in low birth weight individuals. The project has been carried 
out at Department of Biotechnology and Biomedicine, Technical University of Denmark, Kongens 
Lyngby, Denmark with supervision from Associate Professor Lars I. Hellgren, Associate Professor 
Susanne Brix Pedersen, and Associate Professor Kristian Fog Nielsen, and in addition at 
Department of Endocrinology, Diabetes and Metabolism, Rigshospitalet, Copenhagen, Denmark 
with supervision from Chief Physician and Professor Allan A. Vaag and Post Doc Rasmus Ribel-
Madsen. The population of low and normal birth weight men was collected and thoroughly 
clinically and physiologically characterised by Allan A. Vaag and co-workers prior to the start of 
the present project. Therefore, the project has involved plasma metabolome analyses on already 
generated data as regards the first two studies and experimental work for further such analyses as 
concerns the third study. The findings from the first two studies have been published in original 
research journal articles, and the results from the third study are submitted for publication in article 
form as well:   
• Study 1: Plasma acylcarnitine profiling indicates increased fatty acid oxidation relative to 
tricarboxylic acid cycle capacity in young, healthy low birth weight men. Physiological 
Reports, September 2016. 
• Study 2: Plasma amino acid levels are elevated in young, healthy low birth weight men 
exposed to short-term high-fat overfeeding. Physiological Reports, December 2016.  
• Study 3: Plasma ceramide levels are altered in low and normal birth weight men in response 
to short-term high-fat overfeeding. Re-submitted to Scientific Reports, 22 December 2017. 
The articles are enclosed to the thesis in Appendix 1, 2, and 3, respectively. 
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SUMMARY 
Background and aims: Low birth weight (LBW) individuals have an increased risk of developing 
insulin resistance and type 2 diabetes compared with normal birth weight (NBW) individuals. 
Accordingly, young, healthy, LBW men of the study population examined in the present plasma 
metabolome studies show impaired hepatic insulin sensitivity and, in contrast to NBW men, 
develop impaired peripheral insulin sensitivity in response to a 5-day high-fat overfeeding. 
However, the metabolic mechanisms behind the type 2 diabetes susceptible phenotype in LBW 
individuals are not clear. Our primary aim of the present studies was to get novel insights into such 
mechanisms. LBW men of the present study population have lower pre-adipocyte mRNA 
expression levels of several differentiation markers, which may potentially lead to an impaired fatty 
acid storage capacity of these cells and a resulting increased fatty acid load to non-adipose tissue. 
Also, the LBW men display an increased fatty acid oxidation and a decreased glucose oxidation 
during both the isocaloric control diet and 5-day high-fat, high-calorie (HFHC) diet. Our specific 
aims of the present studies were to test the hypotheses that LBW men could have 1) an increased, 
incomplete fatty acid beta-oxidation in mitochondria, 2) an altered amino acid metabolism to ensure 
an adequate supply of tricarboxylic acid (TCA) cycle intermediates and thereby enable an efficient 
acetyl-CoA oxidation, and 3) an increased fatty acid flux into lipogenesis, including de novo 
ceramide synthesis, in non-adipose tissue.  
Methods: Fasting plasma levels of 45 acylcarnitines, 15 amino acids, and 27 ceramides were 
measured in the young, healthy, LBW (≤ 10th percentile) and NBW (50-90th percentile) men of the 
above mentioned study population after the isocaloric control diet and 5-day HFHC (60 E % from 
fat, 50 % extra calories) diet intervention. 
Results and interpretations: LBW men had higher plasma C2 and C4-OH acylcarnitine levels after 
the control diet, compared with NBW men, indicating an increased, incomplete fatty acid beta-
oxidation in mitochondria with the limiting step at the acetyl-CoA oxidation via the TCA cycle and 
an increased ketogenesis, respectively. Furthermore, LBW men had higher plasma C6-DC, C10-
OH/C8-DC, and total hydroxyl-/dicarboxyl-acylcarnitine levels after the control diet, compared 
with NBW men, suggesting an increased fatty acid omega-oxidation in the endoplasmic reticulum 
of mainly the liver. Interestingly, the total hydroxyl-/dicarboxyl-acylcarnitine level was negatively 
associated with the fasting serum insulin level and hepatic insulin resistance after this diet. An 
increased omega-oxidation rate may therefore limit the amount of fatty acid substrates available for 
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lipogenesis, including the synthesis of lipotoxic lipids such as ceramides and diacylglycerols that 
impair insulin signalling. In the second study, we demonstrated that LBW men had higher plasma 
alanine, proline, methionine, citrulline, and total amino acid levels after the HFHC diet compared 
with NBW men. The alanine level was negatively associated with the plasma C2 acylcarnitine level 
after this diet. A higher alanine level in the LBW men after the HFHC diet could therefore be 
accompanied by an increased anaplerotic formation of oxaloacetate to enable an efficient acetyl-
CoA oxidation via the TCA cycle. Furthermore, the alanine and total amino acid levels tended to be 
negatively associated with the insulin-stimulated glucose uptake rate after the HFHC diet. Higher 
alanine and total amino acid levels in the LBW men after this diet could therefore be a consequence 
of their reduction in skeletal muscle insulin sensitivity due to high-fat overfeeding with a following 
increased skeletal muscle proteolysis and/or may potentially contribute to the impaired insulin 
sensitivity. Moreover, the alanine level was positively associated with the hepatic glucose 
production after the HFHC diet. A higher alanine level in the LBW men could therefore also be 
accompanied by an increased gluconeogenesis in the liver. In the third study, we found that LBW 
men did not show altered plasma ceramide levels after the control or HFHC diet compared with 
NBW men. An increased fatty acid oxidation rate in the LBW men during both diets may limit the 
amount of fatty acids available for de novo ceramide synthesis and thereby compensate for a likely 
increased fatty acid load to non-adipose tissue in these individuals.  
Conclusions: LBW men showed alterations in fasting plasma acylcarnitine and amino acid levels 
after the isocaloric control diet and 5-day HFHC diet, respectively, that have been described to be 
associated with insulin resistance and type 2 diabetes. Additional plasma and tissue metabolome 
studies in LBW and NBW individuals, as well as supplementary functional studies, are needed to 
further explain the metabolic events leading to the altered plasma metabolite profiles in LBW men, 
and moreover to determine the extent to which these events may be part of the type 2 diabetes 
susceptible phenotype in LBW individuals. 
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SAMMENFATNING 
Baggrund og formål: Individer med lav fødselsvægt (LBW) har en øget risiko for at udvikle 
insulinresistens og type 2 diabetes sammenlignet med individer med normal fødselsvægt (NBW). I 
overensstemmelse hermed udviser unge, raske, LBW-individer fra studiepopulationen, der er blevet 
nærmere undersøgt i de nærværende metabolomstudier, nedsat hepatisk insulinfølsomhed og, i 
modsætning til NBW-individer, udvikling af nedsat perifer insulinfølsomhed under en 5-dages høj-
fedt overfodring. Mekanismerne bag den type 2 diabetes-følsomme fænotype in LBW-individer er 
ikke fuldt ud klarlagte. Vores primære formål med metabolomstudierne var at opnå ny indsigt i 
sådanne mekanismer. LBW-individerne fra den aktuelle studiepopulation har lavere pre-adipocyt 
mRNA-ekspressionsniveauer af flere differentieringsmarkører, hvilket potentielt kunne føre til en 
nedsat evne af fedtvævet til at lagre fedtsyrer og således give anledning til et øget fedtsyreload til 
øvrige væv såsom leveren og skeletmuskel. LBW-individerne udviser endvidere en øget 
fedtsyreoxidation og en nedsat glukoseoxidation under både kontrol- og høj-fedt, høj-kalorie- 
(HFHC) kosten. Vores specifikke formål med studierne var at teste hypoteserne, at LBW-individer 
kunne have 1) en øget, ufuldstændig beta-oxidation af fedtsyrer i mitokondrierne, 2) en ændret 
aminosyremetabolisme for at kunne sikre en tilstrækkelig mængde TCA-cyklus-intermediater til at 
opnå en effektiv acetyl-CoA-oxidation og 3) et øget fedtsyreflux til lipogenese, herunder de novo 
ceramidsyntese, til andre væv end fedtvæv. 
Metoder: Faste-plasmaniveauer af 45 acylcarnitiner, 15 aminosyrer og 27 ceramider blev målt i de 
unge, raske, LBW- (≤ 10. percentil) og NBW- (50.-90. percentil) mænd fra den oven for nævnte 
studiepopulation efter både den isokaloriske kontrolkost og 5-dages HFHC- (60 E % fra fedt, 50 % 
ekstra kalorier) kost. 
Resultater: LBW-individer havde højere plasma-C2 og C4-OH acylcarnitinniveauer efter 
kontrolkosten, sammenlignet med NBW-individer, hvilket indikerer en øget, ufuldstændig beta-
oxidation af fedtsyrer i mitokondrierne med acetyl-CoA-oxidationen via TCA-cyklus som det 
begrænsende trin henholdsvis en øget ketogenese. LBW-individerne havde endvidere højere 
plasma-C6-DC, C10-OH/C8-DC og total hydroxyl-/dicarboxyl-acylcarnitinniveauer efter 
kontrolkosten, sammenlignet med NBW-individer, hvilket kunne tyde på en øget omega-oxidation 
af fedtsyrer i det endoplasmatiske retikulum i primært leveren. Interessant var det totale hydroxyl-
/dicarboxyl-acylcarnitinniveau negativt associeret med faste-serum-insulinniveauet og hepatisk 
insulinresistens efter kontrolkosten. En øget omega-oxidation kunne således begrænse mængden af 
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fedtsyrer, der er tilgængelig for lipogenese, herunder syntesen af lipotoksiske lipider såsom 
ceramider og diacylglyceroler, der hæmmer insulinsignaleringen. I det andet studie viste vi, at 
LBW-individer havde højere plasma-alanin-, prolin-, methionin-, citrullin- og total 
aminosyreniveauer efter HFHC-kosten sammenlignet med NBW-individer. Alaninniveauet var 
negativt associeret med plasma-C2 acylcarnitinniveauet efter denne kost. Et højere alaninniveau i 
LBW-individerne efter HFHC-kosten kunne således føre til en øget anaplerotisk dannelse af 
oxaloacetat for derved at kunne sikre en effektiv acetyl-CoA-oxidation via TCA-cyklus. 
Alaninniveauet og det totale aminosyreniveau tenderede endvidere til at være negativt associeret 
med det insulin-stimulerede glukoseoptag efter HFHC-kosten. Højere alanin- og total 
aminosyreniveauer i LBW-individerne efter denne kost kunne derfor være en følge af deres 
reduktion i den perifere insulinfølsomhed under høj-fedt overfodringen med en efterfølgende øget 
proteolyse i skeletmuskel og/eller kunne potentielt give anledning til den nedsatte insulinfølsomhed. 
Alaninniveauet var desuden positivt associeret med den hepatiske glukoseproduktion efter HFHC-
kosten. Et højere alaninniveau i LBW-individerne kunne således også føre til en øget 
glukoneogenese i leveren. I det tredje studie fandt vi, at LBW-individer ikke havde ændrede 
plasmaniveauer af ceramider efter kontrol- eller HFHC-kosten sammenlignet med NBW-individer. 
En øget fedtsyreoxidation i LBW-individerne under begge kostinterventioner kunne således 
begrænse mængden af fedsyrer, der er tilgængelige for de novo ceramidsyntese, og derved 
kompensere for et muligt øget fedtsyreload til leveren og skeletmuskel i disse individer. 
Konklusioner: LBW-individer udviste ændringer i faste-plasmaniveauer af acylcarnitiner og 
aminosyrer efter kontrol- henholdsvis 5-dages HFHC-kosten, der har været beskrevet at være 
associeret med insulinresistens og type 2 diabetes. Yderligere metabolomstudier på både plasma- og 
vævsniveau i LBW- og NBW-individer, samt supplerende funktionelle studier, vil være nødvendige 
for nærmere at forstå de metaboliske forandringer, der giver anledning til de ændrerede 
metabolitprofiler i LBW-individer, og endvidere for at kunne bestemme, hvorvidt disse 
forandringer er en del af den type 2 diabetes-følsomme fænotype i LBW-individer.      
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CHAPTER 1 – INTRODUCTION 
Type 2 diabetes mellitus is a complex metabolic disorder characterised by impaired insulin 
sensitivity, insufficient insulin secretion, and eventual pancreatic beta-cell failure (1) (Figure 1.1). 
Insulin regulates the fuel homeostasis through 1) stimulation of glucose uptake into peripheral 
tissues, including skeletal muscle, cardiac muscle, and adipose tissue, 2) stimulation of glycolysis in 
the liver, skeletal muscle, and adipose tissue, 3) stimulation of glycogenesis and suppression of 
glycogenolysis in the liver and skeletal muscle, 4) suppression of gluconeogenesis in the liver, 5) 
stimulation of fatty acid synthesis in the liver, 6) stimulation of lipogenesis in the liver and adipose 
tissue and suppression of lipolysis in adipose tissue, 7) stimulation of uptake of certain amino acids 
into skeletal muscle, and 8) stimulation of protein synthesis in the liver, skeletal muscle, and 
adipose tissue and suppression of proteolysis in skeletal muscle (2). An impaired insulin secretion 
and action therefore leads to multiple metabolic abnormalities, including hyperglycaemia and 
dyslipidaemia. Also, increases in circulating glucose and lipid levels can further impair insulin 
secretion and sensitivity and cause tissue damage. Accordingly, the diagnostic criteria of diabetes 
include, as defined by the American Diabetes Association, a haemoglobin A1c (HbA1c) ≥ 6.5 %, a 
fasting plasma glucose level ≥ 7.0 mmol/L, or a 2 hour plasma glucose level ≥ 11.1 mmol/L during 
a 75 g oral glucose tolerance test (OGTT) (3). 
 
 
 
 
 
 
 
 
 
Figure 1.1: Aetiological factors of type 2 diabetes and metabolic events leading to this disease. Obesity is an 
important risk factor of insulin resistance and type 2 diabetes, and so are a genetic susceptibility to obesity and 
environmental factors such as overnutrition and physical inactivity important risk factors of these metabolic diseases. 
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Aetiological factors of type 2 diabetes include genetic and environmental components and, in the 
interface between these, epigenetic components (Figure 1.1). Obesity is a particularly important risk 
factor of insulin resistance and type 2 diabetes, and so are the risk factors of obesity, including a 
genetic susceptibility to this condition as well as overnutrition and physical inactivity, central in the 
development of these metabolic diseases. Furthermore, among the environmental components, it 
has become apparent from research by in particular C.N. Hales and D.J.P. Barker with co-workers 
that an adverse intrauterine milieu, and an associated low birth weight (LBW), is an important risk 
factor of several metabolic diseases, including obesity, cardiovascular disease, and type 2 diabetes 
(4-7). Accordingly, studies performed in human LBW subjects, including the high-fat overfeeding 
study that the present studies are part of, have demonstrated several metabolic abnormalities in 
these individuals relevant to the pathophysiology of type 2 diabetes. Thus, young (23-27 years of 
age), apparently healthy, LBW (≤ 10th percentile) men of the present overfeeding study population 
have higher fasting blood glucose, serum insulin, and serum C-peptide levels, compared with 
normal birth weight (NBW) (50-90th percentile) men, and moreover an impaired hepatic insulin 
sensitivity (8). Furthermore, these same LBW men, in contrast to NBW men, develop impaired 
peripheral insulin sensitivity in response to a 5-day high-fat overfeeding (9). Nevertheless, the 
underlying or exacerbating metabolic mechanisms behind the type 2 diabetes susceptible phenotype 
in LBW individuals are not clear.  
Our primary overall aim of the present studies included in this thesis was to get novel insights into 
such mechanisms, as outlined in the section below. Specifically, we performed a series of 
interrelated plasma metabolome analyses in the young, healthy, LBW and NBW men of the above 
mentioned overfeeding study population after the isocaloric control diet and 5-day high-fat, high-
calorie (HFHC) (60 E % from fat, 50 % extra calories) diet intervention (8; 9). 
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CHAPTER 2 – AIMS AND HYPOTHESES 
LBW men of the present overfeeding study population show, in addition to the metabolic 
abnormalities mentioned above, an increased fatty acid oxidation rate and a decreased glucose 
oxidation rate at night time during both the isocaloric control diet and HFHC diet compared with 
NBW men (10; 11). Also, the LBW men display a higher adjusted total energy expenditure at night 
during the HFHC diet, compared with NBW men, and a higher relative contribution of fatty acid 
oxidation to the total energy expenditure during this diet (11).  
Our primary specific aims of the first two studies were to test the following hypotheses:   
• Study 1: LBW men could have an increased, incomplete fatty acid beta-oxidation in 
mitochondria during the control diet and HFHC diet, expected to be reflected by higher 
plasma acylcarnitine levels. Also, as acylcarnitines may potentially impair insulin signalling, 
higher such levels could be associated with their impaired insulin sensitivity. 
• Study 2: LBW men could, as a consequence of their changes in fatty acid oxidation and 
glucose oxidation partitioning during both diets, have an altered amino acid metabolism, 
expected to be reflected in plasma amino acid levels, to ensure an adequate supply of 
tricarboxylic acid (TCA) cycle intermediates and thereby enable an efficient or enhanced 
acetyl-CoA oxidation. Furthermore, such alterations in amino acid metabolism could be part 
of the adverse metabolic events leading to their higher fasting blood glucose level after the 
control diet and impaired insulin sensitivity. 
LBW men of the present study population moreover show lower pre-adipocyte mRNA expression 
levels of several differentiation markers (12), which may potentially lead to an impaired fatty acid 
storage capacity of these cells and a resulting increased fatty acid load to non-adipose tissue such as 
the pancreas, liver, and skeletal muscle. Also, young (20-30 years of age), healthy, LBW men of 
another study population than the presently examined show an increased whole body (13) and 
adipose tissue (14) lipolysis. This was, however, not followed by elevated plasma non-esterified 
fatty acid (NEFA) or triacylglycerol levels (13; 14), indicating an increased uptake of fatty acids 
from the blood by other organs or tissues and/or an increased clearance or metabolism of fatty acids 
in the adipose tissue.   
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Our primary specific aims of the third study were therefore to test the following hypotheses:   
• Study 3: LBW men could, as a result of a likely increased fatty acid load to non-adipose 
tissue, have an increased lipogenesis, including de novo ceramide synthesis, in these tissues, 
expected to be reflected by higher plasma ceramide levels. Also, as ceramides are known to 
impair insulin signalling and promote inflammation, higher such levels could be associated 
with their impaired insulin sensitivity, including in particular their reduced hepatic insulin 
sensitivity after the control diet. 
In order to test these hypotheses, we measured fasting plasma levels of 45 acylcarnitines, 15 amino 
acids, and 27 ceramides (individual or pools of species) in the LBW and NBW men of the 
overfeeding study population after both the isocaloric control diet and 5-day HFHC diet and 
associated these plasma levels to measures of, among others, insulin secretion and sensitivity. 
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CHAPTER 3 – BACKGROUND 
The current knowledge on the type 2 diabetes susceptible phenotype in LBW individuals, as 
obtained from epidemiological studies as well as animal and human experimental studies, are 
presented in the following sections, and subsequent to this, the background and motivation for the 
present plasma metabolome studies are presented. 
 
Epidemiological studies on the type 2 diabetes risk in LBW individuals  
Several years ago, it was recognised that the early in life environment has long-term effects on 
health. Some of the first studies describing this concern examinations of geographical variations in 
mortality rates from cardiovascular disease in Norway (15) and England and Wales (16), 
respectively. Thus, a higher mortality rate from arteriosclerotic heart disease in particular counties 
of Norway was found to be linked to a higher past infant mortality rate (15). Therefore, it was 
suggested that poverty in childhood and adolescence followed by prosperity is a risk factor of 
arteriosclerotic heart disease (15). A similar relationship between mortality rates from ischaemic 
heart disease and infant mortality rates was found in a population from England and Wales (16). In 
connection with these observations, it was proposed that poor nutrition in early life increases the 
susceptibility to the adverse effects of an affluent diet (16). To further investigate this hypothesis, 
men born in Hertfordshire, England, for whom data on weight in infancy were recorded, were 
traced. In one study on this population, it was found that men with a lower weight at birth or at one 
year had a higher mortality rate from ischaemic heart disease (17). Following, it was sought to 
investigate if early in life factors could impact on as well subsequent development of glucose 
intolerance and type 2 diabetes. This idea was based on the knowledge that foetal and neonatal life 
seemed to be important periods for the development of the pancreatic beta-cells (18). So, 370 men 
of 64 years of age from Hertfordshire, for whom data on birth weight were available, were 
subjected to a glucose tolerance test and other clinical examinations (5; 6). From these 
investigations, it was found that men with a lower weight at birth or at one year were more likely to 
have an impaired glucose tolerance, defined as a 2 hour plasma glucose level of 7.8-11.0 mmol/L, 
and type 2 diabetes, defined as a 2 hour plasma glucose level ≥ 11.1 mmol/L (5). Among the men 
with the lowest birth weight (BW ≤ 2495 g), 40 % of these had either an impaired glucose tolerance 
or type 2 diabetes, whereas only 14 % of the men with the highest birth weight (BW > 4309 g) were 
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affected by one of these diseases (5). These LBW men were thereby 6.6 times more likely to have 
either an impaired glucose tolerance or type 2 diabetes compared with the men with the highest 
birth weight (5). Also, these same LBW men were 18 times more likely to be affected by the 
metabolic syndrome, defined as a 2 hour plasma glucose level > 7.8 mmol/L, a fasting plasma 
triacylglycerol level ≥ 1.4 mmol/L, and a systolic blood pressure > 160 mmHg (6).  
In order to obtain a possible explanation of the observations in the above epidemiological studies, 
C.N. Hales and D.J.P. Barker formulated in 1992 the “thrifty phenotype” hypothesis (19) (Figure 
3.1), as a parallel to the prior “thrifty genotype” hypothesis (20). This latter proposes that when a 
population goes through longer periods of poor or unstable nutrition, “thrifty genes” are selected to 
improve the survival of later generations under such conditions (20). The thrifty phenotype 
hypothesis similarly suggests that a foetus who is exposed to an adverse intrauterine environment, 
including in particular under- and/or malnutrition, adapt to these settings to increase its chances of 
pre- and post-natal survival. So, the foetus selectively distributes the sparse nutrients to the different 
organs to favour the growth and development of the vital organs, including the brain, at the expense 
of other organs and tissues, including the pancreas, liver, and skeletal muscle (19). 
 
 
 
 
 
 
 
 
 
Figure 3.1: Hales and Barker’s thrifty phenotype hypothesis. A foetus that is exposed to poor nutrition saves the 
sparse nutrients to the vital organs, including the brain, to the detriment of other organs and tissues and furthermore 
changes its metabolism. These adaptions increase its chances of pre- and post-natal survival under persisting poor 
nutrition, but render the foetus more susceptible to develop metabolic diseases, if it after birth is exposed to good or rich 
nutrition. Figure modified from C.L. Walker, 2012 (21). 
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Also, the foetus changes its metabolism to manage poor nutrition. These physiological adaptions, 
however, render the foetus more susceptible to develop metabolic diseases such as obesity, 
cardiovascular disease, and type 2 diabetes, if it after birth is exposed to good nutrition (19). 
The thrifty phenotype hypothesis extends the concept of “programming” to metabolic diseases, 
defined by A. Lucas as a “process whereby a stimulus or insult at a critical period of development 
has lasting or lifelong significance” (22). Since the hypothesis was formulated, it has been 
extensively investigated in further epidemiological studies and in animal and human models of 
intrauterine growth restriction. An important epidemiological study is the “Dutch Hunger Winter” 
study (23). In this study, 702 individuals who were in utero immediately before, during, and after 
the famine in the Netherlands at the end of World War II (November 1944-May 1945), respectively, 
were studied. Thereby, it was possible to investigate the effects of maternal undernutrition during 
specific periods of gestation on metabolic outcomes in the offspring. It was found that individuals 
exposed to the famine during mid or late gestation had a lower birth weight, were shorter in length, 
and had a higher head circumference to birth weight ratio compared with individuals exposed to the 
famine during early gestation or not exposed to this before birth (23). The latter finding was 
suggested to be due to brain sparing, as consistent with the theories by Hales and Barker (19). 
Furthermore, individuals exposed to the famine at any stage during gestation had higher 2 hour 
plasma glucose and insulin levels compared with individuals not exposed to the famine in utero 
(23). Also, those exposed to the famine during mid or late gestation had the highest 2 hour plasma 
glucose levels (23). Notably, among these individuals, those with lower birth weights or that 
became obese as adults had the highest 2 hour plasma glucose levels (23). These findings strongly 
support the observations by Hales and Barker that LBW is a risk factor of glucose intolerance and 
type 2 diabetes, and furthermore their suggestion that poor nutrition in pre-natal life followed by 
good or rich nutrition in later stages of life can explain this association (19). Many other 
epidemiological studies have replicated and extended the findings by Hales and Barker in several 
different study populations, including in women and men, different age groups, and different 
ethnicity groups (7; 24-27). Some of these studies have reported a U-shaped relation between birth 
weight and risk of type 2 diabetes (7; 28; 29). Thus, in a large meta-analysis, including a total of 
132,180 individuals, it has been found that LBW (BW < 2500 g) or high birth weight (HBW) (BW 
> 4000 g) individuals have a 1.47- and 1.36-fold increased risk, respectively, of developing type 2 
diabetes compared with NBW (2500 g ≤ BW ≤ 4000 g) individuals (7). This odd ratio of type 2 
diabetes in LBW individuals is quite lower than that found in the Hertfordshire population (5).  
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Explanatory studies on the type 2 diabetes susceptible phenotype in LBW individuals  
Following the findings of the association between a LBW and an increased susceptibility to 
metabolic diseases, several studies aimed to provide insights into the causal background of this 
relation. 
 
Influence of genes versus the intrauterine environment on the type 2 diabetes risk in LBW 
individuals 
A number of studies have first of all sought to determine whether the association between a LBW 
and type 2 diabetes is mainly due to genes associated with both these traits or an adverse 
intrauterine environment. The first possibility forms the basis of the “foetal insulin” hypothesis, 
which proposes that genetically determined insulin resistance results in both an impaired foetal 
growth and an increased susceptibility to develop type 2 diabetes in adult life (30). In this regard, it 
is, however, notable that only 2 of the 45 genes known to be associated with type 2 diabetes are also 
associated with a LBW (31). A study performed in middle-aged monozygotic twin pairs who were 
discordant for type 2 diabetes has furthermore shown that twins with type 2 diabetes have a lower 
birth weight compared with their genetically identical co-twins, suggesting that the association 
between a LBW and type 2 diabetes in twins is at least partly independent of the genotype and may 
be due to intrauterine malnutrition (32). A couple of studies have, however, demonstrated a link 
between a LBW and paternal diabetes, which has supported the notion that the association between 
a LBW and type 2 diabetes could be due to the inheritance of genes associated with both these traits 
(33). Nevertheless, the thrifty phenotype hypothesis, with its idea that an adverse intrauterine 
environment has a major influence on the susceptibility to type 2 diabetes (20), is generally well 
accepted. 
 
Influence of maternal under- and malnutrition on the type 2 diabetes risk in rat offspring 
Along with the recognition of the thrifty phenotype hypothesis, several experimental studies have 
investigated the consequences of different intrauterine conditions, including a limited oxygen or 
nutrient supply to the foetus, on the growth, development, and metabolic function of the offspring at 
birth and in later stages of life. 
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Already prior to the thrifty phenotype hypothesis, a number of studies had described several adverse 
effects of maternal protein restriction during gestation on the rat offspring, including a lower birth 
weight and a reduced pancreatic beta-cell proliferation and islet size (34). The thrifty phenotype 
hypothesis therefore initially focused on an impaired insulin secretion as a key consequence of poor 
nutrition in pre-natal life (19), and the rat model of maternal protein restriction was identified as an 
appropriate model to test the validity of this hypothesis. In the standard protein restriction model, 
rat dams are fed either a low-protein (8 E %), isocaloric diet or a normal-protein (20 E %) control 
diet during the whole gestation and lactation (0-21 days of age of the offspring) periods (34). After 
lactation, pups of both groups of rat dams are weaned onto a standard chow containing 20 % of the 
total energy from protein (34). From studies in this model, it has been found that rats of protein-
restricted dams have a higher glucose tolerance in early adult (6 weeks-3 months of age) life 
compared with control offspring (35-37), but an impaired glucose tolerance at 15 months of age 
(36). Also, male rats of protein-restricted dams have diabetes at 17 months of age (38). In addition 
to the studies in the standard protein restriction model, cross-fostering setups have been used to 
evaluate the separate effects of maternal protein restriction during gestation or lactation, 
respectively. Thus, it has been shown that rat pups of protein-restricted dams during gestation or 
lactation only, as for rat pups of protein-restricted dams during both periods, have a higher glucose 
tolerance at 6 weeks of age compared with control offspring (37). Therefore, it was suggested that 
maternal protein restriction in each of the gestation and lactation periods have an influence on long-
term glucose tolerance in the offspring (37).  
Also, a number of studies have focused on the effects of global maternal calorie restriction during 
gestation on the offspring. In studies concerning severe undernutrition, rat dams were either 
subjected to nutrient restriction (30 % food intake of the ad libitum intake) or fed ad libitum during 
the whole gestation period and subsequently fed ad libitum (39-41). It was found that rat pups of 
nutrient-restricted dams have a lower body weight in late gestation (39) and at birth (39-41) 
compared with control offspring. Furthermore, nutrient-restricted rat dams have lower plasma 
insulin-like growth factor 1 (IGF-1) levels during gestation, and their offspring have likewise lower 
such levels in late gestation and until 9 days of age (39). The latter study therefore proposed that 
IGF-1 is important in the regulation of foetal growth, and that both maternal and foetal plasma IGF-
1 levels are regulated by nutrient availability (39). Moreover, it was shown that rat pups of nutrient-
restricted dams have a higher systolic blood pressure (40) and a higher fasting plasma insulin level 
(41) in adulthood. 
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Mechanistic studies on the type 2 diabetes susceptible phenotype in LBW individuals 
Several of the studies performed in the rat model of maternal protein restriction also aimed to 
provide insights into the mechanistic background of the increased risk of developing type 2 diabetes 
in individuals exposed to such protein restriction in pre-natal and/or early post-natal life. Thus, 
isolated organs or tissues from rats of protein-restricted dams have been extensively analysed to 
investigate possible alterations in metabolic functions of these that may be linked to later 
development of insulin resistance and type 2 diabetes. Furthermore, studies performed in human 
LBW and NBW subjects, including in particular the present high-fat overfeeding study as well as 
additional studies performed by A.A.Vaag and co-workers, have provided insights into some of the 
molecular mechanisms behind the type 2 diabetes susceptible phenotype in LBW individuals. 
 
Influence of maternal protein restriction on metabolic functions in rat offspring 
First of all, it has been found that rat pups of protein-restricted dams during the whole gestation and 
lactation (0-21 days of age of the offspring) periods, or during lactation only, have reduced weights 
of all isolated organs or tissues, including the brain, heart, lung, thymus, pancreas, spleen, liver, 
kidney, and skeletal muscle, at 21 days of age compared with control offspring, whereas rat pups of 
protein-restricted dams during gestation only have reduced weights of the liver and skeletal muscle 
(42). Interestingly, rats exposed to maternal protein restriction in pre-natal and/or early post-natal 
life show a non-uniform growth restriction of the different organs and tissues, as evaluated from the 
weights of these relative to the total body weight (42). Thus, rat pups of protein-restricted dams 
during both gestation and lactation, or during lactation only, have a higher relative weight of the 
brain and lower relative weights of the pancreas, liver, and skeletal muscle compared with control 
pups (42). These findings are consistent with the idea in the thrifty phenotype hypothesis that the 
growth of the brain is sparred at the expense of the growth and development of other organs and 
tissues in the setting of poor pre-natal nutrition (19). Rats exposed to maternal protein restriction in 
pre-natal life only have also been shown to have lower relative weights of the liver and skeletal 
muscle compared with control rats (42). From examinations in adult (11 months of age) rats that 
have experienced maternal protein restriction, and that after lactation were weaned onto a standard 
chow, it has been found that both female and male rat offspring of protein-restricted dams during 
both gestation and lactation still have a higher relative weight of the brain compared with control 
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offspring (42). Also, these rats, as well as female and male adult (11 months of age) rats exposed to 
maternal protein restriction in early pre-natal life only, have a lower relative weight of skeletal 
muscle compared with control rats (42). 
In continuation to these studies, it has been found that rat offspring of protein-restricted dams show 
several alterations in metabolic functions of individual organs and tissues related to the 
development of insulin resistance and type 2 diabetes. As concerns the pancreas, it has been shown 
that beta-cells isolated from adult rat offspring of protein-restricted dams during both gestation and 
lactation do not have an altered insulin release compared with beta-cells from control offspring 
(43). However, beta-cells isolated from adult rat offspring that have been exposed to maternal 
protein restriction, and later in life been allowed to access sucrose or fed a high-fat diet, show a 
reduced glucose-stimulated insulin release (43). These findings support the proposals of the thrifty 
phenotype hypothesis that poor nutrition in pre-natal and early post-natal life leads to an impaired 
pancreatic beta-cell function, and furthermore that a shift from poor nutrition in pre-natal life to 
good or rich nutrition in later stages of life may lead to metabolic diseases such as type 2 diabetes 
(19). As regards insulin-sensitive tissues, it has been shown that livers isolated from male adult (3 
months of age) rat offspring of protein-restricted dams during both gestation and lactation have a 
decreased glucagon-stimulated hepatic glucose production compared with control rats (44). This 
was found to be due to a significantly lower expression of glucagon receptors in the liver from the 
rats of protein-restricted dams (44). Furthermore, livers from these rats show an anomalous 
response to insulin with this hormone initially stimulating the hepatic glucose production and 
subsequently, as expected, reducing this glucose production (44). Skeletal muscle and adipocytes 
isolated from male adult (3 months of age) rat offspring of protein-restricted dams during both 
gestation and lactation have increased insulin-stimulated glucose uptake rates compared with 
control offspring, likely due to a higher expression of insulin receptors in these tissues (45; 46). 
These findings are consistent with the observations of a higher glucose tolerance in young or adult 
(6 weeks-3 months of age) rats exposed to maternal protein restriction compared with control 
offspring (35-37; 45). Also, skeletal muscle and adipocytes isolated from older (15 months of age) 
male rat offspring of protein-restricted dams have decreased insulin-stimulated glucose uptake rates 
compared with control rats (46; 47) in line with the age-dependent loss of glucose tolerance in rats 
exposed to maternal protein restriction (36; 38). Moreover, adipocytes isolated from the rat 
offspring at 15 months of age are less responsive to insulin in terms of its inhibition of lipolysis 
(46). 
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Taken together, several of the findings from the rat model of maternal protein restriction have 
supported the thrifty phenotype hypothesis. Also, studies in the standard protein restriction model 
have revealed age-dependent changes in organ and tissue functions in rats exposed to maternal 
protein restriction during both gestation and lactation, compared with control offspring, and 
corresponding age-dependent changes in glucose tolerance. Furthermore, studies involving cross-
fostering setups have proposed that maternal protein restriction during either gestation or lactation 
only, as for protein restriction during both these periods, have an influence on long-term glucose 
tolerance in the offspring. 
 
Investigations of metabolic functions in LBW individuals 
In the high-fat overfeeding study in young, healthy, LBW (≤ 10th percentile) and NBW (50-90th 
percentile) men, which the present plasma metabolome studies are part of, it has been found that 
LBW men have higher fasting blood glucose, serum insulin, and serum C-peptide levels after the 
isocaloric control diet compared with NBW controls (8). These findings were accompanied by the 
observation that the LBW men show an impaired hepatic insulin sensitivity after this diet compared 
with NBW men (8). The LBW men did not show altered peripheral insulin sensitivity after the 
control diet compared with NBW men. However, when these individuals were subjected to the 5-
day HFHC (60 E % from fat, 50 % extra calories) diet intervention, the LBW, but not NBW, men 
developed impaired peripheral insulin sensitivity (9). In a study performed in another population of 
young (19 years), healthy, LBW and NBW men by as well A.A.Vaag and co-workers, it was shown 
that LBW men have lower skeletal muscle expression levels of several key proteins in the insulin 
signalling cascade, including glucose transporter 4 (GLUT4) and protein kinase C (PKC), compared 
with NBW men (48). Furthermore, these LBW men show an altered skeletal muscle fiber size and 
composition (49). These structural and functional changes of skeletal muscle were proposed to 
contribute to the development of skeletal muscle insulin resistance and type 2 diabetes in LBW 
individuals (48; 49). LBW men of the latter study population have in addition, as for skeletal 
muscle, lower adipose tissue expression levels of key insulin signalling-proteins, including GLUT4 
and insulin receptor substrate 1 (IRS1) (50). From additional investigations of adipose tissue 
functions in LBW individuals, it has been found that young (20-30 years of age), healthy, LBW 
men show an increased adipose tissue lipolysis (14). This was paradoxically accompanied by 
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decreased adipose tissue mRNA expression levels of several lipases, including triacylglycerol lipase 
and lipoprotein lipase (14). Furthermore, LBW men of the overfeeding study population have a 
higher adipose tissue miR-483-3p level (51) and lower pre-adipocyte mRNA expression levels of 
several differentiation markers (12). Manipulation of adipose tissue miR-483-3p levels in vitro was 
shown to modulate adipocyte differentiation and fatty acid storage capacity (51). From these 
findings, it was suggested that LBW individuals could have an impaired pre-adipocyte maturation 
and that this could result in a lower adipose tissue fatty acid storage capacity (12; 51). A selection 
of the above described metabolic alterations in young (19-30 years of age), healthy, LBW men, as 
well as some additional traits demonstrated in these individuals, are summarised in Figure 3.2.  
In addition to the investigations of metabolic functions at the organ or tissue level in LBW 
individuals, it has been found that LBW men of the overfeeding study population show an increased 
fatty acid oxidation rate and a decreased glucose oxidation rate at night time during both the 
isocaloric control diet and 5-day HFHC diet compared with NBW men (10; 11). Furthermore, the 
LBW men display a higher adjusted total energy expenditure at night during the HFHC diet, 
compared with NBW men, and a higher relative contribution of fatty acid oxidation to the total 
energy expenditure at night and throughout 24 hours during this diet (11).  
 
Translational value of the rat model of intrauterine growth restriction 
In a couple of the above mentioned studies, investigations in the rat model of maternal protein 
restriction were performed in parallel to the examinations in the human LBW subjects. 
Interestingly, rat offspring of protein-restricted dams during both gestation and lactation show traits 
similar to those of the LBW men. Thus, male adult (15 months of age) rats of protein-restricted 
dams during both gestation and lactation display a skeletal muscle expression profile of insulin 
signalling-proteins similar to that of the LBW men, including lower GLUT4 and PKC expression 
levels (48). Furthermore, male rat pups (22 days of age) and adult (3 months of age) rats exposed to 
maternal protein restriction during both gestation and lactation have a higher adipose tissue miR-
483-3p level compared with control offspring (51). These findings support the value of translating 
results from the rat model of intrauterine growth restriction into human LBW subjects. 
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Figure 3.2: Metabolic alterations in young, healthy, LBW men. Findings in LBW men of the overfeeding study 
population are marked with an asterisk. Figure modified from A.A. Vaag, 2012 (31). 
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Motivation for the present plasma metabolome studies in LBW individuals 
On the basis of the findings of the altered adipose tissue functions and changes in fatty acid 
oxidation and glucose oxidation partitioning in LBW men, we investigated if these traits were 
accompanied by 1) an incomplete fatty acid beta-oxidation, 2) changes in amino acid metabolism, 
and 3) an accumulation of potentially lipotoxic lipids in the blood. The detailed background of the 
three plasma metabolome studies and the associations between the proposed metabolic changes in 
LBW individuals and type 2 diabetes are described in brief below and in the individual articles 
(Appendix 1, 2, and 3, respectively). 
 
Study 1 – Incomplete fatty acid oxidation in the pathogenesis of insulin resistance and type 2 
diabetes   
High-fat overfeeding and an increased fatty acid load to skeletal muscle leads to an increased 
expression of genes encoding proteins in the fatty acid beta-oxidation pathway, including carnitine 
palmitoyl-transferase I (CPT-I) that catalyses the condensation of activated long-chain fatty acids 
(acyl-CoAs) and carnitine to form acylcarnitines and thereby regulates the entry of these acyl-CoAs 
into the mitochondrial matrix (52-54). In the state of high-fat overfeeding, an increased beta-
oxidation capacity has, however, been suggested to not necessarily be matched by that of the TCA 
cycle and electron transport chain, which results in an incomplete fatty acid oxidation (1; 52; 53; 
55). This leads to an accumulation of acylcarnitines and reactive oxygen species that may contribute 
to metabolic stress and thereby ultimately impair insulin signalling (56-59). Increased intracellular 
concentrations of long-chain acyl-CoAs may in addition lead to an increased lipogenesis, including 
the synthesis of potentially lipotoxic lipids that as well may impair insulin signalling (1). This 
metabolic fate of long-chain acyl-CoAs has been especially described in the context of high-fat diet- 
induced hepatic insulin resistance. Actually, high-fat overfeeding has been proposed to lead to a 
malonyl-CoA-induced inhibition of CPT-I in the liver with a following diversion of long-chain 
acyl-CoAs away from beta-oxidation and towards other metabolic fates in the cytosol, including 
lipogenesis (1; 60). Some studies, however, indicate that an increased fatty acid load to the liver 
leads to a simultaneously increased beta-oxidation and incorporation of long-chain acyl-CoAs into 
lipids (61).   
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Incomplete fatty acid beta-oxidation downstream of CPT-I is reflected by elevated plasma 
acylcarnitine levels (55), as acyl-CoAs in the mitochondrial matrix can be converted to 
acylcarnitines that subsequently are transported through the mitochondrial membranes and then 
from the cytosol to the blood (55; 62; 63). Interestingly, higher plasma acylcarnitine levels have 
been demonstrated in adults with pre-diabetes and type 2 diabetes (56; 64-66). Acylcarnitine 
profiles may reveal defects in specific steps of beta-oxidation (67-69) as well as the involvement of 
other metabolic pathways upstream of beta-oxidation (55). Thus, an incomplete beta-oxidation give 
rise to even-chain C4-C22 acylcarnitines, and amino acid catabolism is a source for C3, C4, and C5 
acylcarnitines (55). These pathways are, together with glucose oxidation, in addition sources of C2 
acylcarnitine (acetylcarnitine), when acetyl-CoA is generated in excess in the mitochondrial matrix 
relative to its flux into the TCA cycle (55; 70) (Figure 3.3). In this situation, carnitine acetyl-CoA 
transferase (CrAT) catalyses the transfer of acetyl-CoA to carnitine to form acetylcarnitine, which is 
subsequently transported to the cytosol (70; 71). 
 
 
 
 
  
 
 
 
Figure 3.3: Acylcarnitine species generated from glucose, amino acid, and fatty acid metabolism. C2 acylcarnitine 
is generated from both glucose, amino acid, and fatty acid oxidation. Other even-chain C4-C22 acylcarnitines are 
formed during incomplete fatty acid beta-oxidation, and C4 is also generated from amino acid catabolism. Odd-chain 
C3-C5 acylcarnitines are formed from metabolism of branched-chain amino acids, including valine, leucine, and 
isoleucine. Hydroxyl- and dicarboxyl-acylcarnitines (not shown) are formed from hydroxyl- and dicarboxyl-fatty acids, 
respectively. These fatty acids are intermediates in fatty acid omega-oxidation in the endoplasmic reticulum of mainly 
the liver. Hydroxyl-fatty acids are in addition generated in fatty acid beta-oxidation in mitochondria and peroxisomes. 
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Increased intracellular concentrations of acyl-CoAs, as a consequence of an increased fatty acid 
load to the cells and/or an incomplete beta-oxidation, may also lead to an increased fatty acid 
omega-oxidation in the endoplasmic reticulum of mainly the liver (72-74). Omega-oxidation is a 
minor pathway for oxidation of fatty acids under normal physiological conditions (73; 74), but an 
important supplementary pathway to beta-oxidation when the intracellular NEFA levels are high 
such as following high-fat feeding or under fasting and starvation (74; 75). Fatty acid metabolism 
via omega-oxidation generates hydroxyl- and dicarboxyl-fatty acids that are further oxidized in 
beta-oxidation in mitochondria and peroxisomes (73; 76). An increased fatty acid flux into omega-
oxidation is therefore expected to be reflected in higher plasma hydroxyl-/dicarboxyl-acylcarnitine 
levels (73; 76). Hydroxyl-fatty acids are, however, also intermediates in beta-oxidation (73; 77). 
 
Study 2 – Amino acid metabolism and type 2 diabetes   
Incomplete fatty acid beta-oxidation, with the limiting step at the acetyl-CoA entry into the TCA 
cycle, may result from a depletion of TCA cycle intermediates (78; 79). Amino acids are precursors 
of pyruvate and several of the TCA cycle intermediates, including oxaloacetate, alpha-ketoglutarate, 
succinyl-CoA, and fumarate (80). LBW men of the present study population display an increased 
fatty acid oxidation rate and a decreased glucose oxidation rate at night time during both the control 
diet and HFHC diet compared with NBW men (10; 11). Furthermore, the LBW men have a higher 
adjusted total energy expenditure at night during the HFHC diet compared with NBW men (11), 
suggesting that the TCA cycle is likely to be upregulated in the LBW men at night. The changes in 
fatty acid oxidation and glucose oxidation partitioning in the LBW men during both diets, and in 
addition in the total energy expenditure during the HFHC diet, could be expected to be 
accompanied by changes in amino acid metabolism to ensure an adequate supply of TCA cycle 
intermediates and thereby enable an efficient acetyl-CoA oxidation. This may in turn lead to 
changes in tissue and plasma amino acid levels. Altered plasma amino acid levels have repeatedly 
been demonstrated in individuals with pre-diabetes and type 2 diabetes and found to associate with 
insulin resistance (81-86). In particular, plasma levels of branched-chain amino acids, aromatic 
amino acids, and alanine have been shown to be predictive of type 2 diabetes several years before 
its onset (87-90). An overview of amino acid anaplerotic and cataplerotic pathways that replenish or 
deplete TCA cycle intermediates, respectively, is shown in Figure 5.2 in the result section. 
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Study 3 – Lipotoxicity in the pathogenesis of insulin resistance and type 2 diabetes 
Increased fatty acid exposures to tissues such as the pancreas, liver, and skeletal muscle may, as 
described in the section above on incomplete fatty acid beta-oxidation, lead to an increased 
lipogenesis, including the synthesis of lipotoxic lipids such as ceramides and diacylglycerols that 
may impair insulin signalling (1). Young (20-30 years of age), healthy, LBW men of another study 
population than the presently examined display an increased whole body (13) and adipose tissue 
(14) lipolysis. These traits were, however, not accompanied by elevated fasting plasma NEFA or 
triacylglycerol levels (13; 14), suggesting that the LBW men could have an increased uptake of 
fatty acids from the blood into tissues and/or an increased clearance or metabolism of fatty acids in 
adipose tissue. From the acylcarnitine profiling in the LBW and NBW men of the overfeeding study 
population, we found that LBW men had higher fasting plasma hydroxyl-/dicarboxyl-acylcarnitine 
levels, including 3-hydroxy-butyrylcarnitine, indicating an increased hepatic fatty acid oxidation 
rate, involving omega-oxidation, and an increased ketogenesis (91). The LBW men could therefore 
likely have an increased fatty acid load to non-adipose tissue, including in particular the liver, and a 
resulting increased lipogenesis and ectopic fat deposition.   
Ectopic fat comprises potentially lipotoxic lipids such as long-chain acyl-CoAs, ceramides, and 
diacylglycerols (92), and the extent of it has been linked to pancreatic beta-cell dysfunction and 
insulin resistance (93; 94). Furthermore, individuals with pre-diabetes and type 2 diabetes have 
elevated plasma ceramide levels (95-97). Ceramides are synthesised de novo in the endoplasmic 
reticulum or from salvage pathways of other sphingolipids (98). The de novo synthesis involves the 
condensation of L-serine and palmitoyl-CoA, catalysed by serine palmitoyl-transferase (SPT), to 
form 3-ketosphinganine that is subsequently reduced to sphinganine. Then, a variable acyl-CoA is 
attached to sphinganine, catalysed by one of six different ceramide synthases (CerS1-6), to form a 
dihydroceramide (d18:0- species) that is finally converted to a ceramide (d18:1- species) by a 
dihydroceramide desaturase (98). Ceramide synthases have different selectivity for acyl-CoAs 
based on the carbon chain length of these activated fatty acids. CerS2, for instance, has highest 
selectivity for very-long chain acyl-CoAs (C20-C26), and CerS6 for long chain acyl-CoAs (C14-
C18) (99). SPT is the rate-limiting enzyme of de novo ceramide synthesis, and an increased 
availability of palmitic acid enhances this synthesis (100-102). An increased uptake of fatty acids 
from the blood into non-adipose tissue is therefore expected to increase ceramide synthesis.  
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Ceramides are potentially lipotoxic to the cells in several ways (101; 103). Thus, these lipids inhibit 
the phosphorylation and thereby activation of Akt/protein kinase B (PKB) of the insulin signalling 
cascade, which is a central regulator of glucose and amino acid uptake, anabolic processes, and cell 
survival (104; 105). Moreover, ceramides activate Jun and NF-KB transcription factors and may 
thereby enhance inflammatory responses that as well may interfere with insulin signalling (101). A 
number of studies have focused on chain length specific actions of ceramides, including 
dihydroceramides, on different cellular processes (99), and ceramide synthase knock-out mouse 
models have been used to further explain these. Thus, CerS6-deficient mice have lower adipose 
tissue and liver d18:1-16:0 ceramide contents compared with wild-type mice (106). Also, these 
CerS6-deficient mice are protected from high-fat diet-induced obesity and glucose intolerance 
(106). In contrast, CerS2-deficient mice have lower liver d18:1-22:0 and d18:1-24:0 ceramide 
contents, a higher liver d18:1-16:0 ceramide content, and unaltered liver total ceramide content 
compared with control mice (107). These mice are more susceptible to develop diet-induced 
steatohepatitis and insulin resistance (107). Alterations in liver ceramide composition as a result of 
changes in the expression and/or activities of the different ceramide synthases could therefore be an 
important mechanism behind the development of insulin resistance and type 2 diabetes. 
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CHAPTER 4 – MATERIALS AND METHODS 
The population of LBW and NBW men was collected and clinically and physiologically 
characterised prior to the present project. Therefore, the project has involved plasma metabolome 
analyses on already generated data as regards the first two studies and experimental work for further 
such analyses on the sample material as concerns the third study.  
 
Study population 
Forty-six young (23-27 years of age), healthy men were recruited from the Danish National Birth 
Registry according to birth weight. Among these, 20 men had a LBW (2717 ± 268 g) (≤ 10th 
percentile) and 26 men a NBW (3901 ± 207 g) (50-90th percentile). All men were born at term (39-
41 weeks of gestation) in Copenhagen, Denmark in the period 1979-1980. Furthermore, all men 
were non-obese (BMI < 30 kg/m2) and ensured to not perform strenuous physical activity > 10 
hours per week, not take pharmaceuticals that affect metabolism, not have an abuse of alcohol or 
drugs, and not have a family history of diabetes in two generations. 
 
Study design 
Diet interventions 
All men were, in a randomised crossover study setup, standardised with regard to diet and physical 
activity and subsequently subjected to a 3-day control diet and a 5-day HFHC diet separated by a 6-
8 week wash out-period (Figure 4.1). The control diet was composed to reflect a habitual, weight-
maintaining diet (2,819 ± 238 kcal/11,800 ± 1,000 kJ) with 15, 50, and 35 E % from protein, 
carbohydrate, and fat, respectively, and the HFHC diet was prepared to contain 50 % extra calories 
(4,228 ± 334 kcal/17,700 ± 1,400 kJ) above the requirements with 7.5, 32.5, and 60 E % from 
protein, carbohydrate, and fat, respectively. Both diets were provided as five daily servings with 
identical meals from day to day. Energy requirements of the individual participants were calculated 
from a World Health Organization equation for men < 30 years of age with a physical activity level 
of 1.4 corresponding to a low physical activity (108), and dietary calculations were made in 
Dankost Pro (The National Food Agency, Copenhagen, Denmark).  
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Figure 4.1: Time line of diet interventions and clinical examinations in young, healthy, LBW and NBW men. All 
participants were subjected to both a 3-day isocaloric control diet and a 5-day HFHC diet separated by a 6-8 week 
wash-out period. Metabolome analyses were performed on plasma obtained from blood samples collected after each of 
the diet interventions and following an overnight fast. 
 
Clinical examinations 
Study activities were carried out over three days, with the first of these days being placed one or 
three days after the start of the control and HFHC diet intervention, respectively (Figure 4.1). 
Anthropometry and a dual-energy X-ray absorptiometry (DEXA) scanning were performed on the 
first study day to evaluate body composition. Furthermore, phosphorous 31 magnetic resonance 
spectroscopy (P31-MRS) was performed on the second study day to evaluate skeletal muscle ATP 
synthesis rates, as described in previously published work on the study population (8). An 
intravenous glucose tolerance test (IVGTT) and a hyperinsulinaemic-euglycaemic clamp were 
carried out in the morning on the third study day to assess insulin secretion and sensitivity, as also 
described previously (8; 9). Moreover, indirect calorimetry was performed throughout 24 hours 
from the first to second study day by use of a respiratory chamber and in addition in the basal and 
insulin-stimulated steady-state periods of the clamp to evaluate substrate utilisation rates and total 
energy expenditures, as also described previously (9-11). Blood samples and skeletal muscle and 
adipose tissue biopsies were collected prior to and during the clamp examination. 
-2               -1               0               1               2               3                                     Day 
Control diet Standardisation Wash-out  
High-fat, high-calorie diet 
Tissue sampling 
Blood sampling 
P31-MRS 
Calorimetry 
Clamp 
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Laboratory measurements 
All plasma metabolome analyses, including acylcarnitine, amino acid, and ceramide profiling, were 
performed on EDTA-plasma obtained from blood samples collected following an overnight fast 
(10.00 PM-7.00 AM) and immediately prior to the clamp examination. Eighteen LBW and 25 NBW 
men of the recruited participants completed the diet interventions and physiological tests and were 
included in the present plasma metabolome study part. 
  
Study 1 – Plasma acylcarnitine analyses 
Acylcarnitine analyses included a semi-quantitative determination of 45 individual or pools of 
species, designated in this text by their acyl group in accordance to its carbon chain length (e.g. 
C16), double bonds (e.g. C16:1), and possible hydroxyl- or a second carboxyl-group (e.g. C16-OH 
or C16-DC, respectively). These analyses were performed by flow injection-MS/MS, as described 
in details in the method section of article 1 (Appendix 1) (91) and supplementary material to this 
article (Appendix 4). 
  
Study 2 – Plasma amino acid analyses 
Amino acid analyses included a quantitative determination of 15 individual or pools of types. These 
analyses were performed, as for the acylcarnitine analyses, by flow injection-MS/MS, as described 
in the method section of article 2 (Appendix 2) (109).  
 
Study 3 – Plasma ceramide analyses 
Ceramide analyses included a semi-quantitative determination of 27 individual or pools of species, 
designated in this text by their sphingoid base in accordance to its carbon chain length and double 
bonds (i.e. d18:0-, d18:1-, or d18:2-) and their acyl group in accordance to as well its carbon chain 
length (e.g. -24:0) and double bonds (e.g. -24:1). These analyses were performed by HPLC-HRMS, 
as described in details in the method section of article 3 manuscript (Appendix 3) and 
supplementary material to this manuscript (also included in Appendix 3). 
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Ethical approval 
All study procedures were in accordance with the principles of The Declaration of Helsinki and 
approved by The Regional Research Ethics Committee of Copenhagen, Denmark. Also, all 
participants were provided with written information on the study purpose and procedures and 
signed an informed consent form prior to their participation.  
 
Statistical analyses 
Plasma metabolite levels and their relation to other lipid levels and physiological measures  
Statistically significant differences in plasma acylcarnitine, amino acid, and ceramide levels 
between NBW and LBW men within each diet or between the control and HFHC diets within each 
birth weight group were assessed by Student’s unpaired or paired t-tests (for normally distributed 
values), respectively, or Wilcoxon ranked-sum or signed-rank tests (for non-normally distributed 
values), respectively, as described in details in the method section of the individual articles 
(Appendix 1, 2, and 3, respectively).   
Associations between plasma metabolite levels and other lipid levels or physiological measures 
were assessed from linear regression analyses. These analyses were performed on the pooled data 
set of LBW and NBW men and were adjusted for age, BMI, and birth weight group, as also 
described in the individual articles. 
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CHAPTER 5 – RESULTS 
The most important findings from the plasma metabolome studies are presented below with focus 
on differences in metabolite levels between LBW and NBW men. Also, the overall interpretations 
of the results are included in this section and collected in schemes of metabolic pathways. 
 
Study 1 – Plasma acylcarnitine profiling 
We hypothesised in the first study that the increased fatty acid oxidation rate and decreased glucose 
oxidation rate in LBW men during both the isocaloric control diet and HFHC diet (10; 11) could be 
accompanied by an incomplete fatty acid beta-oxidation in mitochondria with a resulting 
accumulation of specific acylcarnitines in tissues and the blood. Furthermore, higher such levels 
could contribute to the impaired insulin sensitivity in these individuals.  
We demonstrated that LBW men had a higher plasma C2 acylcarnitine (acetylcarnitine) level after 
the control diet, compared with NBW men, and showed a tendency to this same after the HFHC 
diet, but otherwise had unaltered plasma acylcarnitine levels with exception of some hydroxyl-
/dicarboxyl-species, as described below. LBW men therefore seem to have an increased, incomplete 
fatty acid beta-oxidation in mitochondria, with the limiting step at the acetyl-CoA conversion. This 
could likely be due to a mismatch between fatty acid fluxes through beta-oxidation and the acetyl-
CoA flux into the TCA cycle, resulting in an accumulation of acetyl-CoA in the mitochondrial 
matrix and subsequently of C2 acylcarnitine in the cytosol and blood. The plasma C2 acylcarnitine 
level did not associate with measures of insulin secretion or sensitivity after the control or HFHC 
diet. Furthermore, we found that LBW men had a higher plasma C4-OH acylcarnitine (3-hydroxy-
butyrylcarnitine) level after the control diet compared with NBW men. This indicates an increased 
ketogenesis in the liver, involving the conversion of acetyl-CoA in the mitochondrial matrix to 3-
hydroxy-butyrate. LBW men moreover had higher plasma C6-DC, C10-OH/C8-DC, and total 
hydroxyl-/dicarboxyl-acylcarnitine levels after the control diet compared with NBW men. This 
could be a result of increased fatty acid fluxes through omega-oxidation in the endoplasmic 
reticulum of mainly the liver along with increased dicarboxyl-fatty acid fluxes through beta-
oxidation in peroxisomes, resulting in an accumulation of hydroxyl- and dicarboxyl-acylcarnitines 
in the cytosol. Plasma C10-OH/C8-DC and total hydroxyl-/dicarboxyl-acylcarnitine levels were 
negatively associated with the fasting serum insulin level after the control diet, independent of birth 
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weight group, and the total hydroxyl-/dicarboxyl-acylcarnitine level was in addition negatively 
associated with hepatic insulin resistance after this diet. This suggests that omega-oxidation may be 
a scavenger pathway for oxidation of fatty acids that, if not oxidised, would be available for 
lipogenesis, including the synthesis of lipotoxic lipids such as ceramides and diacylglycerols that 
impair insulin signalling in the liver. The proposed alterations in fatty acid fluxes through beta- and 
omega-oxidation in LBW men after the isocaloric control diet are illustrated in Figure 5.1. 
Furthermore, we demonstrated that both LBW and NBW men decreased plasma levels of several 
acylcarnitines in response to high-fat overfeeding. Also, we found from the 24 hour indirect 
calorimetry that the LBW and NBW men markedly increased fatty acid oxidation rates and total 
energy expenditures due to this challenge. The decreases in plasma levels of several acylcarnitines 
in LBW and NBW men in response to overfeeding could therefore likely be a result of their 
increases in fatty acid oxidation rates and total energy expenditures due to this intervention.  
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Figure 5.1: Model of possible alterations in fatty acid fluxes through beta- and omega-oxidation pathways in 
LBW men after the isocaloric control diet. LBW men have a higher plasma C2 acylcarnitine (acetylcarnitine) level 
after the control diet, compared with NBW men, but otherwise unaltered plasma acylcarnitine levels with exception of 
some hydroxyl-/dicarboxyl-species, indicating an incomplete fatty acid beta-oxidation in mitochondria of skeletal 
muscle (top) and liver (bottom). This could be due to increased fatty acid fluxes through beta-oxidation relative to the 
acetyl-CoA flux into the TCA cycle. LBW men furthermore have higher plasma C6-DC, C10-OH/C8-DC, and total 
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hydroxyl-/dicarboxyl-acylcarnitine levels after the control diet, compared with NBW men, suggesting increased fatty 
acid fluxes through omega-oxidation in the endoplasmic reticulum of mainly the liver along with increased dicarboxyl-
fatty acid fluxes through beta-oxidation in peroxisomes. The plasma total hydroxyl-/dicarboxyl-acylcarnitine level was 
negatively associated with hepatic insulin resistance after the control diet. This suggests that omega-oxidation may be a 
scavenger pathway for oxidation of fatty acids that, if not oxidised, would be available for lipogenesis of lipotoxic lipids 
such as ceramides and diacylglycerols that impair insulin signalling in the liver. 
 
Study 2 – Plasma amino acid profiling 
We hypothesised in the second study that the changes in fatty acid oxidation and glucose oxidation 
partitioning in LBW men during both diets could be followed by alterations in amino acid 
metabolism. Furthermore, such alterations could be part of the adverse metabolic events leading to 
the impaired insulin sensitivity in these individuals.    
We demonstrated that LBW men had higher plasma alanine, proline, methionine, citrulline, and 
total amino acid levels after the HFHC diet compared with NBW men, whereas LBW and NBW 
men did not show differences in plasma amino acid levels after the control diet. The plasma alanine 
level was negatively associated with the fasting plasma C2 acylcarnitine level after the HFHC diet. 
When combined with the findings of an increased, incomplete fatty acid oxidation, a decreased 
glucose oxidation rate, and a higher adjusted total energy expenditure in the LBW men during the 
HFHC diet (11; 91), the higher plasma alanine level in these individuals after this diet could be 
accompanied by an increased anaplerotic formation of oxaloacetate to enable an efficient acetyl-
CoA oxidation via the TCA cycle. Furthermore, plasma alanine and total amino acid levels tended 
to be negatively associated with the insulin-stimulated glucose uptake rate after the HFHC diet. The 
higher plasma alanine and total amino acid levels in LBW men after this diet could therefore be a 
consequence of their reduction in skeletal muscle insulin sensitivity due to the overfeeding 
challenge (9) with a possible increased skeletal muscle proteolysis and/or could potentially 
contribute to the impaired peripheral insulin sensitivity in these individuals. Moreover, the plasma 
alanine level was positively associated with the hepatic glucose production after the HFHC diet. A 
higher plasma alanine level in LBW men could therefore also be accompanied by an increased 
gluconeogenesis in the liver. The proposed changes in amino acid fluxes into the TCA cycle in 
LBW men after the HFHC diet are illustrated in Figure 5.2. 
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Figure 5.2: Model of possible alterations in amino acid fluxes into the TCA cycle in LBW men after the HFHC 
diet. LBW men have higher plasma alanine and total amino acid levels after the HFHC diet compared with NBW men. 
Also, the plasma alanine level was negatively associated with the plasma C2 acylcarnitine level after this diet. 
Combined with the findings of an increased, incomplete fatty acid oxidation, a decreased glucose oxidation rate, and a 
higher adjusted total energy expenditure in LBW men during the HFHC diet (11; 91), the higher plasma alanine level in 
these individuals after this diet could be accompanied by an increased anaplerotic formation of oxaloacetate to enable 
an efficient acetyl-CoA oxidation via the TCA cycle. Plasma amino acids measured in the second study are underlined. 
 
Moreover, we demonstrated that both LBW and NBW men decreased plasma valine and 
leucine/isoleucine levels and increased plasma alanine levels in response to high-fat overfeeding. 
Also, an increase in the plasma alanine level was associated with a decrease in the plasma C2 
acylcarnitine level. An increase in the plasma alanine level due to overfeeding could therefore be 
accompanied by an increased formation of oxaloacetate and a subsequent enhanced acetyl-CoA 
oxidation via the TCA cycle. Furthermore, as valine, leucine, and isoleucine are the major nitrogen 
sources for de novo alanine synthesis in skeletal muscle (110; 111), the decreases in plasma valine 
and leucine/isoleucine levels in LBW and NBW men in response to overfeeding could be due to an 
increased metabolism of these amino acids to alanine in skeletal muscle.  
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Study 3 – Plasma ceramide profiling 
We hypothesised in the third study that the likely increased fatty acid load to non-adipose tissue, 
including in particular the liver, in LBW men during both diets could be followed by higher tissue 
and plasma ceramide levels. Furthermore, higher such levels and subsequent lipotoxicity in insulin-
sensitive tissues could contribute to the impaired insulin sensitivity in these individuals. 
In contrast to expected, we did not demonstrate altered plasma ceramide levels in LBW men after 
the control or HFHC diet compared with NBW men. This may be explained by the increased fatty 
acid oxidation rate in the LBW men during both diets (10; 11). An increased fatty acid oxidation 
rate may thus limit the amount of fatty acid substrates available for lipogenesis, including de novo 
ceramide synthesis, and thereby compensate for a possible increased fatty acid load to non-adipose 
tissue. LBW and NBW men decreased plasma levels of several ceramides, including for both birth 
weight groups d18:0-18:1/d18:1-18:0 and d18:1-24:2/d18:2-24:1, and increased d18:0-24:1a levels 
in response to high-fat overfeeding. The decreases in plasma levels of several ceramides in LBW 
and NBW men could likely be a consequence of their markedly increases in fatty acid oxidation 
rates and total energy expenditures due to the overfeeding (91) with a resulting depletion of fatty 
acid substrates for de novo ceramide synthesis. This interpretation is supported by the findings of 
decreases in fasting plasma levels of several other lipids, including total NEFA, total cholesterol, 
and total triacylglycerol, in the LBW and NBW men in response to overfeeding (9). LBW and 
NBW men of the present study population increased fasting serum fibroblast growth factor 21 
(FGF-21) (112) and plasma adiponectin (9) levels in response to high-fat overfeeding. The 
decreases in plasma levels of several ceramides in LBW and NBW men due to this challenge could 
therefore also be a result of a FGF-21 and adiponectin mediated enhancement of ceramidase 
activities in the liver with a subsequent increase in the ceramide degradation. Moreover, we found 
that plasma levels of several ceramides and total ceramide were positively associated with the 
fasting blood glucose level after the control diet, and d18:0-18:1/d18:1-18:0, d18:0-24:1a, and 
d18:0-26:1/d18:1-26:0 levels were in addition positively associated with the hepatic glucose 
production after this diet. Also, d18:1-22:0 and total ceramide levels were positively associated with 
hepatic insulin resistance after the control diet. An increase in fatty acid oxidation rates in response 
to high-fat overfeeding may thus prevent an accumulation of ceramides that impair insulin 
signalling in the liver. The proposed alterations in fatty acid fluxes into oxidation pathways and 
lipogenesis in LBW and NBW men in response to high-fat overfeeding are shown in Figure 5.3. 
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Figure 5.3: Model of possible alterations in fatty acid fluxes through beta- and omega-oxidation pathways and 
into de novo ceramide synthesis in LBW and NBW men in response to 5-day high-fat overfeeding. LBW and 
NBW men both decrease plasma levels of several ceramides in response to high-fat overfeeding. This could likely be a 
consequence of their increases in fatty acid oxidation rates and total energy expenditures due to overfeeding (91) with a 
resulting depletion of fatty acid substrates for lipogenesis, including de novo ceramide synthesis in the endoplasmic 
reticulum (not illustrated in this organelle, but in the cytosol). Furthermore, the decreases in plasma levels of several 
ceramides in LBW and NBW men could be a result of a FGF-21 and adiponectin mediated enhancement of ceramide 
degradation in the liver (shown here as the only tissue). The plasma total ceramide level was positively associated with 
hepatic insulin resistance. This suggests that increases in fatty acid oxidation rates in response to high-fat overfeeding 
may prevent an accumulation of ceramides that impair insulin signalling in the liver. 
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CHAPTER 6 – DISCUSSION 
A series of plasma metabolome analyses, including acylcarnitine, amino acid, and ceramide 
profiling, were performed in young, healthy, LBW and NBW men after an isocaloric control diet 
and a 5-day HFHC diet to improve the understanding of the metabolic mechanisms behind the type 
2 diabetes susceptible phenotype in LBW individuals and pathogenesis in general. 
 
Insights into the type 2 diabetes susceptible phenotype in LBW individuals obtained from the 
plasma metabolome studies 
LBW men had a higher plasma C2 acylcarnitine level after the control diet compared with NBW 
men, and a tendency to this same after the HFHC diet, indicating, together with the findings of an 
increased fatty acid oxidation rate in these individuals during both diets (10; 11), an increased, but 
incomplete fatty acid beta-oxidation with the limiting step at the acetyl-CoA entry into the TCA 
cycle. An incomplete fatty acid oxidation with a resulting accumulation of acylcarnitines and 
reactive oxygen species in tissues has been proposed to contribute to the development of insulin 
resistance and type 2 diabetes (1; 55). Specifically, acylcarnitines have been shown to activate pro-
inflammatory pathways in a mouse monocyte/macrophage cell line (57) and furthermore to inhibit 
the insulin response in both mouse and human muscle cells at the level of Akt phosphorylation 
and/or glucose uptake (58). However, we did not demonstrate an association between the plasma C2 
acylcarnitine level and insulin secretion or sensitivity. Interestingly, LBW men had higher plasma 
C4-OH, C6-DC, C10-OH/C8-DC, and total hydroxyl-/dicarboxyl-acylcarnitine levels after the 
control diet, compared with NBW men, suggesting an increased fatty acid omega-oxidation rate. 
The higher plasma C4-OH level in LBW men may in addition reflect an increased ketogenesis. This 
interpretation is supported by the finding of the higher plasma C2 acylcarnitine level in these 
individuals, as the C2 acylcarnitine level reflects the intracellular acetyl-CoA pool (56). Hydroxyl-
fatty acids are intermediates in both fatty acid beta-oxidation and omega-oxidation (73; 76; 77), 
whereas dicarboxyl-fatty acids are formed in the omega-oxidation pathway. A limitation of the 
mass spectrometry method used for the acylcarnitine analyses is therefore that isobaric hydroxyl- 
and dicarboxyl-acylcarnitines are not distinguished. Thus, the higher plasma hydroxyl-/dicarboxyl-
acylcarnitine levels in LBW men could reflect an increased omega-oxidation rate, if these 
acylcarnitines are in fact both hydroxyl- and dicarboxyl-species, or, alternatively, an accumulation 
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of intermediates in beta-oxidation pathways, if the pooled species are comprised solely or 
predominantly of the hydroxyl-species. The finding of a higher plasma C4-OH level in LBW men, 
however, supports that these individuals could have an increased fatty acid load to the liver and a 
subsequently increased omega-oxidation rate, as the liver is the primary site of ketogenesis. 
Notably, plasma C10-OH/C8-DC and total hydroxyl-/dicarboxyl-acylcarnitine levels were 
negatively associated with the fasting serum insulin level after the control diet, and the total 
hydroxyl-/dicarboxyl-acylcarnitine level was in addition negatively associated with hepatic insulin 
resistance after this diet. Omega-oxidation may therefore be a scavenger pathway for oxidation of 
fatty acids that, if not oxidised, would be available for lipogenesis, including the synthesis of 
lipotoxic lipids such as ceramides and diacylglycerols that may impair insulin signalling. 
Importantly, omega-oxidation has been shown to be upregulated in experimental models of diabetes 
(113; 114) and in individuals with diabetes (115). An increased omega-oxidation rate could 
therefore be part of the metabolic phenotype of pre-diabetes and diabetes. 
In the second study, we demonstrated that LBW men had higher plasma alanine, proline, 
methionine, citrulline, and total amino acid levels after the HFHC diet compared with NBW men. 
The plasma alanine level was negatively associated with the plasma C2 acylcarnitine level after this 
diet. In the state of a high intracellular acetyl-CoA level, which seems to be the case in LBW men 
after both diets compared with NBW men (91), pyruvate dehydrogenase is inhibited and pyruvate 
carboxylase is activated, favouring pyruvate carboxylation to oxaloacetate as well as pyruvate 
transamination to alanine (116). This promotes anaplerosis and gluconeogenesis, respectively, 
(116). The higher plasma alanine level in LBW men after the HFHC diet could therefore reflect an 
increased pyruvate transamination to alanine in tissues, and the negative association between the 
plasma alanine and C2 acylcarnitine levels may be due to an increased anaplerotic formation of 
oxaloacetate. Alternatively, the higher plasma alanine level in LBW men could be a result of an 
increased skeletal muscle proteolysis, as discussed below. The LBW men show a higher adjusted 
total energy expenditure at night during the HFHC diet compared with NBW men (11), suggesting 
that the TCA cycle is likely to be upregulated in the LBW men during high-fat overfeeding. The 
higher plasma alanine level in LBW men after the HFHC diet could reflect an increased availability 
of alanine and pyruvate in tissues for anaplerotic formation of oxaloacetate, which may enhance the 
acetyl-CoA oxidation. Notably, the TCA cycle activity has been shown to be upregulated in the 
liver of mice progressing to hepatic insulin resistance during high-fat feeding (117). These mice 
also show an increased fatty acid oxidation rate (117). Furthermore, we demonstrated that plasma 
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alanine and total amino acid levels tended to be negatively associated with the insulin-stimulated 
glucose uptake rate after the HFHC diet. The LBW men decrease this rate in response to high-fat 
overfeeding (9). Whether the higher plasma alanine and total amino acid levels in LBW men could 
be a consequence of and/or contribute to impaired skeletal muscle insulin sensitivity in these 
individuals is uncertain. Insulin suppresses tissue proteolysis, and so an impaired skeletal muscle 
insulin sensitivity may increase the amino acid release from muscle (118). The amino acid release 
from skeletal muscle following an overnight fast does not reflect the amino acid composition of this 
tissue (119). Thus, relatively more alanine and glutamine, which are the main amino acid 
gluconeogenic precursors in the liver and kidney, respectively, are released from muscle (111; 119). 
This has been suggested to be due to an in situ amino acid metabolism that leads to de novo 
synthesis of non-essential amino acids, including in particular alanine and glutamine (111; 119). 
Interestingly, LBW men showed a tendency to a larger relative contribution of alanine and non-
essential amino acids to the total plasma amino acid level after the HFHC diet compared with NBW 
men (Appendix 2). The higher plasma alanine level in LBW men after this diet could therefore be a 
result of both an increased skeletal muscle proteolysis and an increased de novo alanine synthesis 
from other amino acids (119; 120). Moreover, we found that plasma alanine and total amino acid 
levels were positively associated with the hepatic glucose production after the HFHC diet. Amino 
acids may enhance the endogenous glucose production via indirect and/or direct mechanisms. Thus, 
certain amino acids could stimulate insulin and glucagon secretion (121-123), and changes in the 
portal vein concentration of these hormones may increase the hepatic glucose production (124). 
Also, amino acids could by acting as substrates induce gluconeogenesis and thereby enhance the 
endogenous glucose production (125). Interestingly, higher fasting serum levels of gluconeogenic 
precursors, including alanine, lactate, and pyruvate, have been shown to be predictive of an 
increased 2 hour post-challenge blood glucose level after a 6.5 year follow-up (88). Gluconeogenic 
precursors were therefore proposed to be potential markers of long-term impaired insulin sensitivity 
(88). A higher plasma alanine level in LBW men after the HFHC diet may thus reveal additional 
metabolic abnormalities in these individuals associated with the development of type 2 diabetes. 
In the third study, we did not demonstrate altered plasma ceramide levels in LBW men after the 
control or HFHC diet compared with NBW men. This may be explained by the increased fatty acid 
oxidation rates in the LBW men during both diets (10; 11). An increased fatty acid oxidation rate 
may limit the amount of fatty acids available for lipogenesis, including de novo ceramide synthesis, 
and thereby compensate for a likely increased fatty acid load to non-adipose tissue in LBW men. 
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An overview of the findings from the plasma metabolome studies on the birth weight dimension is 
shown in Figure 6.1 together with the proposed metabolic events leading to the respective changes 
in plasma metabolite levels in LBW men. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.1: Metabolic alterations in young, healthy, LBW men, as proposed from the plasma metabolome 
analyses. Findings in LBW men of the overfeeding study population are marked with an asterisk. Metabolic events 
expected to cause the changes in plasma metabolite levels are listed to the right of the individual findings. 
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Insights into metabolic responses to 5-day high-fat overfeeding obtained from the plasma 
metabolome studies  
LBW and NBW men displayed changes in plasma levels of all the three groups of metabolites in 
response to high-fat overfeeding. In the first study, we found that both birth weight groups 
decreased plasma levels of several acylcarnitine species and total acylcarnitine in response to 
overfeeding and increased plasma levels of a few acylcarnitines due to this challenge. Both LBW 
and NBW men showed markedly increases in fatty acid oxidation rates and total energy 
expenditures in response to high-fat overfeeding (91). The decreases in plasma levels of several 
acylcarnitines, including C2 acylcarnitine, in LBW and NBW men in reaction to overfeeding could 
therefore be a result of an upregulation of fatty acid beta-oxidation and the TCA cycle due to this 
challenge. This interpretation is strongly supported by the findings of decreases in fasting plasma 
levels of several other lipid classes, including total NEFA, VLDL-cholesterol, and total 
triacylglycerol, in the LBW and NBW men in response to high-fat overfeeding (9). A study has 
reported that mice fed a 12-week high-fat (45 E %) diet have higher serum levels of several 
medium- and long-chain acylcarnitines, compared with mice fed a standard chow, when studied in 
the fed state (55). This was suggested to be due to an incomplete fatty acid beta-oxidation in 
mitochondria (55). Important differences between this and the present overfeeding study in LBW 
and NBW men are the duration of the high-fat diet interventions and the blood sampling in the fed 
or fasted state, respectively. An upregulation of fatty acid oxidation pathways and the TCA cycle in 
the LBW and NBW men in response to the 5-day overfeeding is probably only a transient, 
compensatory mechanism and may not persist for long-term high-fat overfeeding exposures. This 
hypothesis, however, requires further investigations. 
In the second study, we demonstrated that LBW and NBW men decreased plasma valine and 
leucine/isoleucine levels and increased plasma alanine levels in response to high-fat overfeeding. 
An increase in the plasma alanine level was associated with a decrease in the plasma C2 
acylcarnitine level. Thus, an increase in the alanine level due to overfeeding could be accompanied 
by an increase in the formation of oxaloacetate and following in the acetyl-CoA oxidation via the 
TCA cycle. Interestingly, LBW men showed a tendency to a larger increase in the plasma alanine 
level in response to overfeeding, compared with NBW men, and a tendency to a larger increase in 
the relative contribution of alanine to the total plasma amino acid level (Appendix 2). This could be 
due to an increased skeletal muscle alanine release in LBW men as a consequence of their decline 
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in skeletal muscle insulin sensitivity during high-fat overfeeding (9). Valine, leucine, and isoleucine 
are the major nitrogen sources for de novo alanine synthesis in skeletal muscle (110; 111). Thus, the 
decreases in plasma valine and leucine/isoleucine levels in LBW and NBW men in response to 
overfeeding may indicate an increased metabolism of these amino acids to alanine in muscle. A 
decrease in the plasma levels of these amino acids could also be a result of the lower protein content 
in the HFHC diet compared with the control diet (Appendix 5). In this regard, it is, however, 
remarkable that an increase in the relative plasma alanine level was strongly significantly associated 
with decreases in both relative plasma valine and leucine/isoleucine levels (Appendix 2), indicating 
that an increased metabolism of these amino acids to alanine could take place.  
In the third study, we found that both LBW and NBW men decreased plasma levels of several 
ceramide species, including for both birth weight groups d18:0-18:1/d18:1-18:0 and d18:1-
24:2/d18:2-24:1, and increased d18:0-24:1a levels in response to high-fat overfeeding. The 
decreases in plasma levels of several ceramides in both LBW and NBW men could, as for the 
decreases in acylcarnitine levels, likely be a result of their increases in fatty acid oxidation rates and 
total energy expenditures due to the overfeeding challenge (91). Several studies have reported 
altered plasma and/or tissue ceramide levels in mice exposed to high-fat feeding (126-129), and a 
recent study has described changes in plasma ceramide levels in human subjects exposed to high-fat 
overfeeding (130). Thus, sedentary women and men decrease fasting serum d18:0-18:0, d18:1-18:0, 
and d18:1-24:1 levels and increase d18:0-22:0, d18:0-24:0, d18:1-22:0, d18:1-24:0, and total d18:1- 
ceramide levels in response to a 28-day high-fat overfeeding (45 E % from fat, 1,250 extra kcal) 
(130). Important differences between this and the present overfeeding study are the duration and fat 
content of the HFHC diet interventions. An upregulation of fatty acid oxidation pathways in the 
LBW and NBW men in response to the 5-day overfeeding is probably a transient, compensatory 
mechanism. Among the studies performed in mice, it has been found that mice fed a 16-week high-
fat (60 E % from fat) diet have higher plasma levels of all the measured ceramides, compared with 
mice fed a low-fat (10 E % from fat) diet, and also a higher plasma total ceramide level and adipose 
tissue total ceramide content (126). Furthermore, mice fed an 8-week high-fat (60 E % from fat) 
diet have higher liver total ceramide and total diacylglycerol contents compared with mice fed a 
standard chow (127). Plasma ceramide levels were not measured in these mice (127). Interestingly, 
adiponectin administration to the mice fed the 8-week high-fat diet, and in addition to leptin 
deficient (ob/ob) mice, rapidly normalises liver ceramide, but not diacylglycerol, contents, 
regardless of ceramide species (d18:0- or d18:1-) (127). Also, adiponectin administration to the 
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ob/ob mice leads to a reduction of the hepatic glucose production and an improvement in hepatic, 
but not skeletal muscle, insulin sensitivity (127). Adiponectin exerted these effects through 
lowering of the liver ceramide content via receptor-mediated enhancement of ceramidase activities 
(127). A recent study has shown that FGF-21 stimulates adiponectin secretion and reduces serum 
ceramide levels in mice fed a high-fat (60 E % from fat) diet, and that adiponectin-knockout mice 
are refractory to FGF-21 effects, including lowering of ceramide levels (131). Therefore, it was 
concluded that FGF-21 is dependent on adiponectin to exert its insulin-sensitising effects (131). 
LBW and NBW men of the overfeeding study population increases fasting plasma adiponectin 
levels in response to the high-fat overfeeding (9). Furthermore, both birth weight groups increases 
serum FGF-21 levels due to this challenge, likely as a result of an increased FGF-21 secretion from 
the liver (112). Taken together, the decreases in plasma levels of several ceramides in LBW and 
NBW men in response to high-fat overfeeding could be due to their increases in fatty acid oxidation 
rates, potentially evoked by the increases in serum FGF-21 levels, and/or a FGF-21 and adiponectin 
mediated activation of ceramidases in the liver with a subsequent increase in the ceramide 
degradation. Moreover, we demonstrated that plasma levels of several ceramides and total ceramide 
were positively associated with the fasting blood glucose level and hepatic insulin resistance after 
the control diet. These findings are consistent with the observed link between a higher liver 
ceramide content and hepatic insulin sensitivity in the mice models used to investigate adiponectin 
effects (127). NBW men of the overfeeding study population develop impaired hepatic insulin 
sensitivity and increase the hepatic glucose production in response to high-fat overfeeding, while 
the LBW men show an impaired hepatic insulin sensitivity already after the control diet and do not 
reduce this sensitivity further due to the overfeeding (8; 9). The decreases in plasma levels of 
several ceramides in response to overfeeding in the NBW men do not support a possible role of 
ceramides in promoting hepatic insulin resistance in these individuals. However, it is remarkable 
that some dihydroceramides (d18:0- species) were only or predominantly detected in plasma from 
the LBW and NBW men after the HFHC diet (Appendix 3). Furthermore, LBW and NBW men 
increased, as the only of the measured ceramides, d18:0-24:1a levels in response to overfeeding. 
The d18:0-24:1a level was strongly significantly positively associated with the hepatic glucose 
production after the control diet. Interestingly, a newly study has reported that individuals who 
progress to type 2 diabetes have elevated plasma levels of specific long-chain fatty acid-containing 
d18:0- species up to 9 years before its onset (132). Plasma dihydroceramides were therefore 
suggested to be potential biomarkers of pre-diabetes (132).  
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An overview of the findings from the plasma metabolome studies on the diet dimension is shown in 
Figure 6.2 together with the proposed metabolic events leading to the respective changes in plasma 
metabolite levels in LBW and NBW men in response to 5-day high-fat overfeeding. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.2: Metabolic alterations in young, healthy, LBW and NBW men in response to 5-day high-fat 
overfeeding, as proposed from the plasma metabolome analyses. Findings in both LBW and NBW men of the 
overfeeding study population are marked with an asterisk. Metabolic events expected to cause the changes in plasma 
metabolite levels are listed to the right of the individual findings. 
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CHAPTER 7 – CONCLUSIONS 
Young, healthy, LBW men showed alterations in fasting plasma metabolite levels that have been 
described to be associated with insulin resistance and type 2 diabetes. Thus, LBW men had higher 
plasma C2 and C4-OH acylcarnitine levels after the isocaloric control diet, compared with NBW 
controls, indicating an increased, incomplete fatty acid beta-oxidation and an increased ketogenesis, 
respectively. Furthermore, LBW men had higher plasma C6-DC, C10-OH/C8-DC, and total 
hydroxyl-/dicarboxyl-acylcarnitine levels after as well the control diet, suggesting an increased fatty 
acid omega-oxidation in the liver. The plasma total hydroxyl-/dicarboxyl-acylcarnitine level was 
negatively associated with hepatic insulin resistance after this diet, suggesting that an increased 
fatty acid omega-oxidation rate may prevent an accumulation of lipotoxic lipids that impair insulin 
signalling. LBW men moreover had higher plasma alanine and total amino acid levels after the 5-
day HFHC diet, compared with NBW men, possible as a result of an increased skeletal muscle 
proteolysis and de novo alanine synthesis from other amino acids. The observed alterations in 
plasma metabolite levels in LBW men could be a result of an impaired maturation of the 
subcutaneous adipose tissue. This would be in agreement with the thrifty phenotype hypothesis with 
its idea of saving nutrients to the vital organs at the expense of the growth and development of other 
organs and tissues in the setting of poor pre-natal nutrition. Thus, the LBW men show lower pre-
adipocyte mRNA expression levels of several differentiation markers, which may potentially lead to 
an impaired fatty acid storage capacity of these cells and a resulting increased fatty acid load to 
non-adipose tissue. The higher plasma C2 acylcarnitine level in LBW men after the control diet, 
and the increased fatty acid oxidation rates in these individuals during both diets, could likely be 
due to an increased fatty acid load to non-adipose tissue. Also, the higher C4-OH and total 
hydroxyl-/dicarboxyl-acylcarnitine levels in LBW men may reflect an increased fatty acid load to 
the liver, as this organ is the primary site of ketogenesis and fatty acid omega-oxidation. LBW men 
did not show elevated plasma ceramide levels after the control or HFHC diet compared with NBW 
men. The increased fatty acid oxidation rate in LBW men during both diets may limit the amount of 
fatty acid substrates available for lipogenesis, including de novo ceramide synthesis, and thereby 
compensate for a likely increased fatty acid load to non-adipose tissue. Additional plasma and tissue 
metabolome studies in LBW and NBW individuals, as well as supplementary functional studies, are 
needed to further explain the metabolic events leading to the altered plasma metabolite profiles in 
LBW men, and moreover to determine the extent to which these events may be part of the type 2 
diabetes susceptible phenotype in LBW individuals. 
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Abstract
We hypothesized that an increased, incomplete fatty acid beta-oxidation in
mitochondria could be part of the metabolic events leading to insulin resis-
tance and thereby an increased type 2 diabetes risk in low birth weight (LBW)
compared with normal birth weight (NBW) individuals. Therefore, we mea-
sured fasting plasma levels of 45 acylcarnitine species in 18 LBW and 25 NBW
men after an isocaloric control diet and a 5-day high-fat, high-calorie diet.
We demonstrated that LBW men had higher C2 and C4-OH levels after the
control diet compared with NBW men, indicating an increased fatty acid
beta-oxidation relative to the tricarboxylic acid cycle flux. Also, they had
higher C6-DC, C10-OH/C8-DC, and total hydroxyl-/dicarboxyl-acylcarnitine
levels, which may suggest an increased fatty acid omega-oxidation in the liver.
Furthermore, LBW and NBW men decreased several acylcarnitine levels in
response to overfeeding, which is likely a result of an upregulation of fatty
acid oxidation due to the dietary challenge. Moreover, C10-OH/C8-DC and
total hydroxyl-/dicarboxyl-acylcarnitine levels tended to be negatively associ-
ated with the serum insulin level, and the total hydroxyl-/dicarboxyl-acylcarni-
tine level additionally tended to be negatively associated with the hepatic
insulin resistance index. This indicates that an increased fatty acid omega-oxi-
dation could be a compensatory mechanism to prevent an accumulation of
lipid species that impair insulin signaling.
Introduction
Low birth weight (LBW) individuals have an increased
risk of developing obesity, cardiovascular disease, and
type 2 diabetes, compared with normal birth weight
(NBW) individuals, when exposed to an affluent life style
such as overfeeding (Ravelli et al. 1976; Hales et al. 1991;
Barker et al. 1993; Harder et al. 2007). In a short-term
ª 2016 The Authors. Physiological Reports published by Wiley Periodicals, Inc. on behalf of
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high-fat overfeeding study in young, healthy LBW and
NBW men, we have shown that LBW men display a
number of metabolic abnormalities relevant to the patho-
physiology of type 2 diabetes, including a decreased hepatic
insulin sensitivity (Brons et al. 2008) prior to, and develop-
ment of a decreased peripheral insulin sensitivity in
response to a high-fat, high-calorie diet intervention (Brons
et al. 2012). Furthermore, we have shown that LBW men
exhibit an increased fatty acid oxidation rate, but an unal-
tered total energy expenditure, during night time compared
with NBW men (Brons et al. 2013). However, the extent to
which the disproportionately increased fatty acid oxidation
rate could contribute to the decreased insulin sensitivity in
LBW men as a result of a differential and potentially
incomplete fatty acid oxidation remains to be studied.
High-fat overfeeding and an increased lipid exposure to
skeletal muscle has been shown to lead to an increased
expression of genes in the fatty acid beta-oxidation path-
way, including the gene encoding carnitine palmitoyl-
transferase I (CPT-I) that catalyzes the condensation of
activated long-chain fatty acids (acyl-CoAs) to carnitine
to form acylcarnitines and thereby regulates the entry of
these acyl-CoAs into the mitochondrial matrix (Koves
et al. 2005; Muoio and Newgard 2006; Turner et al.
2007). Also, in the state of high-fat overfeeding, an
increased beta-oxidation has been suggested to not neces-
sarily be matched by increased tricarboxylic acid (TCA)
cycle and electron transport chain fluxes, which results in
an incomplete fatty acid oxidation (Koves et al. 2005,
2008; Muoio and Newgard 2006, 2008b). This leads to an
accumulation of acylcarnitines and reactive oxygen species
that may contribute to metabolic stress and thereby ulti-
mately impair insulin signaling (Bloch-Damti and Bashan
2005; Adams et al. 2009; Rutkowsky et al. 2014; Aguer
et al. 2015). In addition to an incomplete beta-oxidation,
increased intracellular concentrations of long-chain acyl-
CoAs may lead to an increased lipogenesis, hereunder the
synthesis of lipid species that impair insulin signaling
(Muoio and Newgard 2008b). This metabolic fate of
long-chain acyl-CoAs has been especially described in the
context of high-fat diet-induced hepatic insulin resistance.
Actually, high-fat overfeeding has been proposed to lead
to malonyl-CoA induced inhibition of CPT-I activity in
the liver, and a following diversion of long-chain acyl-
CoAs away from beta-oxidation and toward other meta-
bolic fates in the cytosol, including lipogenesis (Muoio
and Newgard 2008a,b). However, studies also point to
that an increased lipid exposure to the liver leads to a
simultaneously increased beta-oxidation and incorpora-
tion of long-chain acyl-CoAs into lipids (Ciapaite et al.
2011).
Incomplete fatty acid beta-oxidation downstream of
CPT-I is reflected by elevated plasma acylcarnitine levels
(Koves et al. 2008), as acyl-CoAs in the mitochondrial
matrix can be converted into acylcarnitines that subse-
quently are transported through the mitochondrial mem-
branes and thereafter from the cytosol to the blood (Koves
et al. 2008; Millington and Stevens 2011; Violante et al.
2013). Actually, higher plasma acylcarnitine levels have
been found in adults with prediabetes and type 2 diabetes
(Adams et al. 2009; Mihalik et al. 2010; Ha et al. 2012; Mai
et al. 2013). Also, defects in specific steps of beta-oxidation
can be revealed by altered acylcarnitine levels, as made use
of in the diagnosis of inborn errors in fatty acid metabo-
lism (Millington et al. 1990; Chace et al. 2001, 2003).
Moreover, the involvement of other metabolic pathways
upstream of beta-oxidation may be reflected in the compo-
sition and concentrations of acylcarnitine species (Koves
et al. 2008). Thus, an incomplete beta-oxidation give rise
to even-chain C4–C22 acylcarnitine species, and amino
acid catabolism is a source for C3, C4, and C5 species
(Koves et al. 2008). These pathways are, together with glu-
cose oxidation, in addition sources of acetylcarnitine, C2,
when acetyl-CoA is generated in excess in the mitochon-
drial matrix relative to the flux into the TCA cycle (Zam-
mit 1999; Koves et al. 2008). In this situation, carnitine
acetyl-CoA transferase (CrAT) catalyzes the transfer of
acetyl-CoA to carnitine to form acetylcarnitine, which is
subsequently transported to the cytosol (Zammit 1999;
Muoio Deborah et al. 2012). An accumulation of acyl-
CoAs in the cytosol due to an incomplete beta-oxidation
may lead to an increased fatty acid omega-oxidation in the
endoplasmic reticulum of mainly the liver (Bjorkhem 1976;
Reddy and Hashimoto 2001; Patsouris et al. 2006). This
latter is expected to be reflected in higher plasma hydro-
xyl-/dicarboxyl-acylcarnitine levels (Reddy and Hashimoto
2001; Houten et al. 2012).
We hypothesized that an increased, incomplete fatty
acid beta-oxidation could contribute to the impaired
insulin sensitivity in LBW individuals, reflected by ele-
vated plasma acylcarnitine levels. Accordingly, we ana-
lyzed fasting plasma levels of 45 acylcarnitine species,
including even-chain C2–C22 species, odd-chain C3–C7
species, and hydroxyl-/dicarboxyl-species, in LBW and
NBW men following an isocaloric control diet and a
5-day high-fat, high-calorie diet.
Materials and Methods
Study population
Forty-six young (23–27 years of age), healthy men were
recruited from the Danish National Birth Registry accord-
ing to birth weight. All individuals were born at term (39–
41 weeks of gestation) and in Copenhagen in the period
1979–1980. LBW was defined as a birth weight below the
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10th percentile, as earlier studies have shown that individu-
als within this range have an increased risk of developing
type 2 diabetes (Jaquet et al. 2000; Jensen et al. 2002), and
NBW was defined as a birth weight within the 50th–90th
percentile range. Among the recruited men, 20 had LBW
(2717  268 g) and 26 had NBW (3901  207 g). Fur-
thermore, all participants were ensured to not have a family
history of diabetes in two generations, not have a body
mass index (BMI) greater than 30 kg/m2, not perform
strenuous physical activity more than 10 h per week, not
take pharmaceuticals that affect metabolism, and not have
an abuse of alcohol or drugs.
Study design
Diet interventions
All individuals were in a randomized crossover setup
standardized with respect to diet and physical activity and
following given a 3-day control diet and a 5-day high-fat,
high-calorie diet separated by a 6–8 weeks wash-out per-
iod. Energy requirements of the individual subjects were
calculated from a World Health Organization equation for
men less than 30 years of age and a physical activity
level of 1.4 corresponding to a low physical activity
(WHO, 2001). The control diet was composed to reflect
a habitual, weight-maintaining diet (2819  238 kcal/
11,800  1000 kJ) with 15% of the total energy from
protein, 50% from carbohydrate, and 35% from fat, and
the high-fat, high-calorie diet was prepared to contain
50% extra calories (4228  334 kcal/17,700  1,400 kJ)
with 7.5% of the total energy from protein, 32.5% from
carbohydrate, and 60% from fat (Table S1). Both diets
were provided as five daily servings with 25% of the total
energy from breakfast, 10% from morning snack, 25%
from lunch, 10% from afternoon snack, and 30% from
dinner, and the meals were identical from day to day.
Dietary calculations were made in Dankost Pro
(http://dankost.dk/english) (The National Food Agency,
Copenhagen, Denmark).
Clinical examinations
Study activities were carried out over 3 days, with the
first of these days being placed 1 or 3 days after the
start of the control and high-fat, high-calorie diet inter-
vention, respectively. Anthropometry was performed on
the first study day. An intravenous glucose tolerance
test (IVGTT) and a hyperinsulinemic-euglycemic clamp
were carried out in the morning on the third study
day following an overnight fast to assess insulin secre-
tion and sensitivity, as previously described (Brons et al.
2008, 2012). Furthermore, calorimetry was performed
throughout 24 h from the first to second study day by
use of a respiratory chamber and in the basal and insu-
lin-stimulated steady-state periods of the clamp to eval-
uate substrate utilization rates and energy expenditures,
as previously described (Brons et al. 2012, 2013, 2015).
Blood samples were collected prior to and during the
clamp.
Laboratory measurements
Acylcarnitine analyses
Acylcarnitine analyses were performed on EDTA-plasma
samples collected following an overnight fast (10.00
PM–7.00 AM) and immediately prior to the clamp exami-
nation. These analyses included a semi-quantitative
determination of 45 a priori selected acylcarnitine spe-
cies or sets of species (ions with equal mass), noted in
this text by their acyl group in accordance to its car-
bon chain length (e.g., C16), possible double bonds
(e.g., C16:1), and possible hydroxyl- or a second car-
boxyl-group (e.g., C16-OH or C16-DC, respectively)
(Table 3, Table S2), and were performed by use of
sample preparation procedures and flow injection-tan-
dem mass spectrometry (MS/MS), as previously
described (An et al. 2004; Ferrara et al. 2008; Milling-
ton and Stevens 2011). In brief, plasma samples were
spiked with a selection of deuterium-labeled acylcar-
nitine standards, including D3-C2, D3-C3, D3-C4, D9-
C5, D3-C8, and D3-C16 carnitines (Cambridge Isotope
Laboratories, Andover, MA). Following, proteins were
removed by precipitation with methanol, and the super-
natants were then transferred to a 96-well plate, evapo-
rated to dryness under nitrogen gas, and incubated
with either acidified methanol or butanol to form
methyl and butyl ester derivatives of the acylcarnitines,
respectively. After this, the reagents were evaporated to
dryness under nitrogen gas, and the residues were
redissolved in 85:15 (v/v) methanol:water. Subsequently,
the samples were introduced into a Quattro Micro MS/
MS system (Waters, Milford, MA) equipped with a
model HTS-PAL autosampler (Leap Technologies, Car-
rboro, NC) and a model 1100 HPLC solvent delivery
system (Agilent Technologies, Santa Clara, CA). Mass
spectra of the acylcarnitine esters were obtained by pos-
itive precursor ion scanning of m/z 99 and m/z 85 for
methyl or butyl esters, respectively. Following, acylcar-
nitines were identified from the peaks of these deriva-
tives and quantified from the ratio of their molecular
signals to respective internal standards (Table S2). Some
acylcarnitine species shared the same internal standard
due to the limited number of commercially available
analytical standards. Addition of more internal
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standards, however, does not appear to significantly
improve the analytical precision (Millington and Stevens
2011). Mass spectra were analyzed by use of MassLynx
4.0 (Waters). Acylcarnitine analyses were performed in
The Sarah W. Stedman Nutrition and Metabolism Cen-
ter Metabolomics/Biomarker Core Laboratory, Duke
University, Durham, NC. The laboratory was blinded to
the birth weight of the individuals.
Ethical approval
All study procedures were in accordance with the principles
of The Declaration of Helsinki and were approved by The
Regional Research Ethics Committee of Copenhagen, Den-
mark. Also, all participants were provided with written
information on the study purpose and procedures and
signed an informed consent prior to their participation.
Table 1. Clinical characteristics of low (LBW) and normal birth weight (NBW) men following the control (C) and high-fat, high-calorie (O)
diets.
NBW
(n = 25)
LBW
(n = 18)
LBW versus NBW
(n = 18, n = 25)
C
(Mean  SD)
O
(Mean  SD)
PNBW C
(Mean  SD)
O
(Mean  SD)
PLBW PC PO PD
Anthropometry
Birth weight (g) 3901  207 – – 2717  268 – – ≤0.001 – –
Weight (kg) 78.4  9.3 78.6  9.7 n.s. 77.1  11.3 77.1  11.4 n.s. n.s. n.s. n.s.
Height (m) 1.83  0.07 – – 1.77  0.05 – – ≤0.05 – –
Body mass index (kg/m2) 23.3  2.4 23.3  2.5 n.s. 24.6  3.8 24.6  3.8 n.s. n.s. n.s. n.s.
Lipid profiling
P-TG (mmol/L) 0.92  0.35 0.73  0.35 ≤0.05 1.07  0.37 0.72  0.24 ≤0.01 n.s. n.s. n.s.
P-CHOL (mmol/L) 4.36  0.83 4.18  0.82 n.s. 4.36  0.78 4.27  0.79 n.s. n.s. n.s. n.s.
P-VLDL-CHOL (mmol/L) 0.42  0.16 0.33  0.16 ≤0.05 0.49  0.18 0.32  0.12 ≤0.01 n.s. n.s. n.s.
P-LDL-CHOL (mmol/L) 2.51  0.72 2.28  0.78 ≤0.05 2.69  0.76 2.57  0.80 n.s. n.s. n.s. n.s.
P-HDL-CHOL (mmol/L) 1.40  0.22 1.56  0.25 ≤0.01 1.19  0.23 1.38  0.28 ≤0.01 ≤0.01 ≤0.05 n.s.
Clamp
Basal
B-Glucose (mmol/L) 4.59  0.47 5.05  0.40 ≤0.001 4.97  0.48 5.18  0.34 ≤0.05 ≤0.01 n.s. n.s.
S-Insulin (pmol/L) 30.2  14.7 43.4  29.2 ≤0.05 41.7  14.6 44.7  21.9 n.s. ≤0.01 n.s. n.s.
S-C-peptide (pmol/L) 408  146 529  260 ≤0.01 492  116 539  172 n.s. ≤0.05 n.s. n.s.
P-NEFA (lmol/L) 334  136 205  82 ≤0.001 406  200 188  91 ≤0.001 n.s. n.s. n.s.
HGP (mg/kgFFM/min) 2.21  0.48 2.85  0.99 ≤0.01 2.40  0.5 2.48  0.5 n.s. n.s. n.s. ≤0.05
Hepatic IR (mg/kgFFM/
minpmol/L)
68.7  34.1 113.7  61.5 ≤0.001 102.3  50.8 108.7  55.5 n.s. ≤0.05 n.s. ≤0.05
GOX (mg/kgFFM/min) 2.34  0.76 2.43  0.71 n.s. 1.95  0.78 2.20  0.56 n.s. n.s. n.s. n.s.
FOX (mg/kgFFM/min) 1.00  0.38 1.02  0.33 n.s. 1.11  0.53 1.17  0.33 n.s. n.s. n.s. n.s.
Insulin-stimulated
P-NEFA (lmol/L) 9.29  4.39 12.42  6.43 ≤0.01 9.56  5.03 14.39  7.76 ≤0.01 n.s. n.s. n.s.
M-value
(mg/kgFFM/min)
13.73  2.32 13.29  3.32 n.s. 13.47  3.14 11.89  3.57 ≤0.05 n.s. n.s. n.s.
GOX (mg/kgFFM/min) 5.18  0.82 5.04  0.98 n.s. 4.95  0.92 4.78  0.82 n.s. n.s. n.s. n.s.
FOX (mg/kgFFM/min) 0.01  0.25 0.17  0.33 n.s. 0.13  0.46 0.37  0.35 ≤0.05 n.s. ≤0.05 n.s.
IVGTT
FPIR (pmol/L) 1894  1431 2604  1793 ≤0.001 2135  1034 2750  1509 ≤0.01 n.s. n.s. n.s.
Hepatic DI 0.38  0.63 0.25  0.21 n.s. 0.21  0.11 0.24  0.13 n.s. n.s. n.s. n.s.
Peripheral DI 0.29  0.19 0.35  0.20 ≤0.05 0.33  0.13 0.32  0.17 n.s. n.s. n.s. n.s.
Data are presented as mean  SD. P-values from Student’s t-tests are presented unadjusted for multiple comparisons, and P-values ≤0.5 are
considered statistically significant. PNBW and PLBW: O versus C diet within each birth weight group, PC and PO: LBW versus NBW individuals
within each diet, PD: LBW versus NBW individuals on response values. n.s.: Not significant. P-values ≤0.05 are marked in bold. Abbreviations:
B, Blood; CHOL, Cholesterol; DI, Disposition index; FFM, Fat free mass; FOX, Fatty acid oxidation; FPIR, First-phase insulin response; GOX, Glu-
cose oxidation; HDL, High-density lipoprotein; HGP, Hepatic glucose production; IR, Insulin resistance; IVGTT, Intravenous glucose tolerance
test; LDL, Low-density lipoprotein; NEFA, Nonesterified fatty acid; P, Plasma; S, Serum; TG, Triacylglycerol; VLDL, Very low-density lipoprotein.
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Statistical analyses
Acylcarnitine levels and their relation to
physiological measures
Differences in plasma acylcarnitine levels between NBW
and LBW individuals within each diet or between the
control and high-fat, high-calorie diets within each birth
weight group were assessed from Student’s unpaired or
paired t-test (for normally distributed values), respec-
tively, or Wilcoxon ranked-sum or signed-rank test (for
not normally distributed values), respectively. Prior to
these tests, statistical outliers (1.5 interquartile range)
were removed from the dataset. Also, values below the
lower limit of detection were replaced by 0.5 times this
limit, which was defined as the minimum value for the
actual metabolite. Following, outliers were replaced by the
mean value within the group. Normal distribution of
values (variables or differences between variables,
respectively) was evaluated from Shapiro–Wilk test.
Finally, after P-values were calculated, adjustment for
multiple testing was done by calculating false discovery
rates, Q-values, by the Benjamini and Hochberg method
(Benjamini and Hochberg 1995). Data in Table 3 are pre-
sented as mean value plus or minus standard deviation
(SD) together with P- and Q-values. P-values ≤0.05 were
considered statistically significant if their corresponding
Q-values were ≤0.1. Student’s t-tests and Wilcoxon tests
were performed in SAS Enterprise Guide 6.1 (SAS
Institute, Cary, NC), and Benjamini and Hochberg cor-
rections were performed in R 3.1.0 (https://www.r-
project.org/).
Associations between plasma acylcarnitine levels and
physiological measures were assessed from linear regres-
sion analyses. These analyses were performed on the
pooled dataset of LBW and NBW individuals and were
adjusted for age, BMI, and birth weight group. Only acyl-
carnitine levels that significantly differed between NBW
Table 2. Glucose, fatty acid, and protein oxidation rates and total energy expenditures in low (LBW) and normal birth weight (NBW) men dur-
ing the control (C) and high-fat, high-calorie (O) diets.
(kJ/min)
LBW versus NBW
(n = 26)
LBW versus NBW
(C: n = 20, O: n = 18)
LBW versus NBW
(n = 20/n = 18,
n = 26)
C
(Mean  SEM)
O
(Mean  SEM)
PNBW C
(Mean  SEM)
O
(Mean  SEM)
PLBW PC PO PD
Calorimetry 24 h
GOX
Day 3.85  0.17 3.50  0.08 0.0297 3.69  0.16 3.30  0.14 0.0609 0.52 0.19 0.94
Night 1.97  0.10 2.07  0.07 0.3126 1.78  0.09 1.84  0.10 0.3391 0.18 0.06 0.97
Sleep 1.91  0.12 1.89  0.08 0.9131 1.58  0.10 1.77  0.11 0.0836 0.05 0.37 0.21
24 h 3.10  0.13 2.93  0.07 0.1510 2.92  0.13 2.73  0.09 0.2620 0.34 0.09 0.97
FOX
Day 3.34  0.16 4.23  0.14 <0.0001 3.46  0.14 4.52  0.21 <0.0001 0.60 0.23 0.60
Night 2.34  0.10 2.80  0.10 0.0005 2.60  0.08 3.06  0.12 0.0023 0.07 0.10 0.93
Sleep 2.14  0.14 2.72  0.12 0.0001 2.50  0.09 2.87  0.13 0.0221 0.05 0.38 0.40
24 h 2.92  0.12 3.63  0.12 <0.0001 3.11  0.11 3.91  0.14 <0.0001 0.24 0.14 0.76
POX
Day 1.13  0.04 0.79  0.03 <0.0001 1.08  0.04 0.74  0.04 <0.0001 0.48 0.32 0.71
Night 1.13  0.04 0.79  0.03 <0.0001 1.08  0.04 0.74  0.04 <0.0001 0.48 0.32 0.71
Sleep 1.13  0.04 0.79  0.03 <0.0001 1.08  0.04 0.74  0.04 <0.0001 0.48 0.32 0.71
24 h 1.13  0.04 0.79  0.03 <0.0001 1.08  0.04 0.74  0.04 <0.0001 0.48 0.32 0.71
EE
Day 8.32  0.15 8.52  0.13 0.0142 8.24  0.16 8.56  0.18 0.0021 0.71 0.86 0.39
Night 5.43  0.09 5.65  0.10 0.0001 5.46  0.11 5.66  0.13 0.0017 0.82 0.97 0.99
Sleep 5.17  0.09 5.39  0.09 0.0010 5.16  0.11 5.30  0.13 0.0009 0.96 0.93 0.82
24 h 7.14  0.12 7.36  0.12 0.0005 7.12  0.14 7.38  0.15 0.0008 0.88 0.90 0.55
Data are presented as mean  SEM. P-values from Student’s t-tests are presented unadjusted for multiple comparisons, and P-values ≤0.5 are
considered statistically significant. PNBW and PLBW: O versus C diet within each birth weight group, PC and PO: LBW versus NBW individuals
within each diet, PD: LBW versus NBW individuals on response values. P-values ≤0.05 are marked in bold. P-values on intervention effects are
presented here for the first time. Details on the measurements have been described in previous articles (Brons et al. 2013, 2015). Abbrevia-
tions: EE, Energy expenditure; FOX, Fatty acid oxidation; GOX, Glucose oxidation; POX, Protein oxidation.
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Table 3. Plasma acylcarnitine levels in low (LBW) and normal birth weight (NBW) men following the control (C) and high-fat, high-calorie (O)
diets.
(lmol/L)
NBW
(n = 25)
LBW
(n = 18)
LBW versus NBW
(n = 18, n = 25)
C
(Mean  SD)
O
(Mean  SD)
PNBW
QNBW
C
(Mean  SD)
O
(Mean  SD)
PLBW
QLBW
PC
QC
PO
QO
PD
QD
Lipid profiling
Acylcarnitines
C2 4.771  0.797 3.985  0.738 0.0015 5.985  1.587 4.393  0.784 0.0007 0.0066 0.0886 0.0595
0.0095 0.0046 0.0660
C3 0.317  0.102 0.273  0.075 0.0487 0.298  0.103 0.259  0.054 0.1582 0.5694 0.5058 0.8998
0.1131
C4/Ci4 0.146  0.057 0.126  0.037 0.1054 0.162  0.047 0.123  0.049 0.0082 0.3243 0.7823 0.2661
0.0291
C5:1 0.088  0.040 0.073  0.030 0.1275 0.084  0.026 0.088  0.039 0.5944 0.7246 0.1369 0.2252
C5’s 0.122  0.032 0.116  0.030 0.5296 0.129  0.029 0.128  0.048 0.9683 0.4736 0.3526 0.7215
C4-OH 0.038  0.016 0.034  0.010 0.3581 0.054  0.019 0.030  0.012 <0.0001 0.0039 0.2229 0.0006
0.0020 0.0520 0.0222
C6 n.d. n.d. – n.d. n.d. – – – –
C5-OH/C3-DC 0.118  0.047 n.d. – 0.114  0.054 n.d. – 0.8051 – –
C4-DC/Ci4-DC 0.033  0.013 0.036  0.017 0.5226 0.042  0.013 0.044  0.009 0.5642 0.0328 0.0431 0.9323
0.1966 0.6667
C8:1 0.100  0.032 0.190  0.054 <0.0001 0.116  0.032 0.222  0.067 <0.0001 0.1354 0.0957 0.3314
0.0013 0.0020
C8 0.122  0.049 0.105  0.030 0.1010 0.127  0.042 0.111  0.030 0.1193 0.6921 0.5241 0.9872
C5-DC 0.048  0.012 0.047  0.015 0.7495 0.050  0.013 0.050  0.020 0.9169 0.7073 0.5795 0.7856
C8:1-OH/C6:1-DC 0.037  0.009 0.062  0.023 <0.0001 0.034  0.014 0.060  0.023 0.0013 0.3884 0.5660 0.5679
0.0013 0.0072
C6-DC 0.064  0.022 0.080  0.022 0.0039 0.084  0.017 0.089  0.019 0.4862 0.0032 0.1926 0.1504
0.0165 0.0520
C10:3 n.d. 0.088  0.031 – 0.053  0.034 0.102  0.035 0.0005 – 0.1965 –
0.0039
C10:2 n.d. n.d. – n.d. n.d. – – – –
C10:1 0.136  0.053 0.121  0.037 0.2216 0.138  0.039 0.131  0.023 0.5697 0.9120 0.3127 0.5908
C10 0.347  0.160 0.311  0.117 0.3218 0.297  0.125 0.287  0.102 0.8378 0.2736 0.4908 0.6401
C7-DC n.d. n.d. – n.d. n.d. – – – –
C8:1-DC 0.024  0.009 0.028  0.012 0.1054 0.028  0.012 0.026  0.007 0.5224 0.1744 0.4497 0.1216
C10-OH/C8-DC 0.033  0.014 0.032  0.010 0.6502 0.048  0.015 0.036  0.010 0.0048 0.0025 0.1459 0.0585
0.0208 0.0520
C12:1 0.093  0.040 0.067  0.017 0.0074 0.109  0.039 0.072  0.016 0.0005 0.1226 0.3820 0.3802
0.0263 0.0039
C12 0.082  0.037 0.083  0.031 0.9887 0.089  0.028 0.084  0.024 0.5806 0.5344 0.8875 0.6768
C12-OH/C10-DC 0.008  0.004 0.006  0.003 0.0327 0.007  0.002 0.006  0.002 0.2281 0.5988 0.4714 0.3471
0.0866
C14:2 0.026  0.015 0.018  0.009 0.0076 0.031  0.012 n.d. – 0.3231 – –
0.0263
C14:1 0.056  0.018 0.049  0.020 0.1900 0.071  0.025 0.049  0.016 0.0054 0.0308 0.8905 0.1259
0.0211 0.1966
C14 n.d. n.d. – n.d. 0.026  0.011 – – – –
C14:1-OH/C12:1-DC 0.012  0.006 0.011  0.005 0.3108 0.014  0.006 0.012  0.005 0.2743 0.2065 0.2887 0.7372
C14-OH/C12-DC 0.008  0.004 0.007  0.003 0.1782 0.009  0.002 0.008  0.004 0.7148 0.4479 0.1429 0.5903
C16:2 0.006  0.003 0.005  0.003 0.0199 0.006  0.002 0.004  0.003 0.0251 0.9316 0.2900 0.3964
0.0630 0.0699
C16:1 0.019  0.009 0.010  0.005 <0.0001 0.020  0.009 0.011  0.007 0.0121 0.6717 0.5271 0.9987
0.0013 0.0393
C16 0.077  0.012 0.066  0.008 0.0006 0.083  0.016 0.072  0.015 0.0133 0.1681 0.1796 0.9050
0.0057 0.0399
C16:1-OH/C14:1-DC 0.008  0.003 0.006  0.003 0.0022 0.008  0.003 0.006  0.003 0.0912 0.7204 0.8956 0.8272
(Continued)
2016 | Vol. 4 | Iss. 19 | e12977
Page 6
ª 2016 The Authors. Physiological Reports published by Wiley Periodicals, Inc. on behalf of
the American Physiological Society and The Physiological Society.
Plasma Acylcarnitine Profiling A. Ribel-Madsen et al.
and LBW individuals after the control or high-fat, high-
calorie diet were included in the analyses. Data in Tables
4, 5, and 6 are presented as slope plus or minus SD
together with P- and Q-values. P-values were considered
statistically significant as described above. Linear regres-
sion analyses were performed in R.
Results
Eighteen LBW and 25 NBW men were included in this
study. Two LBW individuals of the recruited participants
failed to consume all the food provided during the high-
fat, high-calorie diet, and a NBW subject felt discomfort
in connection with the clamp after the control diet and
therefore did not further participate in this test in either
the control or high-fat, high-calorie diet study part.
Clinical characteristics
Low birth weight and NBW men displayed differences in
body composition and glucose and lipid metabolism after
the control and high-fat, high-calorie diets, and both
birth weight groups showed changes in metabolism in
response to the dietary challenge, as previously reported
(Brons et al. 2008, 2012, 2013, 2015). A selection of vari-
ables that provide background for the current findings is
shown in Tables 1 and 2 and also presented here.
Low birth weight men had higher fasting blood glucose
and serum insulin levels after the control diet compared
with NBW men (Table 1). Also, LBW and NBW men
both increased the fasting blood glucose level and
decreased the fasting plasma nonesterified fatty acid level
in response to overfeeding (Table 1). NBW men addition-
ally increased the fasting serum insulin level due to this
challenge. LBW and NBW men did not show differences
in basal glucose or fatty acid oxidation rates after the
control or high-fat, high-calorie diet when evaluated from
the indirect calorimetry examination in connection with
the clamp on the last study day, and they also did not
change these rates in response to overfeeding (Table 1).
However, when studied during the 24 h calorimetry dur-
ing the interventions, LBW men had a higher fatty acid
Table 3. Continued.
(lmol/L)
NBW
(n = 25)
LBW
(n = 18)
LBW versus NBW
(n = 18, n = 25)
C
(Mean  SD)
O
(Mean  SD)
PNBW
QNBW
C
(Mean  SD)
O
(Mean  SD)
PLBW
QLBW
PC
QC
PO
QO
PD
QD
0.0119
C16-OH/C14-DC 0.005  0.002 0.004  0.002 0.2545 0.004  0.002 0.005  0.003 0.3113 0.2796 0.3719 0.1247
C18:2 0.032  0.006 0.033  0.008 0.6651 0.036  0.013 0.036  0.007 0.9486 0.3153 0.2563 0.8531
C18:1 0.096  0.021 0.076  0.016 0.0012 0.110  0.024 0.083  0.020 0.0002 0.0488 0.1802 0.4145
0.0091 0.0026 0.2440
C18 0.049  0.008 0.042  0.011 0.0342 0.051  0.011 0.045  0.012 0.0307 0.4460 0.3463 0.7884
0.0866 0.0798
C18:2-OH 0.005  0.004 n.d. – 0.005  0.005 0.004  0.003 0.2252 0.7582 – –
C18:1-OH/C16:1-DC 0.006  0.002 0.004  0.002 0.0028 0.007  0.004 0.003  0.002 0.0015 0.3136 0.3860 0.1537
0.0133 0.0073
C18-OH/C16-DC 0.006  0.003 0.005  0.003 0.6185 0.007  0.003 0.006  0.002 0.2424 0.0344 0.2525 0.4401
0.1966
C20:4 0.006  0.003 0.006  0.004 0.6264 0.007  0.003 0.006  0.004 0.5415 0.5908 0.8081 0.8447
C20 0.004  0.002 0.005  0.002 0.4190 0.006  0.003 0.005  0.003 0.3517 0.1378 0.6414 0.1991
C20:1-OH/C18:1-DC 0.008  0.004 0.006  0.002 0.0506 0.007  0.003 0.007  0.003 0.8446 0.6730 0.1213 0.1343
C20-OH/C18-DC 0.008  0.003 0.009  0.004 0.4546 0.009  0.003 0.010  0.002 0.6724 0.2669 0.5315 0.7204
C22 0.004  0.002 0.005  0.002 0.0243 0.005  0.003 0.006  0.002 0.2680 0.2850 0.5532 0.6343
0.0710
Total levels
OH/DC 0.345  0.061 0.377  0.075 0.0511 0.412  0.057 0.397  0.041 0.3833 0.0007 0.2679 0.0488
Non-OH/DC 6.674  0.913 5.746  0.865 0.0006 7.928  1.822 6.215  0.888 0.0008 0.0049 0.0901 0.0901
All 7.019  0.945 6.122  0.905 0.0011 8.340  1.854 6.614  0.885 0.0009 0.0039 0.0836 0.0790
Data are presented as mean  SD, unless the acylcarnitine was not detected (n.d.) in more than 25% of the samples. P-values ≤0.05 are pre-
sented together with Q-values, and P-values ≤0.05 with corresponding Q-values ≤0.1 are considered statistically significant. PNBW and PLBW, O
versus C diet within each birth weight group; PC and PO, LBW versus NBW individuals within each diet; PD, LBW versus NBW individuals on
response values. P-values ≤0.05 and Q-values ≤0.1 are marked in bold.
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Table 4. Associations between C2 or C4-OH level and physiological measures following the control (C) and high-fat, high-calorie (O) diets
and between response values (D).
C2
(Slope, SD, P, Q)
C4-OH
(Slope, SD, P, Q)
C O D C O D
Lipid profiling
P-TG 0.050 0.103 0.057 1.540 1.123 0.926
0.039 0.054 0.045 2.817 3.623 3.132
0.2140 0.0683 0.2079 0.5880 0.7580 0.7691
Clamp
Basal
B-Glucose 0.009 0.023 0.053 0.881 5.257 0.954
0.059 0.078 0.047 4.160 4.786 3.577
0.8855 0.7649 0.2696 0.8335 0.2790 0.7912
S-Insulin 0.246 2.109 1.451 99.78 358.9 165.8
1.389 2.893 1.368 96.49 178.0 100.4
0.8604 0.4713 0.2970 0.3080 0.0522 0.1080
P-NEFA 52.92 29.97 43.43 650.3 521.6 2038
18.70 17.25 17.79 1335 1136 1274
0.0075 0.0908 0.0197 0.6290 0.6490 0.1183
0.1050 0.2352
HGP 0.000 0.078 0.051 0.222 0.453 1.593
0.068 0.111 0.082 4.804 7.012 6.030
0.9990 0.4875 0.5339 0.9630 0.9490 0.7931
Hepatic IR 1.222 0.865 0.262 154.2 527.8 565.4
4.012 10.31 5.149 283.6 653.4 387.0
0.7625 0.9336 0.9600 0.5902 0.4247 0.1532
GOX 0.115 0.085 0.129 0.371 4.375 13.61
0.111 0.159 0.099 7.973 10.82 7.284
0.3070 0.5973 0.1990 0.9630 0.6883 0.0704
FOX 0.048 0.130 0.057 0.678 4.477 5.303
0.065 0.068 0.051 4.604 4.455 3.854
0.4640 0.0634 0.2790 0.8840 0.3219 0.1780
Insulin-stimulated
M-value 0.306 0.974 0.016 2.371 69.74 7.566
0.286 0.547 0.289 21.08 34.32 21.17
0.2920 0.0842 0.9560 0.9111 0.0500 0.7230
0.1827
GOX 0.032 0.191 0.166 1.444 30.09 7.168
0.122 0.196 0.128 9.430 10.84 9.759
0.7930 0.3350 0.2040 0.8790 0.0088 0.4680
0.0616
FOX 0.017 0.012 0.041 2.894 12.19 7.563
0.053 0.068 0.050 4.043 3.781 3.517
0.7430 0.8619 0.4210 0.4790 0.0027 0.0394
0.0378 0.2760
IVGTT
FPIR 100.5 202.2 181.9 4261 8831 1.0 E4
113.5 309.3 94.15 8032 2.1 E4 7553
0.3819 0.5175 0.0618 0.5992 0.6700 0.1880
(Continued)
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oxidation rate and a lower glucose oxidation rate during
sleep on the control diet compared with NBW men
(Table 2). Also, LBW and NBW men both increased fatty
acid oxidation rates and decreased protein oxidation rates
in all measured time intervals during the 24 h calorimetry
in response to overfeeding, and NBW men decreased the
glucose oxidation rate during day time due this challenge
(Table 2). Furthermore, LBW and NBW men both
increased total energy expenditures in response to over-
feeding (Table 2). LBW men had a higher hepatic insulin
resistance index after the control diet compared with
NBW men, but LBW and NBW men did not have a dif-
ferent insulin-stimulated glucose infusion rate, M-value,
after this diet (Table 1). Furthermore, NBW men
increased the hepatic insulin resistance index in response
to overfeeding, whereas LBW men decreased the M-value
in reaction to overfeeding. LBW and NBW men did not
show a different first-phase insulin response (FPIR) and
nor different hepatic or peripheral disposition indices
(DI) following the control or high-fat, high-calorie diet
(Table 1). However, LBW and NBW men both increased
the FPIR in response to overfeeding, and NBW men addi-
tionally increased the peripheral DI due to this challenge.
Acylcarnitine levels and their relation to
physiological measures
Low birth weight and NBW men showed differences in
plasma acylcarnitine levels after the control diet, but not
after the high-fat, high-calorie diet, and both birth weight
groups furthermore showed changes in acylcarnitine levels
in response to overfeeding (Table 3).
Low birth weight men had higher C2, C4-OH,
C6-DC, and C10-OH/C8-DC levels after the control
diet compared with NBW men, and they also displayed
higher total hydroxyl-/dicarboxyl-acylcarnitine and total
acylcarnitine levels after this diet. However, LBW men
did not have a higher total acylcarnitine level when C2
was excluded from the sum (data not shown). Further-
more, LBW and NBW men both decreased C2, C12:1,
C16:2, C16:1, C16, C18:1, C18, C18:1-OH/C16:1-DC,
and total acylcarnitine levels in response to overfeeding.
LBW men additionally decreased C4/C4i, C4-OH, C10-
OH/C8-DC, and C14:1 levels when exposed to overfeed-
ing, whereas NBW men decreased C12-OH/C10-DC,
C14:2, and C16:1-OH/C14:1-DC levels due to this chal-
lenge. Moreover, LBW and NBW men both increased
C8:1 and C8:1-OH/C6:1-DC levels in response to over-
feeding. Also, LBW men increased the C10:3 level,
whereas NBW men increased C6-DC and C22 levels
due to overfeeding.
C10-OH/C8-DC, total hydroxyl-/dicarboxyl-acylcarni-
tine, and total acylcarnitine levels were positively associ-
ated with the plasma nonesterified fatty acid level after
the control diet (Tables 5 and 6). Also, C10-OH/C8-DC
and total hydroxyl-/dicarboxyl-acylcarnitine levels tended
to be negatively associated with the serum insulin level
after the control diet. In addition, the C10-OH/C8-DC
level tended to be positively associated with the M-value
after the control diet, and the total hydroxyl-/dicarboxyl-
acylcarnitine level tended to be negatively associated with
the hepatic insulin resistance index after this diet. Fur-
thermore, the C4-OH level was positively associated with
the insulin-stimulated glucose oxidation rate and nega-
tively associated with the insulin-stimulated fatty acid oxi-
dation rate after the high-fat, high-calorie diet, and
tended to be positively associated with the M-value
after this diet (Table 4). Moreover, a decrease in total
hydroxyl-/dicarboxyl-acylcarnitine and total acylcarnitine
levels in response to overfeeding was associated with a
decrease in the plasma nonesterified fatty acid level, and a
decrease in the total hydroxyl-/dicarboxyl-acylcarnitine
Table 4. Continued.
C2
(Slope, SD, P, Q)
C4-OH
(Slope, SD, P, Q)
C O D C O D
Hepatic DI 0.012 0.011 0.029 0.953 1.588 2.153
0.016 0.032 0.013 1.062 2.107 1.044
0.4430 0.7230 0.0336 0.3760 0.4560 0.0470
0.2352 0.2760
Peripheral DI 0.021 0.031 0.026 1.774 0.2400 2.457
0.016 0.037 0.018 1.081 2.423 1.358
0.1950 0.4080 0.1480 0.1104 0.9220 0.0795
Data are presented as slope, SD, and P-value. P-values ≤0.05 are presented together with Q-values, and P-values ≤0.05 with corresponding Q-
values ≤0.1 are considered statistically significant. P-values ≤0.05 and Q-values ≤0.1 are marked in bold. Regression analyses were performed
on the pooled data set of LBW and NBW individuals and were adjusted for age, BMI, and birth weight group. Abbreviations: See Table 1.
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Table 5. Associations between C6-DC or C10-OH/C8-DC level and physiological measures following the control (C) and high-fat, high-calorie
(O) diets and between response values (D).
C6-DC
(Slope, SD, P, Q)
C10-OH/C8-DC
(Slope, SD, P, Q)
C O D C O D
Lipid profiling
P-TG 0.893 1.170 5.201 1.976 0.774 5.816
2.298 1.847 2.184 3.209 3.828 3.574
0.6999 0.5302 0.0227 0.5420 0.8410 0.1124
0.1589
Clamp
Basal
B-Glucose 1.683 5.724 2.958 7.441 9.371 4.710
3.409 2.404 2.522 4.689 4.895 3.395
0.6245 0.0226 0.2487 0.1211 0.0635 0.2392
0.1848
S-Insulin 113.9 45.45 16.15 257.4 64.69 47.87
77.68 96.33 70.67 102.1 225.3 114.1
0.1512 0.6402 0.8210 0.0162 0.7760 0.6780
0.1134
P-NEFA 2775 138.1 801.9 5505 894.5 3793
992.8 602.5 978.8 1338 1169 1423
0.0082 0.8200 0.4180 0.0002 0.4490 0.0114
0.1148 0.0028 0.1596
HGP 0.662 3.164 1.891 2.140 6.143 8.350
3.900 3.712 4.235 5.419 7.286 6.613
0.8660 0.3994 0.6578 0.6950 0.4050 0.2140
Hepatic IR 296.3 3561 125.2 397.3 353.2 681.8
224.6 336.6 268.9 315.9 760.8 416.6
0.1956 0.2973 0.6440 0.2168 0.6454 0.1110
GOX 11.80 3.977 10.08 14.41 0.277 12.05
6.210 5.189 5.197 8.846 10.78 8.477
0.0654 0.4486 0.0608 0.1120 0.9796 0.1640
FOX 7.191 5.105 6.744 6.254 7.978 7.003
3.567 2.203 2.627 5.190 4.642 4.322
0.0513 0.0264 0.0148 0.2360 0.0945 0.1140
0.1848 0.1589
Insulin-stimulated
M-value 33.49 20.55 5.711 46.84 23.39 1.585
17.21 18.70 15.25 21.59 37.19 23.35
0.0595 0.2793 0.7104 0.0367 0.5336 0.9463
0.1713
GOX 1.617 5.470 1.158 2.194 23.63 12.30
7.505 6.240 6.853 11.41 12.31 11.49
0.8310 0.3867 0.8670 0.8490 0.0630 0.2930
FOX 2.189 1.103 0.904 1.085 0.947 1.110
3.222 2.237 2.642 4.930 4.599 4.451
0.5020 0.6249 0.7350 0.8270 0.8380 0.8047
IVGTT
FPIR 4457 1.4 E4 8198 1.0 E4 1.8 E4 1.3 E4
6603 1.0 E4 5370 9035 2.0 E4 8439
0.5043 0.1780 0.1361 0.2615 0.3572 0.1193
(Continued)
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level was additionally associated with a decrease in the
plasma triacylglycerol level and an increase in FPIR.
Discussion
In order to investigate a possible differential and poten-
tially incomplete fatty acid oxidation in LBW individuals,
we measured fasting plasma levels of 45 acylcarnitine spe-
cies or sets of species in 18 LBW and 25 NBW men fol-
lowing an isocaloric control diet and a 5-day high-fat,
high-calorie diet.
We demonstrated that LBW men had higher C2, C4-
OH, C6-DC, and C10-OH/C8-DC levels after the control
diet compared with NBW men, and also a higher total
hydroxyl-/dicarboxyl-acylcarnitine level after this diet.
Moreover, C10-OH/C8-DC and total hydroxyl-/dicar-
boxyl-acylcarnitine levels tended to be negatively associ-
ated with the serum insulin level after the control diet,
and the total hydroxyl-/dicarboxyl-acylcarnitine level
additionally tended to be negatively associated with the
hepatic insulin resistance index after this diet.
Low birth weight individuals’ higher C2 level after the
control diet is reflective of an excess of acetyl-CoA in the
mitochondrial matrix. This indicates increased fatty acid,
glucose, and/or amino acid oxidation rates relative to the
TCA cycle flux (Fig. 1). Also, their unaltered total acylcar-
nitine level when excluding C2 suggests that they do not
have limitations in fatty acid beta-oxidation. In previous
studies, we have found that LBW men have an increased
fatty acid oxidation rate and a decreased glucose oxida-
tion rate at night time during the control diet compared
with NBW men, whereas they do not have a different
protein oxidation rate (Brons et al. 2013). Thus, an accu-
mulation of acetyl-CoA in LBW men is likely to be due
to an increased fatty acid beta-oxidation. Furthermore, we
have shown that LBW and NBW men do not show differ-
ences in expression levels of genes involved in oxidative
phosphorylation or differences in ATP synthesis in skele-
tal muscle (Brons et al. 2008). Thus, at least in skeletal
muscle, available data indicate that LBW individuals
could have an increased beta-oxidation rate and an
unchanged TCA cycle flux, which would cause an accu-
mulation of acetyl-CoA in the mitochondrial matrix
(Fig. 1). Their higher 3-hydroxy-butyrylcarnitine, C4-OH,
level is thought to reflect ketogenesis (McGarry and Fos-
ter 1972), consistent with an excess pool of acetyl-CoA.
As the liver is a primary site of ketogenesis, these findings
may suggest increased rates of hepatic fatty acid oxidation
in LBW men (Fig. 1). Hydroxyl- and dicarboxyl-fatty
acids are products of fatty acid omega-oxidation in the
endoplasmic reticulum of mainly the liver (Reddy and
Hashimoto 2001), and with regards to medium-chain
dicarboxyl-fatty acids and their acylcarnitine esters, in
addition of beta-oxidation in peroxisomes, as long-chain
dicarboxyl-fatty acids derived from omega-oxidation are
oxidized in peroxisomes (Houten et al. 2012). Omega-
oxidation is a minor route for oxidation of fatty acids
under normal physiological conditions (Reddy and Hashi-
moto 2001; Patsouris et al. 2006). However, the flux of
fatty acids through this pathway is increased when intra-
cellular levels of nonesterified fatty acids are high such as
following high-fat feeding (Patsouris et al. 2006) or under
fasting (Patsouris et al. 2006) and starvation (Bjorkhem
1976; Kroetz et al. 1998). In addition to the omega-oxida-
tion pathway, hydroxyl-fatty acids are intermediates in
beta-oxidation in mitochondria and peroxisomes (Reddy
and Hashimoto 2001; Jones and Bennett 2010). Therefore,
the higher C6-DC, C10-OH/C8-DC, and total hydroxyl-/
dicarboxyl-acylcarnitine levels in LBW men could reflect
an increased omega-oxidation (Mortensen and Gregersen
1981) along with an increased beta-oxidation of dicar-
boxyl-fatty acids (Houten et al. 2012) (Fig. 1), if these
acylcarnitines are in fact both hydroxyl- and dicarboxyl-
species, or, alternatively, an accumulation of intermediates
Table 5. Continued.
C6-DC
(Slope, SD, P, Q)
C10-OH/C8-DC
(Slope, SD, P, Q)
C O D C O D
Hepatic DI 0.350 0.433 0.131 0.483 0.794 0.566
0.926 1.029 0.730 1.277 2.111 1.160
0.7080 0.6770 0.8590 0.7080 0.7090 0.6290
Peripheral DI 0.2370 0.119 0.267 0.192 3.438 1.464
0.9630 1.193 1.024 1.329 2.437 1.585
0.8070 0.9210 0.7960 0.8860 0.1672 0.3620
Data are presented as slope, SD, and P-value. P-values ≤0.05 are presented together with Q-values, and P-values ≤0.05 with corresponding Q-
values ≤0.1 are considered statistically significant. P-values ≤0.05 and Q-values ≤0.1 are marked in bold. Regression analyses were performed
on the pooled data set of LBW and NBW individuals and were adjusted for age, BMI, and birth weight group. Abbreviations: See Table 1.
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Table 6. Associations between total OH-/DC-acylcarnitine, total non-OH-/DC-acylcarnitine, or total acylcarnitine level and physiological mea-
sures following the control (C) and high-fat, high-calorie (O) diets and between response values (D).
OH/DC-acylcarnitines
(Slope, SD, P, Q)
Non-OH/DC-acylcarnitines
(Slope, SD, P, Q)
All acylcarnitines
(Slope, SD, P, Q)
C O D C O D C O D
Lipid profiling
P-TG 0.210 0.714 2.119 0.045 0.101 0.071 0.042 0.099 0.074
0.787 0.584 0.696 0.033 0.045 0.041 0.033 0.043 0.039
0.7910 0.2294 0.0043 0.1888 0.0308 0.0893 0.2040 0.0285 0.0697
0.0315 0.2793 0.2772
Clamp
Basal
B-Glucose 1.605 1.190 0.246 0.014 0.665 0.047 0.016 0.068 0.045
1.142 0.786 0.920 0.050 0.064 0.043 0.049 0.061 0.043
0.1681 0.1387 0.7912 0.7778 0.3181 0.2898 0.7393 0.2781 0.2944
S-Insulin 54.46 0.031 5.130 0.307 1.698 1.171 0.389 1.607 1.131
25.91 32.60 25.37 1.184 2.446 1.240 1.156 2.381 1.212
0.0427 0.9920 0.8410 0.7970 0.4930 0.3520 0.7382 0.5050 0.3580
0.1993
P-NEFA 1044 153.9 887.4 49.78 30.20 48.20 49.68 29.34 48.66
339.9 188.6 292.7 15.62 14.16 15.81 15.18 13.74 15.34
0.0040 0.4200 0.0045 0.0029 0.0399 0.0043 0.0023 0.0396 0.0031
0.0560 0.0315 0.0406 0.2793 0.0602 0.0322 0.2772 0.0434
HGP 0.402 0.212 0.191 0.009 0.052 0.042 0.008 0.047 0.039
1.326 1.155 1.507 0.058 0.093 0.077 0.057 0.090 0.075
0.7640 0.8551 0.8999 0.8710 0.5819 0.5910 0.8840 0.6040 0.6041
Hepatic IR 160.9 22.89 20.38 1.182 0.209 1.137 0.835 0.324 1.131
73.23 114.1 95.36 3.400 8.697 4.678 3.323 8.461 4.568
0.0347 0.8422 0.8320 0.7302 0.9810 0.8090 0.8030 0.9697 0.8060
0.1993
GOX 2.652 0.924 4.280 0.125 0.062 0.147 0.124 0.053 0.150
2.156 1.759 2.032 0.094 0.136 0.091 0.092 0.131 0.089
0.2270 0.6025 0.0426 0.1920 0.6514 0.1160 0.1840 0.6906 0.1020
0.1491
FOX 1.159 0.930 1.899 0.056 0.105 0.071 0.056 0.104 0.073
1.256 0.772 1.017 0.055 0.057 0.048 0.053 0.055 0.047
0.3620 0.2365 0.0704 0.3120 0.0736 0.1470 0.3040 0.0673 0.1310
Insulin-stimulated
M-value 10.20 4.765 2.950 0.332 0.799 0.012 0.334 0.776 0.004
5.593 5.715 5.392 0.241 0.450 0.276 0.235 0.435 0.271
0.0764 0.4102 0.5879 0.1770 0.0848 0.9669 0.1640 0.0832 0.9890
GOX 0.568 5.344 2.610 0.030 0.245 0.136 0.028 0.259 0.126
2.590 1.917 2.603 0.105 0.160 0.123 0.102 0.153 0.121
0.8280 0.0085 0.3240 0.7750 0.1340 0.2750 0.7870 0.0994 0.3050
0.1190
FOX 0.509 0.772 1.380 0.019 0.034 0.032 0.017 0.036 0.028
1.116 0.739 0.993 0.045 0.056 0.047 0.044 0.055 0.047
0.6510 0.3035 0.1743 0.6810 0.5513 0.4987 0.7020 0.5124 0.5466
IVGTT
FPIR 1437 4583 4802 1037 232.8 198.0 101.4 246.1 201.0
2214 3368 1810 95.87 260.0 85.64 93.56 252.7 83.68
0.5206 0.1820 0.0120 0.2871 0.3765 0.0270 0.2862 0.3368 0.0219
(Continued)
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in beta-oxidation pathways, if the pooled species are com-
prised solely or predominantly of the hydroxyl-species.
Liquid chromatography-tandem mass spectrometry (LC-
MS/MS) analyses will be required to resolve this issue, as
opposed to the flow injection-MS/MS analyses conducted
herein. White adipose tissue lipolysis is increased during
deficient adipose tissue insulin signaling, and we have
previously described this trait in LBW individuals (Alibe-
govic et al. 2010). Furthermore, our recent studies of adi-
pose tissue cells suggest that LBW is associated with an
impaired development of subcutaneous adipose tissue
(Ferland-McCollough et al. 2012; Schultz et al. 2014). An
increased lipolysis results in a shift in the equilibrium of
fat storage from adipose tissue toward an increased stor-
age in nonadipose tissue such as the liver (Samuel and
Shulman 2016). Also, an increased hepatic fatty acid load
is expected to induce omega-oxidation (Patsouris et al.
2006). Interestingly, omega-oxidation has been shown to
be upregulated in experimental models of diabetes (Yosh-
ioka et al. 1994; Miura 2013) as well as in patients with
diabetes (Lippe et al. 1987). This, together with the pre-
sent findings of a possible increase in omega-oxidation in
LBW individuals, suggests that an increased omega-oxida-
tion could be part of the metabolic phenotype of predia-
betes and diabetes.
Acetylcarnitine, C2, has been reported to be a marker
of prediabetes (Wang-Sattler et al. 2012), and an ele-
vated fasting plasma C2 level has been found in adults
with type 2 diabetes (Adams et al. 2009; Villarreal-Perez
et al. 2014). Also, the fasting plasma C2 level has been
shown to positively associate with the fasting plasma
HbA1c level in women with or without diabetes (Adams
et al. 2009). However, in this study, the C2 level did
not associate with measures of insulin secretion or sensi-
tivity. In addition, the fasting plasma C4-OH level has
been found to be elevated in obese women with type 2
diabetes (Fiehn et al. 2010). Furthermore, the fatty acid
moiety of this acylcarnitine has been shown to interfere
with insulin signaling (Tardif et al. 2001), and its levels
in skeletal muscle have been associated with muscle
insulin resistance in diet-induced obesity rodent models
(An et al. 2004). In this study, we did not observe any
associations between the plasma C4-OH level and insulin
secretion or sensitivity. However, C10-OH/C8-DC and
total hydroxyl-/dicarboxyl-acylcarnitine levels tended to
be negatively associated with the serum insulin level,
and the total hydroxyl-/dicarboxyl-acylcarnitine level
additionally tended to be negatively associated with the
hepatic insulin resistance index. This suggests that
omega-oxidation could act as a scavenger pathway for
oxidation of fatty acids when intracellular acyl-CoA
levels are high to thereby reduce the availability of these
precursors for the synthesis of lipotoxic lipid species
such as ceramides and diacylglycerols that impair insulin
signaling (Chavez and Summers 2012; Jornayvaz and
Shulman 2012) (Fig. 1).
We furthermore demonstrated that LBW and NBW
men decreased levels of 12 and 11 of the measured acyl-
carnitine species, respectively, as well as the total acylcar-
nitine level in response to overfeeding. In addition, they
increased levels of three and four species, respectively,
due to this challenge.
Low birth weight and NBW individuals’ decrease in
several short-, medium-, and long-chain acylcarnitine spe-
cies, including C2, in response to overfeeding could be
due to an increased fatty acid beta-oxidation and TCA
cycle flux following the high-fat, high-calorie diet com-
pared to the control diet. This interpretation is strongly
supported by the findings that LBW and NBW men
increased both fatty acid oxidation rates and total energy
Table 6. Continued.
OH/DC-acylcarnitines
(Slope, SD, P, Q)
Non-OH/DC-acylcarnitines
(Slope, SD, P, Q)
All acylcarnitines
(Slope, SD, P, Q)
C O D C O D C O D
0.0560 0.1549 0.1533
Hepatic DI 0.043 0.136 0.055 0.011 0.012 0.027 0.010 0.013 0.026
0.308 0.347 0.269 0.013 0.027 0.012 0.013 0.026 0.012
0.8890 0.6970 0.8380 0.4320 0.6470 0.0332 0.4390 0.6350 0.0357
0.1549 0.1666
Peripheral DI 0.185 0.451 0.329 0.016 0.030 0.023 0.016 0.031 0.023
0.323 0.393 0.363 0.014 0.031 0.017 0.014 0.030 0.016
0.5710 0.2590 0.3720 0.2490 0.3450 0.1700 0.2500 0.3150 0.1640
Data are presented as slope, SD, and P-value. P-values ≤0.05 are presented together with Q-values, and P-values ≤0.05 with corresponding Q-
values ≤0.1 are considered statistically significant. P-values ≤0.05 and Q-values ≤0.1 are marked in bold. Regression analyses were performed on
the pooled dataset of LBW and NBW individuals and were adjusted for age, body mass index, and birth weight group. Abbreviations: See Table 1.
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Figure 1. Proposed differences in fatty acid oxidation pathways between low (LBW) and normal birth weight (NBW) individuals. LBW
individuals may have an increased beta-oxidation in mitochondria of skeletal muscle (upper panel) and liver (bottom panel) that is not matched
by an equivalently increased TCA cycle flux, resulting in an accumulation of acetyl-CoA in the mitochondrial matrix and following of
acetylcarnitine in the cytosol. Also, an excess of acetyl-CoA could lead to an increased ketogenesis in the liver and following an accumulation
of 3-hydroxy-butyrylcarnitine (not shown). Furthermore, LBW individuals may have an increased omega-oxidation in the endoplasmic reticulum
of the liver along with an increased beta-oxidation of dicarboxyl-fatty acids in peroxisomes, leading to an accumulation of hydroxyl- and
dicarboxyl-acylcarnitine species. Omega-oxidation may be a scavenger pathway for oxidation of fatty acids that otherwise could be available for
synthesis of lipotoxic lipid species such as ceramides and diacylglycerols that impair insulin signaling.
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expenditures during all time intervals of the 24 h
calorimetry in response to overfeeding, and furthermore
from the finding that they reduced the plasma nonesteri-
fied fatty acid level due to this challenge (Brons et al.
2012). In a prior rodent study, mice fed a high-fat diet
had higher serum levels of several medium- and long-
chain acylcarnitines compared with mice fed a standard
diet (Koves et al. 2008). It was suggested that the high-fat
feeding resulted in an incomplete fatty acid beta-oxidation
(Koves et al. 2008). However, in this study, the high-fat
overfeeding was for only 5 days and the blood samples
were collected after an overnight fast, as opposite to the
rodent study in which the intervention was for 12 weeks,
and the samples were collected in the fed state (Koves
et al. 2008). Thus, an increased beta-oxidation and TCA
cycle flux in response to short-term high-fat overfeeding
could be a compensatory mechanism to prevent an accu-
mulation of lipids in nonadipose tissue. Such a mecha-
nism is probably only transient and may not persist for
long-term high-fat overfeeding exposure. This hypothesis,
however, requires further studies. Their increase in C8:1
and C8:1-OH/C6:1-DC levels in response to overfeeding
may be explained by the markedly higher n-3 fatty acid
content in the high-fat, high-calorie diet compared to the
control diet (Table S1), as C8:1 and C6:1 n-3 fatty acids
are oxidation products of several n-3 fatty acids, including
alpha-linolenic acid, C18:3 n-3 fatty acid.
Our study is the first to describe fasting plasma acylcar-
nitine levels in LBW individuals with an increased risk of
developing type 2 diabetes. It has its strengths in the care-
ful selection of LBW and NBW men, highly standardized
study setup, and in depth physiological and metabolic
characterization of the individuals. In relation to the bio-
logical interpretation of the results, however, it has its
limitations in the acylcarnitine profiling being on the
plasma level, as plasma acylcarnitines represent the sum
of contributions of acylcarnitines from various tissues,
mainly skeletal muscle and liver, that may respond differ-
ently to a given metabolic challenge (Schooneman et al.
2013, 2014). Also, plasma and these tissues may have dif-
ferent turnover rates of acylcarnitines (Schooneman et al.
2014). In summary, we demonstrated that LBW men had
higher C2 and C4-OH levels after the control diet com-
pared with NBW men, suggestive of an increased fatty
acid beta-oxidation in mitochondria relative to the TCA
cycle flux. Furthermore, we showed that LBW men had
higher C6-DC, C10-OH/C8-DC, and total hydroxyl-/
dicarboxyl-acylcarnitine levels, which may suggest an
increased fatty acid omega-oxidation in the endoplasmic
reticulum of the liver concomitant with an increased
beta-oxidation in peroxisomes of omega-oxidation-
derived dicarboxyl-fatty acids. Interestingly, a cluster of
short-chain, dicarboxyl-acylcarnitine species, including
C6-DC, has recently been shown to be prognostic for
myocardial infarction and all-cause cardiac mortality
(Shah et al. 2010, 2012). Moreover, we found that C10-
OH/C8-DC and total hydroxyl-/dicarboxyl-acylcarnitine
levels tended to be negatively associated with the serum
insulin level, and the total hydroxyl-/dicarboxyl-acylcarni-
tine level additionally tended to be negatively associated
with the hepatic insulin resistance index. Therefore, we
proposed that an increased fatty acid omega-oxidation
could prevent an accumulation of lipotoxic lipid species
that impair insulin signaling in the liver. Intervention
studies that aim to increase the efficiency of fatty acid
oxidation, including hepatic omega-oxidation, and TCA
cycle flux to thereby potentially reduce an accumulation
of lipids and improve insulin action in LBW individuals
are needed.
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Abstract
Low birth weight (LBW) individuals exhibit a disproportionately increased,
incomplete fatty acid oxidation and a decreased glucose oxidation, compared
with normal birth weight (NBW) individuals, and furthermore have an
increased risk of developing insulin resistance and type 2 diabetes. We
hypothesized that changes in amino acid metabolism may occur parallel to
alterations in fatty acid and glucose oxidation, and could contribute to insulin
resistance. Therefore, we measured fasting plasma levels of 15 individual or
pools of amino acids in 18 LBW and 25 NBW men after an isocaloric control
diet and after a 5-day high-fat, high-calorie diet. We demonstrated that LBW
and NBW men increased plasma alanine levels and decreased valine and leu-
cine/isoleucine levels in response to overfeeding. Also, LBW men had higher
alanine, proline, methionine, citrulline, and total amino acid levels after over-
feeding compared with NBW men. Alanine and total amino acid levels tended
to be negatively associated with the insulin-stimulated glucose uptake after
overfeeding. Therefore, the higher amino acid levels in LBW men could be a
consequence of their reduction in skeletal muscle insulin sensitivity due to
overfeeding with a possible increased skeletal muscle proteolysis and/or could
potentially contribute to an impaired insulin sensitivity. Furthermore, the ala-
nine level was negatively associated with the plasma acetylcarnitine level and
positively associated with the hepatic glucose production after overfeeding.
Thus, the higher alanine level in LBW men could be accompanied by an
increased anaplerotic formation of oxaloacetate and thereby an enhanced tri-
carboxylic acid cycle activity and as well an increased gluconeogenesis.
Introduction
Low birth weight (LBW) individuals have an increased
risk of developing insulin resistance and type 2 diabetes
later in life, compared with normal birth weight (NBW)
individuals, when exposed to an affluent life style such as
overfeeding (Hales et al. 1991; Barker et al. 1993; Hofman
et al. 2004; Vaag et al. 2006). Indeed, otherwise healthy
ª 2016 The Authors. Physiological Reports published by Wiley Periodicals, Inc. on behalf of
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LBW men display several prediabetic metabolic abnormal-
ities, including higher fasting blood glucose and serum
insulin levels and a decreased hepatic insulin sensitivity
compared with NBW men (Brons et al. 2008). Also, LBW
in contrast to NBW men develop a decreased peripheral
insulin sensitivity in response to a short-term high-fat,
high-calorie diet (Brons et al. 2012). Nevertheless, the
underlying mechanisms behind the LBW prediabetic phe-
notype are not clear. Previously, we have found that LBW
men exhibit an increased fatty acid oxidation along with
a decreased glucose oxidation at night as determined dur-
ing an isocaloric control diet and a high-fat, high-calorie
diet compared with NBW men (Brons et al. 2013, 2015).
Furthermore, LBW men have a higher relative contribu-
tion of fatty acid oxidation to the total energy expendi-
ture at night and throughout 24 h when studied on the
high-fat, high-calorie diet (Brons et al. 2015). Recently,
we have extended our understanding of the LBW predia-
betic phenotype with the finding of elevated fasting
plasma acetylcarnitine levels in LBW men, pointing
toward an increased acetyl-CoA generation relative to its
oxidation in the tricarboxylic acid (TCA) cycle (Ribel-
Madsen et al. 2016). An accumulation of acetyl-CoA may
theoretically lead to mitochondrial stress responses and
the activation of serine kinases, which in turn may impair
skeletal muscle insulin signaling and glucose transporter 4
(GLUT4) translocation (Muoio and Newgard 2008).
In the present extension study, we hypothesized that
the changes in fatty acid and glucose oxidation partition-
ing in LBW individuals would be associated with changes
in plasma amino acid levels, reflecting the need for an
adequate supply of TCA cycle intermediates to allow an
efficient acetyl-CoA oxidation in the TCA cycle (Fig. 1).
Furthermore, such changes could be parts of the adverse
metabolic events leading to insulin resistance in LBW
individuals. In order to test our hypotheses, we measured
fasting plasma levels of 15 individual or pools of amino
acids in LBW and NBW men after an isocaloric control
diet and after a 5-day high-fat, high-calorie diet, and
associated these levels to the plasma acetylcarnitine level,
as a measure of the intracellular acetyl-CoA level, and to
measures of hepatic and peripheral insulin sensitivity.
Materials and Methods
Study population
Forty-six young (23–27 years of age), healthy men were
recruited from the Danish National Birth Registry accord-
ing to birth weight. Among these, 20 individuals had
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Figure 1. Amino acid anaplerotic and cataplerotic pathways that replenish or deplete tricarboxylic acid cycle intermediates, respectively. Plasma
amino acid levels measured in this study are underlined.
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LBW, which was defined as a birth weight within the
0–10th percentile range (2717  268 g), as in a prior
study (Jensen et al. 2002), and 26 individuals had NBW,
which was defined as a birth weight within the 50–90th
percentile range (3901  207 g). All individuals were
born at term (39–41 weeks of gestation) in Copenhagen
in the period 1979–1980. Also, all participants were
ensured to not have a family history of diabetes in two
generations, not have a body mass index (BMI) greater
than 30 kg/m2, not perform strenuous physical activity
more than 10 h per week, not take pharmaceuticals that
affect metabolism, and not have an abuse of alcohol or
drugs.
Study design
Diet interventions
All individuals were in a randomized crossover setup stan-
dardized with respect to diet and physical activity and fol-
lowing given a 3-day control diet and a 5-day high-fat,
high-calorie diet separated by a 6–8 weeks washout period
(Fig. 2). Energy requirements of the individual subjects
were calculated from a World Health Organization equa-
tion for men less than 30 years of age with a physical activ-
ity level of 1.4 corresponding to a low physical activity
(WHO, 2001). The control diet was composed to replicate
a habitual, weight-maintaining diet (2819  238 kcal/
11,800  1000 kJ) with 15% of the total energy from pro-
tein, 50% from carbohydrate, and 35% from fat, whereas
the high-fat, high-calorie diet was prepared to contain 50%
extra calories above the requirements (4228  334 kcal/
17,700  1400 kJ) with 7.5% of the total energy from pro-
tein, 32.5% from carbohydrate, and 60% from fat
(Table S1). Also, the meals contained in each intervention
were identical from day to day. Dietary calculations were
made in Dankost Pro (http://dankost.dk/english) (The
National Food Agency, Copenhagen, Denmark).
Clinical examinations
Study activities were carried out over 3 days, with the
first of these days being placed 1 or 3 days after the start
of the control and high-fat, high-calorie diet intervention,
respectively (Fig. 2). Anthropometry was performed on
the first study day. An intravenous glucose tolerance test
(IVGTT) and a hyperinsulinemic–euglycemic clamp were
carried out in the morning on the third study day follow-
ing an overnight fast to assess insulin secretion and sensi-
tivity, as described previously (Brons et al. 2008, 2012).
Furthermore, calorimetry was performed throughout 24 h
from the first to second study day by use of a whole-body
respiratory chamber to evaluate substrate oxidation rates
and energy expenditures, as described previously (Brons
et al. 2013, 2015). Blood and tissue samples were col-
lected prior to and during the clamp.
Laboratory measurements
Amino acid analyses
Amino acid analyses were performed on EDTA-plasma
samples collected following an overnight fast (10.00 PM–
7.00 AM) and immediately prior to the clamp examination
–2 –1 0 1 2 3 Day
Standardization Wash-out 
Clamp
High-fat, high-calorie diet
Blood samplingCalorimetry 24 h
Anthropometry
IVGTT
Figure 2. Study setup. Plasma amino acid levels were measured from blood samples collected following an overnight fast and immediately
prior to the clamp examination on the last study day.
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(Fig. 2). These analyses included a quantitative determi-
nation of 15 individual or pools of amino acids, noted in
the tables by their three letter code, and were performed
by use of sample preparation procedures and flow injec-
tion–tandem mass spectrometry, as described previously
(Chace et al. 1995; Ferrara et al. 2008). In brief, plasma
samples were spiked with known quantities of stable
isotope-labeled amino acid standards. Following, proteins
were removed by precipitation with methanol and the
supernatants were then evaporated to dryness under
nitrogen gas and incubated with acidified butanol to form
butyl ester derivatives of the amino acids. After this, the
reagents were evaporated to dryness under nitrogen gas,
and the samples were reconstituted in 1:1 (v/v) methanol:
glycerol. Subsequently, the samples were introduced into
a Quattro Micro MS/MS system (Waters, Milford, MA)
equipped with a data system running MassLynx 4.0
(Waters). Mass spectra of the amino acid butyl esters
were obtained by precursor ion and neutral loss scanning
of [M+H]+ and [M+H–102]+ ions, respectively, the latter
ion corresponding to a loss of butyl formate of 102 Da
from the original [M+H]+ ion. Finally, amino acids were
quantified from the ratio of their molecular signals to
respective internal standards. Leucine and isoleucine were
not resolved by the method, and therefore these amino
acids are reported as a single analyte. Also, the quantifica-
tion of these amino acids includes contributions from
allo-isoleucine and hydroxy-proline, but these isobaric
amino acids generally contribute little to the signal
assigned to leucine and isoleucine (Chace et al. 1995).
Furthermore, partial hydrolysis of asparagine to aspartic
acid and of glutamine to glutamic acid occurs under the
acidic conditions used to form butyl esters, and so the
amounts of these amino acids plus their hydrolysis prod-
ucts are noted as Asx and Glx, respectively. Amino acid
measurements were performed in The Sarah W. Stedman
Nutrition and Metabolism Center Metabolomics/Biomar-
ker Core Laboratory, Duke University, Durham, NC.
The laboratory was blinded to the birth weight of the
individuals.
Acylcarnitine analyses
Acylcarnitine analyses were performed on the same
plasma samples as for the amino acid analyses. These
analyses included a semiquantitative determination of 45
acylcarnitine species or sets of species and were performed
as described previously (Ribel-Madsen et al. 2016).
Ethical approval
All study procedures were in accordance with the princi-
ples of the Declaration of Helsinki and were approved by
the Regional Research Ethics Committee of Copenhagen,
Denmark. Also, all participants were provided with writ-
ten information on the study purpose and procedures
and signed an informed consent prior to their participa-
tion.
Statistical analyses
Amino acid levels and their relation to
physiological measures
Differences in plasma amino acid levels between NBW
and LBW individuals within each diet or between the
control and high-fat, high-calorie diets within each birth
weight group were assessed from Student’s unpaired or
paired t-test (for normally distributed values), respec-
tively, or Wilcoxon ranked-sum or signed-rank test (for
not normally distributed values), respectively. Prior to
these tests, statistical outliers (1.5 interquartile range)
were removed from the dataset and replaced by the mean
value within the given group. Normal distribution of the
values (variables or differences between variables, respec-
tively) was evaluated from Shapiro–Wilk test. Finally,
adjustment for multiple testing was done by calculating
false discovery rates, Q-values, by the Benjamini and
Hochberg method (Benjamini and Hochberg 1995). Data
in Tables 2 and 4 are presented as mean value plus or
minus standard deviation (SD) together with P- and Q-
values. P ≤ 0.05 were considered statistically significant if
Q ≤ 0.2. Student’s t-test and Wilcoxon tests were per-
formed in SAS Enterprise Guide 6.1 (SAS Institute, Cary,
NC), and Benjamini and Hochberg corrections were per-
formed in R 3.1.0 (https://www.r-project.org/).
Associations between individual plasma amino acid
levels or between these levels and other variables were
obtained from linear regression analyses. These analyses
were performed on the pooled dataset of LBW and NBW
individuals and were adjusted for age, BMI, and birth
weight group. Data in Table 3 are presented as slope (plus
or minus signs for a positive or negative association,
respectively) and P-value (number of plus or minus signs
indicates the significance level) for those values meeting the
false discovery rate criteria. P-values were considered statis-
tically significant as described above. Linear regression
analyses and selected plots from these were performed in R.
Results
Eighteen LBW and 25 NBW men were included in the
present study. Two LBW men of the recruited partici-
pants failed to consume all the food during the high-fat,
high-calorie diet, and a NBW subject felt discomfort dur-
ing the clamp after the control diet and therefore did not
2016 | Vol. 4 | Iss. 23 | e13044
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further participate in this test in either the control or
high-fat, high-calorie diet study part.
Clinical characteristics
LBW and NBW men displayed differences in body com-
position and glucose and lipid metabolism after the con-
trol diet and high-fat, high-calorie diet, and both birth
weight groups showed several changes in these parameters
in response to the overfeeding challenge, as published
previously (Brons et al. 2008, 2012, 2013, 2015; Ribel-
Madsen et al. 2016). A selection of these findings is pre-
sented in Tables 1 and S2.
Amino acid levels and their relation to
physiological measures
LBW and NBW men only displayed tendencies to differ-
ences in plasma amino acid levels after the control diet
when accounted for multiple testing, but significant dif-
ferences after the high-fat, high-calorie diet, and both
groups showed several changes in amino acid levels in
response to overfeeding (Table 2).
LBW men tended to have higher proline and tyrosine
levels and a lower serine level after the control diet com-
pared with NBW men. Furthermore, LBW and NBW
men both increased alanine levels and decreased valine,
leucine/isoleucine, and essential amino acid levels in
response to overfeeding. In addition, LBW men increased
citrulline and nonessential amino acid levels and
decreased the phenylalanine level due to overfeeding,
whereas NBW men increased tyrosine and glutamine/
glutamic acid levels and decreased proline, methionine,
and histidine levels in response to this challenge. Also,
LBW men had higher alanine, proline, methionine, and
citrulline levels after the high-fat, high-calorie diet com-
pared with NBW men, and as well higher essential,
nonessential, and total amino acid levels after this diet.
Table 1. Clinical characteristics of low (LBW) and normal birth weight (NBW) men following the control (C) and high-fat, high-calorie (O) diets.
NBW
(n = 25)
LBW
(n = 18)
LBW versus NBW
(n = 18, n = 25)
C
(mean  SD)
O
(mean  SD)
PNBW C
(mean  SD)
O
(mean  SD)
PLBW PC PO PD
Anthropometry
Birth weight (g) 3901  207 — — 2717  268 — — ≤0.001 — —
Weight (kg) 78.4  9.3 78.6  9.7 n.s. 77.1  11.3 77.1  11.4 n.s. n.s. n.s. n.s.
Height (m) 1.83  0.07 — — 1.77  0.05 — — ≤0.05 — —
Body mass index (kg/m2) 23.3  2.4 23.3  2.5 n.s. 24.6  3.8 24.6  3.8 n.s. n.s. n.s. n.s.
Clamp
Basal
B-Glucose (mmol/L) 4.59  0.47 5.05  0.40 ≤0.001 4.97  0.48 5.18  0.34 ≤0.05 ≤0.01 n.s. n.s.
S-Insulin (pmol/L) 30.2  14.7 43.4  29.2 ≤0.05 41.7  14.6 44.7  21.9 n.s. ≤0.01 n.s. n.s.
P-NEFA (lmol/L) 334  136 205  82 ≤0.001 406  200 188  91 ≤0.001 n.s. n.s. n.s.
P-Acetylcarnitine (lmol/L) 4.771  0.797 3.985  0.738 ≤0.01 5.985  1.587 4.393  0.784 ≤0.001 ≤0.01 n.s. n.s.
HGP (mg/kgFFM/min) 2.21  0.48 2.85  0.99 ≤0.01 2.40  0.5 2.48  0.5 n.s. n.s. n.s. ≤0.05
Hepatic IR (mg/kgFFM/
minpmol/L)
68.7  34.1 113.7  61.5 ≤0.001 102.3  50.8 108.7  55.5 n.s. ≤0.05 n.s. ≤0.05
Insulin-stimulated
P-NEFA (lmol/L) 9.29  4.39 12.42  6.43 ≤0.01 9.56  5.03 14.39  7.76 ≤0.01 n.s. n.s. n.s.
M-value (mg/kgFFM/min) 13.73  2.32 13.29  3.32 n.s. 13.47  3.14 11.89  3.57 ≤0.05 n.s. n.s. n.s.
IVGTT
FPIR (pmol/L) 1894  1431 2604  1793 ≤0.001 2135  1034 2750  1509 ≤0.01 n.s. n.s. n.s.
Hepatic DI 0.38  0.63 0.25  0.21 n.s. 0.21  0.11 0.24  0.13 n.s. n.s. n.s. n.s.
Peripheral DI 0.29  0.19 0.35  0.20 ≤0.05 0.33  0.13 0.32  0.17 n.s. n.s. n.s. n.s.
Data are presented as mean  SD. P-values from Student’s t-test are presented unadjusted for multiple comparisons, and P ≤ 0.05 are consid-
ered statistically significant. PNBW and PLBW: O versus C diet within each birth weight group, PC and PO: LBW versus NBW individuals within
each diet, PD: LBW versus NBW individuals on response values. n.s.: Not significant. P ≤ 0.05 are marked in bold.
Abbreviations: B, blood; DI, disposition index; FFM, fat-free mass; FPIR, first-phase insulin response; HGP, hepatic glucose production; IR, insu-
lin resistance; IVGTT, intravenous glucose tolerance test; NEFA, nonesterified fatty acid; P, plasma; S, serum.
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Plasma alanine levels were negatively associated with
the fasting plasma acetylcarnitine level after both the con-
trol diet and high-fat, high-calorie diet (Fig. 3). Further-
more, an increase in the alanine level due to overfeeding
was associated with a decrease in the acetylcarnitine level
(Fig. 3). In addition, both alanine and total amino acid
levels tended to be negatively associated with the insulin-
stimulated glucose uptake rate, M-value, (P = 0.0911,
Q = 0.1707; P = 0.0846, Q = 0.2115, respectively) after
the high-fat, high-calorie diet (Table 3). Also, an increase
in the proline level was associated with a decrease in the
M-value (P = 0.0271, Q = 0.1350) (Table 3). Further-
more, alanine and total amino acid levels were positively
associated with the hepatic glucose production
(P = 0.0022, Q = 0.0110; P = 0.0114, Q = 0.0570, respec-
tively) after the high-fat, high-calorie diet (Table 3).
Discussion
We demonstrated that LBW men had higher fasting
plasma alanine, proline, methionine, citrulline, and total
amino acid levels after the high-fat, high-calorie diet
Table 2. Plasma amino acid levels in low (LBW) and normal birth weight (NBW) men following the control (C) and high-fat, high-calorie (O) diets.
(lmol/L)
NBW
(n = 25)
LBW
(n = 18)
LBW versus NBW
(n = 18, n = 25)
C
(mean  SD)
O
(mean  SD)
PNBW
QNBW
C
(mean  SD)
O
(mean  SD)
PLBW
QLBW
PC
QC
PO
QO
PD
QD
Amino acid
profiling
Gly 320.6  36.0 319.1  35.0 0.8304 319.6  30.4 320.2  38.4 0.9531 0.9205 0.9512 0.8618
Ala 286.5  58.3 345.0  53.3 0.0007
0.0021
288.6  78.0 403.9  87.5 <0.0001
0.0008
0.8929 0.0174
0.1305
0.0134
0.2010
Ser 109.9  16.2 104.3  14.6 0.1590 100.2  13.5 106.7  10.9 0.0673 0.0445
0.2455
0.5590 0.0291
0.2110
Pro 157.2  19.2 145.0  24.6 0.0007
0.0021
180.0  42.8 169.2  42.4 0.1183 0.0462
0.2455
0.0396
0.1485
0.8532
Val 234.4  30.2 205.9  11.0 <0.0001
0.0005
238.0  33.4 216.4  25.9 0.0258
0.0774
0.7138 0.1185 0.4983
Leu/Ile 178.6  24.5 146.0  16.6 <0.0001
0.0005
181.0  19.5 152.9  13.4 <0.0001
0.0008
0.7359 0.1527 0.4522
Met 27.1  3.7 25.5  3.2 0.0358
0.0761
27.8  2.4 28.2  3.7 0.5893 0.4757 0.0135
0.1305
0.0625
His 65.1  6.6 58.4  5.6 <0.0001
0.0005
62.3  7.9 58.8  5.7 0.1042 0.2157 0.8456 0.1920
Phe 60.3  7.8 58.1  7.8 0.1171 60.9  5.2 57.2  6.6 0.0065
0.0244
0.3364 0.8929 0.7413
Tyr 53.7  7.0 57.5  9.3 0.0406
0.0761
58.1  7.2 61.9  10.7 0.1622 0.0491
0.2455
0.1583 0.9917
Asx 144.0  20.8 136.1  24.0 0.2760 148.2  23.7 149.4  24.7 0.9006 0.5486 0.0853 0.4351
Glx 56.1  11.0 63.6  15.8 0.0035
0.0088
63.1  13.6 71.5  19.9 0.1118 0.0687 0.1513 0.6688
Orn 58.4  6.6 61.5  12.1 0.2189 59.3  10.6 58.6  8.6 0.8457 0.7437 0.3972 0.3657
Cit 28.1  4.0 28.8  5.5 0.5057 29.6  3.5 32.6  5.2 0.0065
0.0244
0.1997 0.0284
0.1420
0.1463
Arg 90.0  14.9 85.2  13.1 0.0875 90.4  12.3 92.7  13.5 0.4444 0.9296 0.0763 0.0601
Total levels
Essential 655.5  67.8 579.2  33.2 <0.0001 660.4  53.8 606.2  43.7 0.0035 0.8006 0.0260 0.2603
Nonessential 1128  101.1 1171  107.5 0.0980 1158  98.4 1283  131.8 0.0004 0.3418 0.0038 0.0353
All 1870  157.1 1840  131.9 0.3896 1907  132.7 1980  159.4 0.0805 0.4205 0.0030 0.0556
Data are presented as mean  SD. P ≤ 0.05 are presented together with Q-values, and P ≤ 0.05 with corresponding Q ≤ 0.2 are considered
statistically significant. PNBW and PLBW: O versus C diet within each birth weight group, PC and PO: LBW versus NBW individuals within each
diet, PD: LBW versus NBW individuals on response values. P ≤ 0.05 and Q ≤ 0.2 are marked in bold. Essential amino acids: Val, Leu/Ile, Met,
His, Phe, and Arg; nonessential amino acids: Gly, Ala, Ser, Pro, Tyr, Asx, and Glx.
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compared with NBW men. Furthermore, the plasma ala-
nine level was negatively associated with the fasting
plasma acetylcarnitine level, which reflects the intracellu-
lar acetyl-CoA pool (Adams et al. 2009), after both the
control diet and high-fat, high-calorie diet. Previously, we
have shown that LBW men have a higher plasma acetyl-
carnitine level after the control diet and a tendency to this
after the high-fat, high-calorie diet compared with NBW
men (Ribel-Madsen et al. 2016), and in addition, an
increased fatty acid oxidation and a decreased glucose
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Figure 3. Associations between plasma alanine and acetylcarnitine levels following the control (C) and high-fat, high-calorie (O) diets and
between response values (D). Open circles: Low birth weight (LBW) individuals, filled circles: Normal birth weight (NBW) individuals.
Table 3. Associations between plasma amino acid levels and physiological measures following the control (C) and high-fat, high-calorie (O)
diets and between response values (D).
Gly Ala Ser Pro Val
Leu/
Ile Met His Phe Tyr Asx Glx Orn Cit Arg All
Clamp
Basal
B-Glucose C +
O
D 
S-Insulin C (+)
O  
D
HGP C + +
O + + (+) +
D +
Hepatic IR C +
O ()
D
Insulin-stimulated
M-value C + ()
O () ()
D 
Data are presented as slope (+/ for a positive or negative association, respectively) and P-value (+/: P ≤ 0.05, + +/ : P ≤ 0.01, and (+)/
(): P ≤ 0.1) for those values meeting the false discovery rate criteria. P ≤ 0.05 with corresponding Q ≤ 0.2 are considered statistically signifi-
cant. Regression analyses were performed on the pooled dataset of low (LBW) and normal birth weight (NBW) individuals and were adjusted
for age, BMI, and birth weight group.
Abbreviations: See Table 1.
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oxidation at night during intake of both diets (Brons
et al. 2013, 2015). Taken together, we proposed that the
acetyl-CoA generation from in particular the increased
fatty acid oxidation exceeds its oxidation in the TCA cycle
in LBW individuals (Ribel-Madsen et al. 2016), possibly
due to a depletion of TCA cycle intermediates. In the
state of a high intracellular acetyl-CoA concentration, as
seems to be the case in LBW individuals (Ribel-Madsen
et al. 2016), pyruvate dehydrogenase is inhibited and
pyruvate carboxylase is activated, favoring pyruvate car-
boxylation to oxaloacetate, the four-carbon unit TCA
cycle intermediate that condenses with acyl-CoA to form
citrate, and as well favoring pyruvate transamination to
alanine (Hue and Taegtmeyer 2009). This promotes
anaplerosis and gluconeogenesis, respectively (Hue and
Taegtmeyer 2009). Therefore, the higher plasma alanine
level in LBW men could reflect an increased pyruvate
transamination to alanine in tissues, and the negative
association between the plasma alanine and acetylcar-
nitine levels may be due to an increased anaplerotic for-
mation of oxaloacetate. A recent study has reported that
induced pluripotent stem cells from patients with genetic
insulin resistance have a reduced mitochondrial oxidative
function, including a decreased citrate synthase activity
(Burkart et al. 2016). Also, addition of exogenous
oxaloacetate to the cell culture system could resolve
citrate synthase activity, and it was therefore proposed
that substrate availability could be a limiting factor of
TCA cycle activity in insulin resistance (Burkart et al.
2016). Alternatively, the higher plasma alanine level in
LBW men could be a result of an increased skeletal mus-
cle proteolysis and de novo alanine synthesis, as further
discussed below. Indeed, LBW men display a higher
adjusted total energy expenditure at night during the
high-fat, high-calorie diet compared with NBW men
(Brons et al. 2015). Therefore, the TCA cycle is likely to
be upregulated in LBW individuals at night, and we pro-
pose that a higher plasma alanine level in these individu-
als could reflect an increased availability of alanine
and pyruvate in tissues for anaplerotic formation of
oxaloacetate and furthermore that this may enhance the
acetyl-CoA oxidation in the TCA cycle, which in turn
may contribute to development of hepatic insulin resis-
tance (Satapati et al. 2012).
We furthermore demonstrated that plasma alanine and
total amino acid levels tended to be negatively associated
with the insulin-stimulated glucose uptake rate, M-value,
after the high-fat, high-calorie diet. Also, we have previ-
ously demonstrated that LBW men decreased the M-value
in response to this diet (Brons et al. 2012). Whether the
higher plasma alanine and total amino acid levels in LBW
individuals could be a consequence of and/or contribute
to impaired skeletal muscle insulin sensitivity is uncertain.
Insulin has a suppressive effect on tissue proteolysis, and
so an impaired skeletal muscle insulin sensitivity may
increase the amino acid release from skeletal muscle
(Magkos et al. 2010). Also, the amino acid release from
skeletal muscle following an overnight fast does not
reflect its amino acid composition (Ruderman 1975), and
so relatively more alanine and glutamine, which represent
the main amino acid gluconeogenic precursors in liver
and kidney, respectively, (Felig 1973; Felig et al. 1977;
Stumvoll et al. 1999), are released (Ruderman 1975; Felig
et al. 1977). Actually, alanine and glutamine together
accounts for approximately two thirds of the amino acids
released from skeletal muscle (Ruderman 1975; Garber
et al. 1976). This has been suggested to be due to an
in situ amino acid metabolism that results in de novo
synthesis of nonessential amino acids, primarily alanine
and glutamine (Ruderman 1975; Felig et al. 1977). Ala-
nine is generated through pyruvate transamination (Rud-
erman 1975), and it has been suggested that pyruvate to
this synthesis may be derived from other amino acids, as
skeletal muscle theoretically could generate pyruvate from
glutamate, aspartate, and other amino acids that are
metabolized in the TCA cycle (Ruderman 1975). Notably,
it has been demonstrated that more alanine relative to
glutamine is released from skeletal muscle in subjects with
diabetes (Jungas et al. 1992). It is therefore interesting
that LBW men showed a tendency to a larger relative
contribution of alanine and nonessential amino acids to
the total plasma amino acid level after the high-fat, high-
calorie diet compared with NBW men (Table 4). Accord-
ingly, the higher plasma alanine level in LBW individuals
could be a result of both an increased skeletal muscle
proteolysis due to an impaired skeletal muscle insulin
sensitivity and of an increased de novo alanine synthesis
from other amino acids, including in particular gluta-
mate, aspartate, valine, leucine, and isoleucine, and pyru-
vate (Ruderman 1975; Snell 1980). Although this is
expected to cause reductions in the relative contributions
of these amino acids to the total plasma amino acid level
in LBW men, we did not observe this (Table 4). As con-
cerns, the possibility that the higher plasma amino acid
levels in LBW individuals could contribute to an impaired
skeletal muscle insulin sensitivity, it has been shown that
short-term elevation of plasma amino acid levels to post-
prandial concentrations causes insulin resistance by direct
inhibition of muscle glucose transport and/or phosphory-
lation with a subsequent reduction in glycogen synthesis
rates (Krebs et al. 2002). In addition to the potential
effects of amino acids on skeletal muscle insulin sensitiv-
ity, we demonstrated that plasma alanine and total amino
acid levels were positively associated with the hepatic glu-
cose production after the high-fat, high-calorie diet.
Higher plasma amino acid levels could induce this effect
2016 | Vol. 4 | Iss. 23 | e13044
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on the liver via indirect and/or direct mechanisms. Thus,
amino acids can stimulate insulin and glucagon secretion
(Floyd et al. 1966; Ohneda et al. 1968; Newsholme et al.
2006), and changes in the portal vein concentration of
these hormones could increase the endogenous glucose
production (Roden et al. 1996). On the other hand,
amino acids could by acting as substrates induce gluco-
neogenesis and thereby enhance the endogenous glucose
production (Rui 2014). It is notable that the plasma glu-
tamine/glutamic acid and alanine levels were strongly
positively associated with the hepatic glucose production
after the control or high-fat, high-calorie diet, respec-
tively, (Table 3), keeping in mind that these amino acids
are the main amino acid gluconeogenic precursors (Felig
1973; Felig et al. 1977; Stumvoll et al. 1999). Previously,
we have shown that LBW men have a higher fasting
blood glucose level after the control diet compared with
NBW men (Brons et al. 2008), and we propose that an
increased gluconeogenesis, occurring parallel to an
increased hepatic fatty acid oxidation, may contribute to
Table 4. Relative plasma amino acid levels compared to the total plasma amino acid level in low (LBW) and normal birth weight (NBW) men
following the control (C) and high-fat, high-calorie (O) diets.
(Fraction)
NBW
(n = 25)
LBW
(n = 18)
LBW versus NBW
(n = 18, n = 25)
C
(mean  SD)
O
(mean  SD)
PNBW
QNBW
C
(mean  SD)
O
(mean  SD)
PLBW
QLBW
PC
QC
PO
QO
PD
QD
Amino acid
profiling
Rel Gly 0.172  0.017 0.174  0.016 0.6024 0.168  0.017 0.162  0.018 0.1692 0.4775 0.0306
0.1759
0.1473
Rel Ala 0.152  0.021 0.187  0.019 <0.0001
0.0005
0.150  0.035 0.202  0.033 <0.0001
0.0005
0.8284 0.0607 0.0569
Rel Ser 0.059  0.008 0.057  0.006 0.2302 0.053  0.007 0.054  0.005 0.3978 0.0105
0.1575
0.1345 0.1614
Rel Pro 0.084  0.009 0.079  0.011 0.0007
0.0021
0.094  0.021 0.085  0.018 0.0019
0.0057
0.0385
0.2888
0.1500 0.2023
Rel Val 0.125  0.012 0.112  0.010 <0.0001
0.0005
0.125  0.014 0.109  0.011 0.0003
0.0011
0.8817 0.3412 0.5603
Rel Leu/Ile 0.095  0.008 0.079  0.008 <0.0001
0.0005
0.095  0.008 0.077  0.005 <0.0001
0.0005
0.8682 0.3504 0.5328
Rel Met 0.014  0.002 0.014  0.001 0.0489
0.0917
0.015  0.001 0.014  0.002 0.3376 0.8000 0.4082 0.5281
Rel His 0.035  0.004 0.032  0.002 0.0002
0.0008
0.033  0.005 0.030  0.004 0.0186
0.0465
0.0957 0.0428
0.1759
0.8346
Rel Phe 0.032  0.003 0.032  0.003 0.1942 0.032  0.003 0.029  0.003 <0.0001
0.0005
0.8210 0.0100
0.1500
0.0031
0.0465
Rel Tyr 0.029  0.003 0.031  0.004 0.0052
0.0130
0.030  0.003 0.031  0.004 0.4836 0.0861 0.9512 0.1441
Rel Asx 0.077  0.011 0.074  0.013 0.3956 0.078  0.012 0.076  0.013 0.6593 0.8953 0.6937 0.8523
Rel Glx 0.030  0.005 0.034  0.008 0.0064
0.0137
0.033  0.007 0.037  0.011 0.1960 0.1126 0.4800 0.6973
Rel Orn 0.031  0.004 0.033  0.006 0.1522 0.031  0.006 0.030  0.005 0.4918 0.8797 0.0469
0.1759
0.1479
Rel Cit 0.015  0.002 0.016  0.003 0.1384 0.016  0.002 0.017  0.003 0.0790 0.3957 0.3707 0.6564
Rel Arg 0.048  0.007 0.046  0.007 0.1866 0.048  0.007 0.047  0.007 0.6541 0.7784 0.7904 0.5188
Total levels
Rel Essential 0.350  0.018 0.315  0.017 <0.0001 0.347  0.021 0.307  0.018 <0.0001 0.5284 0.1148 0.4509
Rel Nonessential 0.603  0.018 0.635  0.017 <0.0001 0.607  0.020 0.647  0.021 <0.0001 0.5464 0.0576 0.2379
Data are presented as mean  SD. P ≤ 0.05 are presented together with Q-values, and P ≤ 0.05 with corresponding Q ≤ 0.2 are considered
statistically significant. PNBW and PLBW: O versus C diet within each birth weight group, PC and PO: LBW versus NBW individuals within each
diet, PD: LBW versus NBW individuals on response values. P ≤ 0.05 and Q ≤ 0.2 are marked in bold. Essential amino acids: Val, Leu/Ile, Met,
His, Phe, and Arg; nonessential amino acids: Gly, Ala, Ser, Pro, Tyr, Asx, and Glx.
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this. Alanine and glutamine metabolism in the liver for
gluconeogenesis results in the production of ammonia.
Therefore, the higher plasma citrulline level in LBW men
after the high-fat, high-calorie diet could reflect an
increased metabolism of these amino acids with a subse-
quent increased urea cycle activity due to a greater
demand of ammonia removal.
In similarity to our study, higher plasma amino acid
levels have repeatedly been reported to associate with
insulin resistance (Newgard et al. 2009; Tai et al. 2010;
Wurtz et al. 2012a; Nakamura et al. 2014; Seibert et al.
2015; Pedersen et al. 2016). To this end, plasma amino
acid levels, in particular of the branched chain amino
acids valine, leucine, and isoleucine, aromatic amino acids
tyrosine and phenylalanine, and alanine, are predictive of
development of type 2 diabetes even several years before
its onset (Wang et al. 2011; Wurtz et al. 2012b, 2013;
Yamakado et al. 2015). Importantly, higher fasting serum
valine, leucine, isoleucine, and phenylalanine levels have
been shown to predict increased fasting and 2 h postchal-
lenge blood glucose levels after a 6.5-year follow-up
(Wurtz et al. 2012b), whereas higher levels of gluco-
neogenic precursors, including alanine, lactate, and pyru-
vate, predict increased 2 h postchallenge, but not fasting
blood glucose levels, after this follow-up (Wurtz et al.
2012b). Therefore, it was concluded that gluconeogenic
precursors could be potential markers of long-term
impaired insulin sensitivity that may relate to attenuated
glucose tolerance later in life (Wurtz et al. 2012b).
Another study performed in rodent has described that an
increased plasma citrulline level may predict development
of the metabolic syndrome (Sailer et al. 2013). Thus, our
findings of elevated plasma amino acid levels, including
alanine and citrulline levels, in LBW men exposed to a
high-fat, high-calorie diet challenge reveal additional
metabolic abnormalities in these individuals associated to
early stages of development of insulin resistance and type
2 diabetes.
We, moreover, demonstrated that LBW and NBW men
both increased the plasma alanine level and decreased
valine and leucine/isoleucine levels in response to over-
feeding. Furthermore, an increase in the plasma alanine
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Figure 4. Associations between relative plasma alanine and valine or leucine/isoleucine levels, respectively, following the control (C) and high-
fat, high-calorie (O) diets and between response values (D). Open circles: Low birth weight (LBW) individuals, filled circles: Normal birth weight
(NBW) individuals.
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level was associated with a decrease in the fasting plasma
acetylcarnitine level. Therefore, an increase in the plasma
alanine level due to overfeeding could be accompanied by
an increase in the formation of oxaloacetate that may
enhance the acetyl-CoA oxidation. Interestingly, LBW
men showed a tendency to a larger increase in the plasma
alanine level in response to overfeeding compared with
NBW men (Table 2), and in addition, a tendency to a
larger increase in the relative contribution of alanine to
the total plasma amino acid level (Table 4). This could be
due to an increased skeletal muscle alanine release as a
consequence of their decline in skeletal muscle insulin
sensitivity during overfeeding (Brons et al. 2012). Valine,
leucine, and isoleucine are the major nitrogen sources for
de novo alanine synthesis in skeletal muscle (Felig et al.
1977; Haymond and Miles 1982). Thus, the decrease in
plasma valine and leucine/isoleucine levels in LBW and
NBW men in response to overfeeding could indicate an
increased metabolism of these amino acids to alanine in
skeletal muscle. A decrease in these amino acid levels as
well as in other essential amino acid levels could also be a
result of the lower protein content in the high-fat, high-
calorie diet compared to the control diet (Table S1).
However, it is remarkable that an increase in the relative
plasma alanine level was strongly significantly associated
with decreases in both relative plasma valine and leucine/
isoleucine levels (Fig. 4), indicating that an increased
metabolism of these amino acids to alanine could take
place. LBW men additionally showed a tendency to a lar-
ger increase in the serine level in response to overfeeding
compared with NBW men (Table 2). Serine is, together
with alanine, a precursor to pyruvate, and so an increased
availability of this amino acid may contribute to an
increased anaplerosis and thus an enhanced TCA cycle
activity as well as to an increased gluconeogenesis.
Our study is the first to investigate fasting plasma amino
acid levels in LBW individuals susceptible of developing
type 2 diabetes after a control diet and after a high-fat,
high-calorie diet. It has its strengths in the careful selection
of LBW and NBW subjects, highly standardized study
setup, and thorough physiological and metabolic character-
ization of the individuals. However, in relation to the bio-
logical interpretation of the results, and especially of the
association between the amino acid availability and acetyl-
CoA oxidation in the TCA cycle, it has its limitations in the
metabolite profiling being restricted to plasma amino acids
and acylcarnitines, and thereby not having pyruvate and
TCA cycle intermediates in its range. Furthermore, skeletal
muscle biopsies from the LBW and NBW men collected
prior to and during the clamp examination are snap frozen,
which limits the possibilities of performing supplementary
functional studies, including for instance measurements of
the cellular localization of GLUT4 (Ploug et al. 1998;
Lauritzen et al. 2008). In conclusion, our study describes
elevated fasting plasma amino acid levels in LBW men after
a 5-day high-fat, high-calorie diet, including alanine, pro-
line, methionine, citrulline, and total amino acid levels.
Furthermore, these elevated plasma amino acid levels, and
in particular of alanine, may be a result of an impaired glu-
cose oxidation and/or an increased skeletal muscle proteol-
ysis, and could be part of the adverse metabolic changes
leading to skeletal muscle and hepatic insulin resistance in
LBW individuals.
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ABSTRACT 
Low birth weight (LBW) individuals have an increased risk of developing insulin resistance and 
type 2 diabetes compared with normal birth weight (NBW) individuals. We hypothesised that LBW 
individuals exhibit an increased fatty acid flux into lipogenesis in non-adipose tissue with a 
resulting accumulation of lipotoxic lipids, including ceramides, in the blood. Therefore, we 
measured fasting plasma levels of 27 ceramides in 18 young, healthy, LBW men and 25 NBW 
controls after an isocaloric control diet and a 5-day high-fat, high-calorie diet by HPLC-HRMS. 
LBW men did not show elevated plasma ceramide levels after the control or high-fat, high-calorie 
diet. An increased fatty acid oxidation rate in these individuals during both diets may limit ceramide 
synthesis and thereby compensate for a likely increased fatty acid load to non-adipose tissue. 
Interestingly, LBW and NBW men decreased d18:0-18:1/d18:1-18:0 and d18:1-24:2/d18:2-24:1 
levels and increased the d18:0-24:1a level in response to overfeeding. Plasma d18:0-24:1a and total 
ceramide levels were positively associated with the fasting blood glucose level and endogenous 
glucose production after the control diet, and the total ceramide level was in addition positively 
associated with hepatic insulin resistance. Further studies are needed to determine if lipotoxicity 
contributes to insulin resistance in LBW individuals.  
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INTRODUCTION 
Low birth weight (LBW) individuals have an increased risk of developing insulin resistance and 
type 2 diabetes later in life compared with normal birth weight (NBW) individuals 1-4. Accordingly, 
we have shown that young, healthy, LBW men have higher fasting blood glucose and serum insulin 
levels 5, display impaired hepatic insulin sensitivity 5, and, in contrast to NBW men, develop 
impaired peripheral insulin sensitivity in response to 5-day high-fat overfeeding 6. However, the 
metabolic mechanisms behind the type 2 diabetes susceptible phenotype in LBW individuals are not 
clear. In the present study, our primary aim was to investigate if lipotoxicity induced by ceramides 
could contribute to impaired hepatic insulin sensitivity in LBW men. Moreover, as we have shown 
that NBW men of the above mentioned study population develop impaired hepatic insulin 
sensitivity in response to 5-day high-fat overfeeding 6, our secondary aim was to investigate if 
lipotoxicity could be part of the adverse events leading to this. Therefore, we studied fasting plasma 
ceramide levels, including their precursor dihydroceramides, in the LBW and NBW men of the 
above study population after an isocaloric control diet and after a 5-day high-fat, high-calorie diet 
intervention.  
We have previously found that young, healthy, LBW men of another study population than the 
present herein display an increased whole body and adipose tissue lipolysis 7,8. This was, however, 
not linked to elevated plasma non-esterified fatty acid (NEFA) or triacylglycerol levels, suggesting 
that an increased uptake of fatty acids from the blood into tissues and/or an increased clearance or 
metabolism of fatty acids in adipose tissue could be in play. Furthermore, we have demonstrated 
that LBW men of the present study population have a higher adipose tissue miR-483-3p level, and 
that manipulation of this level in vitro modulates adipocyte differentiation and fatty acid storage 
capacity 9. Pre-adipocytes isolated from the LBW men have lower mRNA expression levels of 
several differentiation markers, supporting a notion of an impaired pre-adipocyte maturation in 
LBW men 10. Moreover, the LBW men show an increased fatty acid oxidation rate 11 and a higher 
fasting plasma acetylcarnitine level 12, indicative of an increased fatty acid flux through beta-
oxidation in mitochondria being non-matched by the acetyl-CoA flux through the tricarboxylic acid 
cycle. Also notably, the LBW men have higher plasma hydroxyl-/dicarboxyl-acylcarnitine levels, 
including 3-hydroxy-butyrylcarnitine, suggestive of an increased hepatic fatty acid oxidation rate, 
involving omega-oxidation in the endoplasmic reticulum, and an increased ketogenesis 12. Omega-
oxidation is a minor pathway for oxidation of fatty acids under normal physiological conditions, but 
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an important supplementary pathway to beta-oxidation when the intracellular NEFA levels are high 
13. Taken together, we speculated that LBW individuals might have an increased fatty acid flux into 
non-adipose tissue, including in particular the liver, and further into lipogenesis with a resulting 
increased ectopic fat deposition.  
Ectopic fat comprises potentially lipotoxic lipids such as long-chain acyl-CoAs, ceramides, and 
diacylglycerols 14, and the extent of it has been linked to pancreatic beta-cell dysfunction and 
insulin resistance 15,16. Also, individuals with type 2 diabetes have elevated plasma ceramide levels 
17-19. Importantly, obese individuals with type 2 diabetes have a higher plasma LDL-ceramide level 
compared with obese, insulin-sensitive individuals 19, indicating that an increased ceramide 
synthesis in the liver may contribute to the development of insulin resistance 20. Ceramides are 
synthesised de novo in the endoplasmic reticulum from L-serine, palmitoyl-CoA, and variable acyl-
CoAs or generated in salvage pathways of other sphingolipids 21-23. Serine palmitoyl-transferase, 
catalysing the condensation of L-serine and palmitoyl-CoA, is the rate-limiting enzyme of ceramide 
synthesis, and an increased availability of palmitic acid enhances this synthesis 24-26. Therefore, an 
increased uptake of fatty acids from the blood into non-adipose tissue is expected to increase 
ceramide synthesis. Ceramides are potentially lipotoxic to cells in several ways 25,27. Thus, these 
lipids inhibit the phosphorylation and thereby activation of Akt/protein kinase B (PKB) of the 
insulin signalling cascade, which is a central regulator of glucose and amino acid uptake, anabolic 
processes, and cell survival 28,29. Furthermore, ceramides activate Jun and NF-KB transcription 
factors and may thereby enhance inflammatory responses that may interfere with insulin signalling 
as well 25. A number of studies have focused on specific actions of individual ceramides, including 
dihydroceramides, on different cellular processes 22. In this regard, d18:1-16:0 ceramide has been 
suggested to be the principal mediator of diet-induced insulin resistance 30,31. In the present study, 
we hypothesised that LBW men have higher fasting plasma ceramide levels, including specific 
ceramide species and/or total ceramide, and that such changes are associated with their impaired 
insulin sensitivity. 
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RESULTS 
Eighteen LBW and 25 NBW men were included in the present study. Two LBW men of the 
recruited participants failed to consume all the food provided during the 5-day high-fat, high-calorie 
(60 E% from fat, 50 % extra calories) diet, and a NBW subject felt discomfort during the clamp 
after the control diet and therefore did not further participate in this test in the control or high-fat, 
high-calorie diet study part. 
 
Clinical characteristics 
LBW and NBW men displayed several differences in glucose, lipid, and protein metabolism after 
the isocaloric control diet and high-fat, high-calorie diet and also differential changes in metabolism 
in response to the overfeeding, as published previously 5,6,11,12,32,33 . Furthermore, both birth weight 
groups displayed several changes in metabolism in response to the overfeeding challenge, as also 
published previously 6,12,33. A selection of these findings is presented in brief below to provide 
background of the current findings and in Table 1 and Supplementary Table S3 online.  
LBW men had higher fasting blood glucose (P≤0.01) and serum insulin (P≤0.01) levels after the 
control diet compared with NBW men 5 (Table 1). Also, both LBW and NBW men increased the 
fasting blood glucose level (P≤0.05 and P≤0.001, respectively) in response to overfeeding, and 
NBW men additionally increased the fasting serum insulin level (P≤0.05) due to this challenge 6. 
LBW men had a higher hepatic insulin resistance index (P≤0.05) after the control diet compared 
with NBW men 5, and NBW men, but not LBW men, showed an increase in the hepatic glucose 
production (P≤0.01) and in the hepatic insulin resistance index (P≤0.001) in response to 
overfeeding 6 (Table 1). LBW and NBW men did not show a different insulin-stimulated glucose 
infusion rate (M-value) after the control diet 5 (Table 1). LBW men, however, in contrast to NBW 
men, decreased this rate (P≤0.05) in reaction to overfeeding 6. In terms of plasma lipid profiles, 
LBW men had a lower fasting plasma HDL-cholesterol level (P≤0.01 and P≤0.05, respectively) 
after both the control and high-fat, high-calorie diets compared with NBW men 6 (Table 1). 
Furthermore, both LBW and NBW men decreased fasting plasma total NEFA (both P≤0.001), 
VLDL-cholesterol (P≤0.01 and P≤0.05, respectively), and total triacylglycerol (P≤0.01 and P≤0.05, 
respectively) levels and increased the HDL-cholesterol level (both P≤0.01) in response to 
overfeeding 6 (Table 1). LBW and NBW men did not show differences in basal glucose or fatty acid 
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oxidation rates after the control or high-fat, high-calorie diet when evaluated from the indirect 
calorimetry in connection with the clamp, and they also did not change these rates in response to 
overfeeding 6 (Table 1). However, LBW men had higher fatty acid oxidation rates (P=0.05/0.07 and 
P=0.10, respectively) and a lower glucose oxidation rate (P=0.05 and P=0.06, respectively) at night 
or during sleep during both the control and high-fat, high-calorie diets, compared with NBW men, 
when studied during the 24-hour indirect calorimetry 11,32 (Supplementary Table S3 online). Also, 
both LBW and NBW men increased the fatty acid oxidation rate in all four reported time intervals 
during the 24-hour indirect calorimetry in reaction to overfeeding (both P<0.0001 for the 24-hour 
period) 12. Moreover, both LBW and NBW men increased the total energy expenditure in all four 
time intervals due to this challenge (P=0.0008 and P=0.0005, respectively, for the 24-hour period) 
12 (Supplementary Table S3 online).   
 
Ceramide levels and their relation to other lipid levels and physiological measures 
LBW and NBW men did not show any differences in fasting plasma ceramide levels after the 
control or high-fat, high-calorie diet intervention, but both birth weight groups changed plasma 
levels of several ceramide species in response to overfeeding (Table 2). Thus, both LBW and NBW 
men significantly decreased d18:0-18:1/d18:1-18:0 (P=0.0004 and P<0.0001, respectively) and 
d18:1-24:2/d18:2-24:1 (P=0.0002 and P=0.0003, respectively) levels and increased the d18:0-24:1a 
level (P=0.0062 and P=0.0147, respectively) in response to overfeeding. NBW men furthermore 
decreased d18:0-16:1/d18:1-16:0 (P=0.0093), d18:1-22:1/d18:2-22:0 (P=0.0072), and d18:1-
23:1/d18:2-23:0 (P=0.0129) levels and showed a tendency to decrease the d18:0-20:1/d18:1-20:0 
level (P=0.0511) in response to overfeeding, while LBW men showed a tendency to decrease 
d18:0-16:1/d18:1-16:0 (P=0.0553) and d18:1-22:1/d18:2-22:0 (P=0.0850) levels and increase the 
d18:0-25:2/d18:1-25:1/d18:2-25:0 level (P=0.0649) due to this challenge.  
Plasma levels of many of the detected ceramides as well as of total ceramide were positively 
associated with fasting plasma VLDL-cholesterol, LDL-cholesterol, total cholesterol, and total 
triacylglycerol levels after both the control and high-fat, high-calorie diets (Supplementary Table S4 
online). Furthermore, d18:0-16:1/d18:1-16:0 (P=0.0298), d18:0-18:1/d18:1-18:0 (P=0.0076), d18:1-
22:0 (P=0.0819), d18:0-24:1a (P=0.0144), d18:0-26:1/d18:1-26:0 (P=0.0054), d18:1-24:1 
(P=0.0049), d18:1-24:2/d18:2-24:1 (P=0.0109), and total ceramide (P=0.0349) levels were or 
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tended to be positively associated with the fasting blood glucose level after the control diet (Fig. 1). 
Among these ceramides, d18:0-18:1/d18:1-18:0 (P=0.0192), d18:0-24:1a (P=0.0010), d18:0-
26:1/d18:1-26:0 (P=0.0362), and d18:1-24:2/d18:2-24:1 (P=0.0879) levels were or tended to be 
positively associated with the hepatic glucose production, and d18:1-22:0 (P=0.0205), d18:1-24:1 
(P=0.0561), and total ceramide (P=0.0252) levels were or tended to be positively associated with 
the hepatic insulin resistance index (Fig. 1). Also, d18:0-16:1/d18:1-16:0 (P=0.0263), d18:0-
18:1/d18:1-18:0 (P=0.0214), d18:1-22:0 (P=0.0279), d18:0-26:1/d18:1-26:0 (P=0.0912), d18:1-24:1 
(P=0.0927), d18:1-24:2/d18:2-24:1 (P=0.0376), and total ceramide (P=0.0326) levels were or 
tended to be positively associated with the fatty acid oxidation rate determined in connection with 
the clamp examination after the control diet (Fig. 1). 
An increase in the d18:0-25:2/d18:1-25:1/d18:2-25:0 level (P=0.0578) in response to overfeeding 
tended to associate with an increase in the hepatic insulin resistance index (Fig. 1). Furthermore, 
decreases in d18:0-18:1/d18:1-18:0 (P=0.0607), d18:1-24:0 (P=0.0793), d18:1-22:1/d18:2-22:0 
(P=0.0487), d18:1-24:1 (P=0.0437), and total ceramide (P=0.0336) levels due to overfeeding were 
or tended to be associated with a decrease in the insulin-stimulated glucose uptake rate (M-value) 
(Fig. 1). 
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DISCUSSION 
In contrast to expected, LBW men did not show altered fasting plasma ceramide levels after the 
control or high-fat, high-calorie diet intervention compared with NBW men. The increased fatty 
acid oxidation rate in the LBW men during both diets 11,32 may limit the amount of fatty acid 
substrates available for de novo ceramide synthesis and thereby compensate for a possible increased 
fatty acid load to non-adipose tissue in these individuals. Both LBW and NBW men decreased 
plasma levels of several ceramide species in response to high-fat overfeeding, all of these d18:0-
/d18:1- or d18:1-/d18:2- levels with the d18:1- species expected to be the dominant isomer in the 
pools, and increased the d18:0-24:1a level. Our findings of decreases in plasma levels of several 
ceramides in response to overfeeding are consistent with decreases in fasting plasma levels of 
several other lipid classes in the LBW and NBW men due to this challenge, including total NEFA, 
VLDL-cholesterol, total triacylglycerol, and total acylcarnitine levels 6,12. The decreases in fasting 
plasma levels of several lipids, including a number of ceramide species, in the LBW and NBW men 
in response to overfeeding could very like be a result of their markedly increases in fatty acid 
oxidation rates and total energy expenditures due to this challenge 12.  
Several studies have reported altered plasma and/or tissue ceramide levels in mice exposed to high-
fat feeding 34-37, and a recent study has described changes in serum ceramide levels in human 
subjects exposed to high-fat overfeeding 38. Thus, sedentary women and men decrease fasting 
serum d18:0-18:0, d18:1-18:0, and d18:1-24:1 levels and increase d18:0-22:0, d18:0-24:0, d18:1-
22:0, d18:1-24:0, and total d18:1- ceramide levels in response to 28-day high-fat overfeeding (45 
E% from fat, 1,250 extra kcal) 38. Furthermore, these individuals increase fasting serum HDL-
cholesterol and total cholesterol levels in response to overfeeding, while they do not change LDL-
cholesterol, total NEFA, and total triacylglycerol levels 38. Important differences between this and 
the present overfeeding study are the duration and fat contents of the high-fat, high-calorie diet 
interventions.  The increases in fatty acid oxidation rates and total energy expenditures in the LBW 
and NBW men in response to the 5-day high-fat overfeeding could be a transient, compensatory 
mechanism to prevent an accumulation of lipids in non-adipose tissue and may not persist for long-
term high-fat overfeeding exposures. This hypothesis, however, requires further investigations. 
Also, both genders are examined in the reported 28-day overfeeding study and these individuals are 
somewhat older (21-65 years of age) (37±2 years of age) 38 than the presently examined men (23-27 
years of age) (24±1 years of age). Among the studies performed in mice, several different 
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experimental setups in regard to the high-fat diet intervention have been used 34-37. Thus, wild-type 
mice fed a 16-week high-fat (60 E% from fat) diet have higher plasma levels of all measured 
ceramides, including seven d18:1- species, compared with mice fed a low-fat (10 E% from fat) diet, 
and also higher plasma total ceramide and adipose tissue total ceramide levels 34. In addition, mice 
fed an 8-week high-fat (60 E% from fat) diet have higher liver total ceramide, including seven 
d18:1- species, and total diacylglycerol contents compared with mice fed a standard chow 35. 
Plasma ceramide levels were not measured in these mice 35. Interestingly, adiponectin 
administration to the mice fed the 8-week high-fat diet, and in addition to leptin deficient (ob/ob) 
mice, rapidly normalises liver ceramide, but not diacylglycerol, contents, regardless of ceramide 
species (d18:0- or d18:1-) 35. Also, adiponectin administration to the ob/ob mice results in a 
reduction of the hepatic glucose production and an improvement in hepatic, but not skeletal muscle, 
insulin sensitivity 35. Notably, adiponectin exerted these effects through lowering of the liver 
ceramide content via receptor-mediated enhancement of ceramidase activities 35. Previously, we 
have found that both LBW and NBW men of the present study population increase the fasting 
plasma adiponectin level in response to overfeeding 6. This, besides to their increases in fatty acid 
oxidation rates, may prevent an accumulation of ceramides in the liver. Furthermore, the LBW and 
NBW men examined herein increase the fasting serum fibroblast growth factor 21 (FGF-21) level in 
response to the overfeeding challenge, apparently due to an increased FGF-21 secretion from the 
liver 39. FGF-21 administration to mice fed a high-fat (40 E% from fat) diet, and in addition to 
ob/ob mice, increases fatty acid oxidation rates and total energy expenditures and reduces 
hepatosteatosis 40. A recent study has shown that FGF-21 stimulates adiponectin secretion and 
reduces serum ceramide levels in mice fed a high-fat (60 E% from fat) diet 41. Also, adiponectin-
knockout mice are refractory to FGF-21 effects, including lowering of ceramide levels 41. 
Therefore, it was concluded that FGF-21 depends on adiponectin to exert its insulin-sensitising 
effects 41.  
We furthermore showed that higher plasma levels of several ceramides as well as of total ceramide 
were associated with a higher fasting blood glucose level and a higher degree of hepatic insulin 
resistance after the control diet. These findings are consistent with the observed link between liver 
ceramide contents and hepatic insulin sensitivity in the mice models used to investigate adiponectin 
effects 35. A recent study has moreover shown that cultured rat hepatocytes exposed to high 
concentrations of palmitic acid have higher intracellular ceramide concentrations and are less 
responsive to insulin 26. The latter was caused by an inhibition of the insulin-stimulated 
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phosphorylation of Akt/PKB and glycogen synthase kinase 26. The NBW men develop impaired 
hepatic insulin sensitivity and increase the hepatic glucose production in response to high-fat 
overfeeding, while the LBW men show impaired hepatic insulin sensitivity already after the control 
diet and do not reduce this sensitivity further in response to the overfeeding challenge 5,6. Our 
findings of decreases in plasma levels of several ceramides in response to overfeeding in the NBW 
men do not support a possible role of ceramides in promoting hepatic insulin resistance in these 
individuals. Nevertheless, it is remarkable that some d18:0- species, or dihydroceramides, were only 
or predominantly detected in plasma from the LBW and NBW men after the high-fat, high-calorie 
diet (Table 2). Furthermore, the LBW and NBW men solely increased the d18:0-24:1a level in 
response to overfeeding. A higher d18:0-24:1a level was strongly significantly associated with an 
increased hepatic glucose production after the control diet. Interestingly, a newly study has reported 
that individuals who progress to type 2 diabetes have elevated plasma levels of specific long-chain 
fatty acid-containing d18:0- species several years before disease onset 42. Moreover, we found that 
decreases in plasma levels of several ceramides and total ceramide in response to overfeeding were 
associated with a decrease in peripheral insulin sensitivity. The LBW men, but not NBW men, 
develop impaired peripheral insulin sensitivity in response to the high-fat overfeeding challenge 6. 
Several studies have reported negative correlations between skeletal muscle total ceramide contents 
and insulin sensitivity 43-45. One of these studies additionally reports a positive correlation between 
skeletal muscle levels of some ceramide species and insulin sensitivity in older individuals 45. 
Interestingly, it has been shown that circulating LDL-ceramide in mice specifically targets skeletal 
muscle and induces insulin resistance 19, emphasising the important role of ceramide metabolism in 
the liver. Here, we demonstrated that higher plasma levels of most of the detected ceramide species 
as well as of total ceramide were strongly significantly associated with higher fasting plasma 
VLDL- and LDL-cholesterol levels after both the control and high-fat, high-calorie diets. However, 
it is unknown to what extent circulating VLDL- or LDL-ceramides formed in the liver versus 
ceramides synthesised in skeletal muscle interfere with insulin signalling in this tissue.  
Our study is the first to investigate plasma ceramide profiles in LBW men at risk of developing type 
2 diabetes, compared with NBW men, and among a few studies to examine plasma ceramide 
profiles in human subjects exposed to short-term high-fat overfeeding. The ceramide profiles 
reported herein are moreover very detailed and related to measures of both hepatic and peripheral 
insulin sensitivity. In conclusion, LBW men did not show altered fasting plasma ceramide levels 
after the control or high-fat, high-calorie diet intervention compared with NBW men. We suggest 
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that the increased fatty acid oxidation rate in the LBW men during both diets 11,32 may limit the 
amount of fatty acid substrates available for lipogenesis, including de novo ceramide synthesis, and 
thereby may compensate for a likely increased fatty acid load to non-adipose tissue in these 
individuals. Both LBW and NBW men decreased plasma levels of several ceramide species in 
response to overfeeding. This could very likely be a result of their increases in fatty acid oxidation 
rates and total energy expenditures due to the overfeeding challenge 12, potentially evoked by their 
increases in fasting serum FGF-21 39 and plasma adiponectin 6 levels. Alternatively, it might be a 
result of a FGF-21 and adiponectin mediated activation of ceramidases in the liver with a following 
increase in the ceramide degradation. A higher plasma total ceramide level was associated with a 
higher degree of hepatic insulin resistance after the control diet. Further studies are needed to 
determine if an accumulation of potentially lipotoxic lipids in tissue and plasma is part of the 
adverse metabolic events leading to insulin resistance in LBW individuals. Also, additional 
investigations are required to determine possible specific roles of individual ceramides, including 
dihydroceramides, in interfering with insulin signalling in the liver and skeletal muscle.  
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METHODS 
Ceramide analyses were performed on plasma samples from LBW and NBW men subjected to 
dietary interventions and physiological tests prior to the present study, as described in short below 
and in earlier publications 5,6,11,12,32. 
 
Study population 
Forty-six young (23-27 years of age), healthy men were recruited from the Danish National Birth 
Registry according to birth weight. Among these, 20 men had a LBW (2717±268 g) (≤10th 
percentile) and 26 men a NBW (3901±207 g) (50-90th percentile). All men were born at term (39-
41 weeks of gestation) in Copenhagen from 1979-1980. Also, all men were non-obese (BMI <30 
kg/m2), did not perform strenuous physical activity >10 h/week, and did not have a family history 
of diabetes in two generations. 
 
Study design 
Diet interventions 
All men were, in a randomised crossover study setup, standardised with regard to diet and physical 
activity and following subjected to a 3-day control diet and a 5-day high-fat, high-calorie diet 
intervention separated by a 6-8 week wash out-period. The control diet was prepared to reflect a 
habitual, weight-maintaining diet (2,819±238 kcal/day) with 15, 50, and 35 E% from protein, 
carbohydrate, and fat, respectively, and the high-fat, high-calorie diet was composed to contain 50 
% extra calories (4,228±334 kcal/day) with 7.5, 32.5, and 60 E% from protein, carbohydrate, and 
fat, respectively (Supplementary Table S1 online). Both diets were provided as five daily servings, 
and the meals were identical from day to day. Energy requirements of the individual participants 
were calculated from a WHO equation for men <30 years of age with a low physical activity level 
46, and dietary calculations were made in Dankost Pro (The National Food Agency, Copenhagen, 
Denmark). 
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Clinical examinations 
Study activities were performed over 3 days with the first of these days being placed 1 or 3 days 
following the start of the control and high-fat, high-calorie diet intervention, respectively. 
Anthropometry measures were recorded on day 1. An intravenous glucose tolerance test (IVGTT) 
and a hyperinsulinaemic-euglycaemic clamp were carried out in the morning on day 3 to assess 
insulin secretion and sensitivity, as described previously 5,6. Furthermore, indirect calorimetry was 
conducted throughout 24 hours from day 1-2 as well as in the basal and insulin-stimulated steady-
state periods of the clamp to determine substrate oxidation rates and total energy expenditures, as 
also described previously 6,11,32. Blood samples were collected prior to and during the clamp. 
 
Laboratory measurements 
Ceramide analyses 
Ceramide analyses were performed on EDTA-plasma samples collected following an overnight fast 
(10.00 PM-7.00 AM) and immediately prior to the clamp examination. These analyses included a 
semi-quantitative determination of 27 ceramide species (individual or pools), denoted by the 
sphingoid base (i.e. d18:0-, d18:1-, or d18:2-) and acyl group (e.g. -24:0) in accordance to their 
carbon chain length and number of double bonds (Table 2, Supplementary Table S2 online).  
Aliquots of 200 µL plasma were spiked with 100 µL d18:1-16:0-2H31 internal standard (Avanti 
Polar Lipids, Alabaster, AL, USA) solution (0.4 nmol/100 µL 2:1 chloroform:methanol), and lipids 
were then extracted with 1.5 mL ice-cold methanol, 3.0 ice-cold mL chloroform, and 960 µL ice-
cold 0.73 % sodium chloride solution according to the Bligh and Dyer method 47. After 
centrifugation, the lower organic phases were transferred to new glass tubes, evaporated to dryness 
under nitrogen gas, and re-dissolved in 200 µL chloroform. Following, the lipid extracts were 
applied to n-hexane washed Strata NH2-columns (55 µm, 500 mg, 3 mL) (Phenomenex, Torrance, 
CA, USA). Cholesterolesters and triacylglycerols were first eluted with 3.0 mL 100:5:5 
hexane:chloroform:ethylacetate, and cholesterol, diacylglycerols, and ceramides were subsequently 
eluted with 6.0 mL 23:1 chloroform:methanol into separate glass tubes. Ceramide fractions were 
evaporated to dryness under nitrogen gas, re-dissolved in 50 µL chloroform and 100 µL iso-
propanol, and transferred to HPLC vials. 
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For HPLC-HRMS analyses, 1.0 µL sample was injected into an UltiMate 3000 HPLC system 
(Dionex, Sunnyvale, CA, USA) and separated through a Kinetex C8-column (2.1×100 mm, 2.7 µm) 
(Phenomenex) at 60 ºC by elution with a water with 20 mM formic acid (A)-1:4 iso-
propanol:acetonitrile (B) gradient. An eluent flow rate of 0.4 mL/min was applied, and the gradient 
started at 35 % B, increased linearly from 35-70 % B (0.0-1.5 min) and further from 70-100 % B 
(1.5-9.5 min), remained at 100 % B (9.5-11.0 min), decreased linearly from 100-35 % B (11.0-11.1 
min), and finally remained at 35 % B (11.1-13.0 min). Following, the effluent was introduced into a 
maXis HD quadrupole TOF-MS (Bruker, Bremen, Germany) equipped with an ESI ion source 
operated in positive ion mode with the collision energy alternating between 0 and 25 eV every 500 
ms (BBCid fragmentation), thereby generating the [M+H]+-ion of the ceramides and [M+H–H2O]+-
fragment ion as well as a fragment ion only containing the sphingoid base moiety of the ceramides. 
Using an aggressive dereplication approach 48 and Bruker Target Analysis 1.3 (Bruker), ceramide 
species were then identified from HPLC retention times and accurate masses of the [M+H]+-ion 
(quantifier ion), [M+H–H2O]+-fragment ion (qualifier ion 1), and sphingoid base moiety fragment 
ion (qualifier ion 2) (for all ions with a m/z tolerance of ±10 ppm). This enables the distinction 
between different position isomers (e.g. d18:0-24:1 and d18:1-24:0). 
A total of 90 ceramide species were searched, including ceramides with a d18:0, d18:1, or d18:2 
sphingoid base in all possible combinations with a 14:0-26:0, 14:1-26:1, 14:2-26:2, 24:3-26:3, or 
26:4 acyl group, listed in Supplementary Table S2 online together with m/z-values of their 
respective [M+H]+-ions, [M+H–H2O]+-fragment ions, and sphingoid base moiety fragment ions. 
Among these, 57 ceramide species were identified in the total set of plasma samples. Some species 
were, however, only detected in a few samples and therefore not included in Table 2. Furthermore, 
the peak areas of several position isomers (e.g. d18:0-16:1 and d18:1-16:0) were combined in the 
HPLC chromatograms due to similar retention times of these isomers. These were therefore pooled. 
Also, a few ceramide species with identical molecular formulas (e.g. d18:0-24:1) were identified at 
two different retention times, presumably corresponding to different structural isomers of the 
unsaturated acyl group. These isomers are denoted a and b, respectively. Taken together, 27 
ceramide species (individual or pools) were selected for quantifications and included in Table 2.  
For quantifications, external standard samples, comprising a dilution row of d18:1-14:0, d18:1-24:0, 
d18:1-18:1, d18:1-24:1, and d18:1-16:0-2H31 standard (Avanti Polar Lipids, Alabaster, AL, USA) 
solutions (1:2 chloroform:iso-propanol), were analysed by HPLC-HRMS parallel to the plasma 
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samples to determine the area-mass relationships of these species. For all standards, this was linear 
within the relevant concentration ranges. Ceramide peak areas in the plasma samples were adjusted 
for the recovery of the d18:1-16:0-2H31 internal standard (79.0±3.6 %) and following converted to 
masses from the response of their respective external standard or an estimated response. 
Calculations of estimated responses were based on the assumption of an equal change in response 
per carbon atom and per double bond in the acyl group. These changes were determined from the 
responses of d18:1-14:0 compared with d18:1-24:0 and d18:1-24:0 compared with d18:1-24:1, 
respectively. d18:0-, d18:1-, and d18:2- species with identical acyl groups were assigned the same 
response. Also, ceramides that were pooled were assigned the response of the d18:1- position 
isomer that was expected to be the dominant isomer. Total d18:0-, or dihydroceramide, levels were 
calculated as the sum of the d18:0-16:0, d18:0-23:0, d18:0-22:1, d18:0-24:1a, d18:0-24:1b, and 
d18:0-25:1a levels, and total ceramide levels were calculated as the sum of the levels of the 27 
ceramide species (individual or pools) included in Table 2. 
Ceramide analyses were performed at the Metabolomics Platform, Department of Biotechnology 
and Biomedicine, Technical University of Denmark, Kongens Lyngby, Denmark. 
 
Ethical approval 
All study procedures were in accordance with the principles of The Declaration of Helsinki and 
approved by The Regional Research Ethics Committee of Copenhagen, Denmark. Furthermore, all 
participants were provided with written information on the study purpose and procedures and 
signed an informed consent prior to their participation. 
 
Statistical analyses 
Ceramide levels and their relation to other lipid levels and physiological measures 
Ceramide data presented in Table 2, including plasma levels of individual species within each 
combination of birth weight group and diet intervention and differences in these levels between the 
two diets (response values) within each birth weight group, were evaluated for normality by 
Shapiro-Wilk tests with a significance level of 0.05. Plasma levels of individual ceramide species 
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within each diet and response values were furthermore evaluated for equality of variances between 
the birth weight groups by F-tests with a significance level of 0.05 as well. Statistically significant 
differences in plasma ceramide levels between NBW and LBW men within each diet and in 
response values between the birth weight groups were subsequently assessed by Student’s two-
tailed, unpaired t-tests (for normally distributed values) or Wilcoxon ranked-sum tests (for non-
normally distributed values). Furthermore, significant differences in plasma ceramide levels 
between the control and high-fat, high-calorie diets within each birth weight group were assessed by 
Student’s two-tailed, paired t-tests (for normally distributed values) or Wilcoxon signed-rank tests 
(for non-normally distributed values). P-values from Student’s t-tests and Wilcoxon tests were 
evaluated in context with false discovery rates (Q-values) to account for multiple testing within 
each diet or birth weight group. Q-values were calculated by the Benjamini and Hochberg method. 
P-values ≤0.05 with Q-values ≤0.05 were considered statistically significant. Data in Table 2 are 
presented as mean values with 95 % confidence intervals together with the number of observations 
within each group. Moreover, P- and Q-values are indicated. Student’s t-tests and Wilcoxon tests 
were not performed, if more than 25 % of the values within one of the two groups to be compared 
were missing. Total d18:0- levels were calculated as the sum of the d18:0-16:0, d18:0-23:0, d18:0-
22:1, d18:0-24:1a, d18:0-24:1b, and d18:0-25:1a levels, and total ceramide levels were calculated as 
the sum of the levels of all 27 ceramides (individual or pools) included in Table 2. 
Associations between plasma ceramide levels and other lipid levels or physiological measures 
within each diet and furthermore between response values, as presented in Figure 1 and 
Supplementary Table S4 online, were assessed from linear regression analyses. These analyses were 
performed on the pooled data set of LBW and NBW men and were adjusted for age, BMI, and birth 
weight group. P-values ≤0.05 were considered statistically significant. Data in Figure 1 and 
Supplementary Table S4 online are presented as Spearman correlation coefficients (r-values) and P-
values.  
 
Data availability 
Plasma ceramide data generated in the present study are available from the corresponding author on 
reasonable request.  
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FIGURE AND TABLE LEGENDS 
Figure 1: Heat-map of associations between plasma ceramide levels and physiological 
measures following the control (C) and high-fat, high-calorie (O) diets and between response 
values (D). Data are presented as r-values (red or blue colour variations for positive or negative 
values, respectively) and P-values (+/–: P≤0.05, + +/– –: P≤0.01, + + +/– – –: P≤0.001, (+)/(–): 
P≤0.1 for positive or negative associations, respectively). r-values are in the range -0.4 to 0.4. P-
values are presented unadjusted for multiple comparisons, and P-values ≤0.05 are considered 
statistically significant. Regression analyses were performed on the pooled data set of LBW and 
NBW men and were adjusted for age, BMI, and birth weight group. B or I indicated in parentheses 
after clamp measures specify basal or insulin-stimulated state, respectively. Other abbreviations: 
See Table 1. 
Table 1: Clinical characteristics of low (LBW) and normal birth weight (NBW) men following 
the control (C) and high-fat, high-calorie (O) diets. Data are presented as mean values ± standard 
deviations (SD). P-values are presented unadjusted for multiple comparisons, and P-values ≤0.05 
are considered statistically significant. PNBW and PLBW: O vs. C diet within each birth weight group, 
PC and PO: LBW vs. NBW men within each diet, PΔ: LBW vs. NBW men on response values. P-
values ≤0.05 are marked in bold. n.s.: Not significant. Other abbreviations: B: Blood, CHOL: 
Cholesterol, DI: Disposition index, FFM: Fat free mass, FOX: Fatty acid oxidation, FPIR: First 
phase insulin response, GOX: Glucose oxidation, HGP: Hepatic glucose production, IR: Insulin 
resistance, P: Plasma, S: Serum, TG: Triacylglycerol. 
Table 2: Plasma ceramide levels in low (LBW) and normal birth weight (NBW) men following 
the control (C) and high-fat, high-calorie (O) diets. Data are presented as mean values with 95 % 
confidence intervals (CI). P-values ≤0.05 are presented together with Q-values, and P-values ≤0.05 
with corresponding Q-values ≤0.05 are considered statistically significant. P-values were not 
calculated, if more than 25 % of the values within one of the two groups to be compared were 
missing. PNBW and PLBW: O vs. C diet within each birth weight group, PC and PO: LBW vs. NBW 
men within each diet, PΔ: LBW vs. NBW men on response values. P-values ≤0.05 and Q-values 
≤0.05 are marked in bold. Total d18:0- levels: d18:0-16:0, d18:0-23:0, d18:0-22:1, d18:0-24:1a, 
d18:0-24:1b, and d18:0-25:1a, Total ceramide levels: All 27 ceramide species (individual or pools). 
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Figure 1: 
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Table 1: 
 NBW  
(n = 25) 
LBW  
(n = 18) 
LBW vs. NBW 
(n = 18, n = 25) 
 C 
(Mean ± SD) 
O 
(Mean ± SD) 
PNBW C 
(Mean ± SD) 
O 
(Mean ± SD) 
PLBW PC PO PΔ 
Anthropometry          
Birth weight (g) 3901 ± 207 - - 2717 ± 268 - - ≤0.001 - - 
Weight (kg) 78.4 ± 9.3 78.6 ± 9.7 n.s. 77.1 ± 11.3 77.1 ± 11.4 n.s. n.s. n.s. n.s. 
Height (m) 1.83 ± 0.07 - - 1.77 ± 0.05 - - ≤0.05 - - 
BMI (kg/m2) 23.3 ± 2.4 23.3 ± 2.5 n.s. 24.6 ± 3.8 24.6 ± 3.8 n.s. n.s. n.s. n.s. 
Lipid profiling          
P-VLDL-CHOL 
(mM) 
0.42 ± 0.16 0.33 ± 0.16 ≤0.05 0.49 ± 0.18 0.32 ± 0.12 ≤0.01 n.s. n.s. n.s. 
P-LDL-CHOL 
(mM) 
2.51 ± 0.72 2.28 ± 0.78 ≤0.05 2.69 ± 0.76 2.57 ± 0.80 n.s. n.s. n.s. n.s. 
P-HDL-CHOL 
(mM) 
1.40 ± 0.22 1.56 ± 0.25 ≤0.01 1.19 ± 0.23 1.38 ± 0.28 ≤0.01 ≤0.01 ≤0.05 n.s. 
P-CHOL (mM) 4.36 ± 0.83 4.18 ± 0.82 n.s. 4.36 ± 0.78 4.27 ± 0.79 n.s. n.s. n.s. n.s. 
P-TG (mM) 0.92 ± 0.35 0.73 ± 0.35 ≤0.05 1.07 ± 0.37 0.72 ± 0.24 ≤0.01 n.s. n.s. n.s. 
Clamp          
Basal          
B-Glucose (mM) 4.59 ± 0.47 5.05 ± 0.40 ≤0.001 4.97 ± 0.48 5.18 ± 0.34 ≤0.05 ≤0.01 n.s. n.s. 
S-Insulin (pM) 30.2 ± 14.7 43.4 ± 29.2 ≤0.05 41.7 ± 14.6 44.7 ± 21.9 n.s. ≤0.01 n.s. n.s. 
P-NEFA (µM) 334 ± 136 205 ± 82 ≤0.001 406 ± 200 188 ± 91 ≤0.001 n.s. n.s. n.s. 
HGP 
(mg/kg·FFM/min) 
2.21 ± 0.48 2.85 ± 0.99 ≤0.01 2.40 ± 0.5 2.48 ± 0.5 n.s. n.s. n.s. ≤0.05 
Hepatic IR  
(mg/kg·FFM/min 
·pM) 
68.7 ± 34.1 113.7 ± 61.5 ≤0.001 102.3 ± 50.8 108.7 ± 55.5 n.s. ≤0.05 n.s. ≤0.05 
GOX 
(mg/kg·FFM/min) 
2.34 ± 0.76 2.43 ± 0.71 n.s. 1.95 ± 0.78 2.20 ± 0.56 n.s. n.s. n.s. n.s. 
FOX 
(mg/kg·FFM/min) 
1.00 ± 0.38 1.02 ± 0.33 n.s. 1.11 ± 0.53 1.17 ± 0.33 n.s. n.s. n.s. n.s. 
Insulin-stimulated          
P-NEFA (µM) 9.29 ± 4.39 12.42 ± 6.43 ≤0.01 9.56 ± 5.03 14.39 ± 7.76 ≤0.01 n.s. n.s. n.s. 
M-value 
(mg/kg·FFM/min) 
13.73 ± 2.32 13.29 ± 3.32 n.s. 13.47 ± 3.14 11.89 ± 3.57 ≤0.05 n.s. n.s. n.s. 
GOX 
(mg/kg·FFM/min) 
5.18 ± 0.82 5.04 ± 0.98 n.s. 4.95 ± 0.92 4.78 ± 0.82 n.s. n.s. n.s. n.s. 
FOX  
(mg/kg·FFM/min) 
0.01 ± 0.25 0.17 ± 0.33 n.s. 0.13 ± 0.46 0.37 ± 0.35 ≤0.05 n.s. ≤0.05 n.s. 
IVGTT          
FPIR (pM) 1894 ± 1431 2604 ± 1793 ≤0.001 2135 ± 1034 2750 ± 1509 ≤0.01 n.s. n.s. n.s. 
Hepatic DI 0.38 ± 0.63 0.25 ± 0.21 n.s. 0.21 ± 0.11 0.24 ± 0.13 n.s. n.s. n.s. n.s. 
Peripheral DI 0.29 ± 0.19 0.35 ± 0.20 ≤0.05 0.33 ± 0.13 0.32 ± 0.17 n.s. n.s. n.s. n.s. 
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Table 2:  
 NBW 
(n = 25) 
LBW 
(n = 18) 
LBW vs. NBW 
(n = 18, n = 25) 
 
(µM) 
C 
 (Mean, CI) 
O 
(Mean, CI) 
PNBW 
QNBW 
C 
 (Mean, CI) 
O 
(Mean, CI) 
PLBW 
QLBW 
PC 
QC 
PO 
QO 
PΔ 
QΔ 
Lipid profiling          
Ceramides          
d18:0-16:0 
 
 
0.39 
(0.25, 0.54) 
(n = 2) 
0.39 
(0.38, 0.41) 
(n = 8) 
- 
 
(n = 1) 
- 
- 
(n = 0) 
0.39 
(0.38, 0.39) 
(n = 9) 
- 
 
(n = 0) 
- 
 
 
- 
 
 
- 
 
 
d18:0-23:0 
 
 
0.31 
(0.29, 0.33) 
(n = 5) 
0.30 
(0.11, 0.50) 
(n = 2) 
- 
 
(n = 0) 
0.30 
(0.24, 0.36) 
(n = 3) 
0.34 
(0.24, 0.45) 
(n = 3) 
- 
 
(n = 0) 
- 
 
 
- 
 
 
- 
 
 
d18:1-14:0 
 
 
0.42 
(0.42, 0.42) 
(n = 3) 
0.41 
(0.40, 0.42) 
(n = 6) 
- 
 
(n = 1) 
0.42 
(0.37, 0.48) 
(n = 3) 
0.41 
(0.40, 0.42) 
(n = 7) 
- 
 
(n = 3) 
- 
 
 
- 
 
 
- 
 
 
d18:0-16:1/ 
d18:1-16:0 
 
0.68 
(0.65, 0.72) 
(n = 25) 
0.64 
(0.60, 0.67) 
(n = 25) 
0.0093 
0.0349 
(n = 25) 
0.68 
(0.64, 0.72) 
(n = 18) 
0.64 
(0.61, 0.68) 
(n = 18) 
0.0553 
 
(n = 18) 
0.9317 
 
 
0.7598 
 
 
0.7528 
 
 
d18:0-18:1/ 
d18:1-18:0 
 
0.54 
(0.51, 0.58) 
(n = 25) 
0.47 
(0.45, 0.50) 
(n = 23) 
<0.0001 
0.0005 
(n = 23) 
0.55 
(0.52, 0.59) 
(n = 18) 
0.49 
(0.46, 0.52) 
(n = 18) 
0.0004 
0.0030 
(n = 18) 
0.4717 
 
 
0.4904 
 
 
0.6504 
 
 
d18:0-20:1/ 
d18:1-20:0 
 
0.56 
(0.52, 0.60) 
(n = 25) 
0.53 
(0.49, 0.57) 
(n = 25) 
0.0511 
 
(n = 25) 
0.56 
(0.51, 0.60) 
(n = 18) 
0.55 
(0.50, 0.59) 
(n = 18) 
0.5866 
 
(n = 18) 
0.3612 
 
 
0.5177 
 
 
0.4032 
 
 
d18:0-21:1/ 
d18:1-21:0 
 
0.39 
(0.37, 0.41) 
(n = 24) 
0.39 
(0.37, 0.41) 
(n = 22) 
0.9066 
 
(n = 21) 
0.40 
(0.37, 0.43) 
(n = 16) 
0.40 
(0.37, 0.42) 
(n = 18) 
0.7817 
 
(n = 16) 
0.4361 
 
 
0.4592 
 
 
0.8432 
 
 
d18:0-22:1 
 
 
- 
- 
(n = 0) 
0.31 
(0.29, 0.32) 
(n = 7) 
- 
 
(n = 0) 
- 
- 
(n = 0) 
0.31 
(0.28, 0.34) 
(n = 3) 
- 
 
(n = 0) 
- 
 
 
- 
 
 
- 
 
 
d18:1-22:0 
 
 
0.93 
(0.86, 1.01) 
(n = 25) 
0.96 
(0.89, 1.04) 
(n = 25) 
0.3741 
 
(n = 25) 
0.93 
(0.85, 1.01) 
(n = 18) 
0.98 
(0.91, 1.06) 
(n = 18) 
0.1514 
 
(n = 18) 
0.8353 
 
 
0.6164 
 
 
0.5904 
 
 
d18:0-23:1/ 
d18:1-23:0 
 
1.03 
(0.93, 1.13) 
(n = 25) 
1.11 
(1.02, 1.20) 
(n = 25) 
0.1032 
 
(n = 25) 
1.05 
(0.94, 1.15) 
(n = 18) 
1.12 
(1.02, 1.23) 
(n = 18) 
0.1684 
 
(n = 18) 
0.7634 
 
 
0.8162 
 
 
0.9146 
 
 
d18:0-24:1a 
 
 
0.34 
(0.32, 0.37) 
(n = 24) 
0.39 
(0.35, 0.42) 
(n = 24) 
0.0147 
0.0368 
(n = 23) 
0.35 
(0.32, 0.38) 
(n = 18) 
0.40 
(0.37, 0.43) 
(n = 18) 
0.0062 
0.0310 
(n = 18) 
0.7144 
 
 
0.4813 
 
 
0.7271 
 
 
d18:0-24:1b 
 
 
0.27 
(0.26, 0.28) 
(n = 7) 
0.27 
(0.22, 0.33) 
(n = 2) 
- 
 
(n = 2) 
0.27 
(0.25, 0.28) 
(n = 6) 
0.26 
(0.14, 0.37) 
(n = 2) 
- 
 
(n = 1) 
- 
 
 
- 
 
 
- 
 
 
d18:1-24:0 
 
 
2.46 
(2.24, 2.69) 
(n = 25) 
2.50 
(2.23, 2.76) 
(n = 25) 
0.7670 
 
(n = 25) 
2.36 
(2.09, 2.63) 
(n = 18) 
2.60 
(2.37, 2.83) 
(n = 18) 
0.1415 
 
(n = 18) 
0.8736 
 
 
0.5577 
 
 
0.5826 
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d18:0-25:1a 
 
 
0.23 
(0.21, 0.25) 
(n = 3) 
0.24 
(0.22, 0.27) 
(n = 7) 
- 
 
(n = 3) 
0.24 
(0.14, 0.34) 
(n = 2) 
0.25 
(0.10, 0.40) 
(n = 2) 
- 
 
(n = 1) 
- 
 
 
- 
 
 
- 
 
 
d18:0-25:1b/ 
d18:1-25:0 
 
0.83 
(0.76, 0.90) 
(n = 23) 
0.84 
(0.75, 0.93) 
(n = 21) 
0.4492 
 
(n = 20) 
0.76 
(0.65, 0.86) 
(n = 17) 
0.81 
(0.72, 0.89) 
(n = 14) 
0.3151 
 
(n = 14) 
0.1708 
 
 
0.4947 
 
 
0.9980 
 
 
d18:0-26:1/ 
d18:1-26:0 
 
0.35 
(0.32, 0.38) 
(n = 25) 
0.35 
(0.32, 0.38) 
(n = 24) 
0.9815 
 
(n = 24) 
0.33 
(0.30, 0.36) 
(n = 18) 
0.35 
(0.32, 0.38) 
(n = 18) 
0.1540 
 
(n = 18) 
0.4142 
 
 
0.8835 
 
 
0.2877 
 
 
d18:0-16:2/ 
d18:1-16:1/ 
d18:2-16:0 
0.40 
(0.39, 0.41) 
(n = 12) 
0.40 
(0.37, 0.44) 
(n = 3) 
- 
 
(n = 3) 
0.40 
(0.39, 0.40) 
(n = 8) 
0.40 
(0.38, 0.42) 
(n = 3) 
- 
 
(n = 2) 
- 
 
 
- 
 
 
- 
 
 
d18:0-18:2/ 
d18:1-18:1/ 
d18:2-18:0 
0.38 
(0.37, 0.40) 
(n = 10) 
0.37 
- 
(n = 1) 
- 
 
(n = 1) 
0.37 
(0.35, 0.39) 
(n = 4) 
0.37 
(0.36, 0.37) 
(n = 3) 
- 
 
(n = 1) 
- 
 
 
- 
 
 
- 
 
 
d18:0-20:2/ 
d18:1-20:1/ 
d18:2-20:0 
0.35 
(0.33, 0.37) 
(n = 6) 
0.35 
(0.33, 0.37) 
(n = 2) 
- 
 
(n = 2) 
0.36 
(0.30, 0.41) 
(n = 2) 
0.34 
- 
(n = 1) 
- 
 
(n = 0) 
- 
 
 
- 
 
 
- 
 
 
d18:1-22:1/ 
d18:2-22:0 
 
0.61 
(0.55, 0.67) 
(n = 25) 
0.55 
(0.49, 0.61) 
(n = 24) 
0.0072 
0.0349 
(n = 24) 
0.60 
(0.53, 0.66) 
(n = 18) 
0.55 
(0.50, 0.60) 
(n = 18) 
0.0850 
 
(n = 18) 
0.7229 
 
 
0.9095 
 
 
0.6341 
 
 
d18:1-23:1/ 
d18:2-23:0 
 
0.43 
(0.39, 0.47) 
(n = 24) 
0.39 
(0.36, 0.42) 
(n = 25) 
0.0129 
0.0368 
(n = 24) 
0.41 
(0.37, 0.44) 
(n = 16) 
0.40 
(0.37, 0.43) 
(n = 16) 
0.8063 
 
(n = 14) 
0.3331 
 
 
0.3484 
 
 
0.4277 
 
 
d18:1-24:1 
 
 
1.80 
(1.61, 1.98) 
(n = 25) 
1.67 
(1.49, 1.85) 
(n = 25) 
0.1996 
 
(n = 25) 
1.74 
(1.54, 1.95) 
(n = 18) 
1.68 
(1.52, 1.85) 
(n = 18) 
0.4831 
 
(n = 18) 
0.7598 
 
 
0.5826 
 
 
0.6266 
 
 
d18:0-25:2/ 
d18:1-25:1/ 
d18:2-25:0 
0.42 
(0.35, 0.48) 
(n = 25) 
0.46 
(0.41, 0.51) 
(n = 25) 
0.1854 
 
(n = 25) 
0.42 
(0.33, 0.50) 
(n = 16) 
0.44 
(0.38, 0.51) 
(n = 18) 
0.0649 
 
(n = 16) 
0.8421 
 
 
0.6268 
 
 
0.9093 
 
 
d18:0-26:2/ 
d18:1-26:1/ 
d18:2-26:0 
0.25 
(0.23, 0.28) 
(n = 15) 
0.23 
(0.22, 0.24) 
(n = 20) 
- 
 
(n = 12) 
0.23 
(0.21, 0.25) 
(n = 12) 
0.24 
(0.23, 0.26) 
(n = 13) 
- 
 
(n = 10) 
- 
 
 
- 
 
 
- 
 
 
d18:1-24:2/ 
d18:2-24:1 
 
0.87 
(0.77, 0.97) 
(n = 25) 
0.66 
(0.55, 0.76) 
(n = 24) 
0.0003 
0.0023 
(n = 24) 
0.84 
(0.73, 0.95) 
(n = 18) 
0.62 
(0.52, 0.73) 
(n = 18) 
0.0002 
0.0030 
(n = 18) 
0.4659 
 
 
0.8498 
 
 
0.9681 
 
 
d18:0-26:3/ 
d18:1-26:2 
 
0.27 
(0.24, 0.31) 
(n = 20) 
0.31 
(0.17, 0.45) 
(n = 5) 
- 
 
(n = 5) 
0.29 
(0.25, 0.32) 
(n = 13) 
0.37 
(0.32, 0.42) 
(n = 7) 
- 
 
(n = 4) 
- 
 
 
- 
 
 
- 
 
 
d18:0-26:4b/ 
d18:1-26:3/ 
d18:2-26:2 
0.15 
(0.13, 0.17) 
(n = 5) 
0.16 
(0.00, 0.32) 
(n = 2) 
- 
 
(n = 0) 
0.16 
(0.13, 0.19) 
(n = 3) 
0.13 
(0.08, 0.18) 
(n = 3) 
- 
 
(n = 1) 
- 
 
 
- 
 
 
- 
 
 
Total levels          
d18:0- 
 
 
0.53 
(0.39, 0.66) 
(n = 25) 
0.70 
(0.53, 0.87) 
(n = 25) 
0.0778 
 
(n = 25) 
0.52 
(0.41, 0.62) 
(n = 18) 
0.76 
(0.56, 0.97) 
(n = 18) 
0.0197 
 
(n = 18) 
0.9244 
 
 
0.6176 
 
 
0.6015 
 
 
All 13.21 12.39 0.1549 12.71 12.82 0.8709 0.7785 0.4569 0.2853 
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(11.93, 14.49) 
(n = 25) 
(11.22, 13.55) 
(n = 25) 
 
(n = 25) 
(11.30, 14.12) 
(n = 18) 
(11.61, 14.02) 
(n = 18) 
 
(n = 18) 
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Table S1: Protein, carbohydrate, and fat contents of the control (C) and high-fat, high-calorie 
(O) diets.  
 C O O/C 
 
 Total 
(Mean) 
Per 100 g 
(Mean) 
Total 
(Mean) 
Per 100 g 
(Mean) 
Total 
(Ratio) 
Per 100 g 
(Ratio) 
Energy (kJ)       
Total 9664 698 14848 1135 1.54 1.63 
Energy (E%)       
Protein 15 15 8 8 0.53 0.53 
Carbohydrate 49 49 33 33 0.67 0.67 
Fat 35 35 60 60 1.71 1.71 
Energy (g)       
Protein 88 6.4 67.1 5.1 0.76 0.80 
Carbohydrate 266.7 19.2 277.6 21.2 1.04 1.10 
Fat 92.1 6.6 239 18.3 2.60 2.77 
Fat (g)       
Saturated fatty 
acids 
35.6 2.6 109.8 8.4 3.08 3.23 
Monounsaturated 
fatty acids 
31.5 2.3 85.4 6.5 2.71 2.83 
Polyunsaturated 
fatty acids 
8.6 0.6 28.5 2.2 3.31 3.67 
n-3 fatty acids 0.9 0.1 5.8 0.4 6.44 4.00 
n-6 fatty acids 7.2 0.5 21.8 1.7 3.03 3.40 
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Table S2: Ceramides searched in the plasma samples and mass to charge ratios (m/z-values) 
of their respective [M+H]+-ions, [M+H–H2O]+-fragment ions, and sphingoid base moiety 
fragment ions. Ceramide position isomers are listed in the same rows according to the total number 
of double bonds in the structures with indication in parentheses of m/z-values of the [M+H]+-ion 
(quantifier ion) and [M+H–H2O]+-fragment ion (qualifier 1 ion). d18:0-, d18:1-, and d18:2- position 
isomers have constant m/z-values of the sphingoid base moiety fragment ion (qualifier 2 ion) of 
266.2842, 264.2686, or 262.2529 Da, respectively, and variable m/z-values of the [M+H]+-ion and 
[M+H–H2O]+-fragment ion dependent on the acyl group in the structures. Ceramides detected in the 
plasma samples are marked in bold.   
 d18:0- species 
 
d18:1- species 
 
d18:2- species 
 
Ceramides 
 
 
(Formula) 
Quantifier ion: [M+H]+ 
Qualifier 1 ion: [M+H–H2O]+ 
Qualifier 2 ion: 266.2842 Da 
(Da) 
Quantifier ion: [M+H]+ 
Qualifier 1 ion: [M+H–H2O]+ 
Qualifier 2 ion: 264.2686 Da 
(Da) 
Quantifier ion: [M+H]+ 
Qualifier 1 ion: [M+H–H2O]+ 
Qualifier 2 ion: 262.2529 Da 
(Da) 
Double bonds    
0    
C32H65NO3 d18:0-14:0 (512.5038, 494.4932) - - 
C33H67NO3 d18:0-15:0 (526.5194, 508.5088) - - 
C34H69NO3 d18:0-16:0 (540.5351, 522.5245) - - 
C35H71NO3 d18:0-17:0 (554.5507, 536.5401) - - 
C36H73NO3 d18:0-18:0 (568.5664, 550.5558) - - 
C37H75NO3 d18:0-19:0 (582.5820, 564.5714) - - 
C38H77NO3 d18:0-20:0 (596.5977, 578.5871) - - 
C39H79NO3 d18:0-21:0 (610.6133, 592.6027) - - 
C40H81NO3 d18:0-22:0 (624.6290, 606.6184) - - 
C41H83NO3 d18:0-23:0 (638.6446, 620.6340) - - 
C42H85NO3 d18:0-24:0 (652.6603, 634.6497) - - 
C43H87NO3 d18:0-25:0 (666.6759, 648.6653) - - 
C44H89NO3 d18:0-26:0 (680.6916, 662.6810) - - 
1    
C32H63NO3 d18:0-14:1 (510.4881, 492.4775) d18:1-14:0 (510.4881, 492.4775) - 
C33H65NO3 d18:0-15:1 (524.5038, 506.4932) d18:1-15:0 (524.5038, 506.4932) - 
C34H67NO3 d18:0-16:1 (538.5194, 520.5088) d18:1-16:0 (538.5194, 520.5088) - 
C35H69NO3 d18:0-17:1 (552.5351, 534.5245) d18:1-17:0 (552.5351, 534.5245) - 
C36H71NO3 d18:0-18:1 (566.5507, 548.5401) d18:1-18:0 (566.5507, 548.5401) - 
C37H73NO3 d18:0-19:1 (580.5664, 562.5558) d18:1-19:0 (580.5664, 562.5558) - 
C38H75NO3 d18:0-20:1 (594.5820, 576.5714) d18:1-20:0 (594.5820, 576.5714) - 
C39H77NO3 d18:0-21:1 (608.5977, 590.5871) d18:1-21:0 (608.5977, 590.5871) - 
C40H79NO3 d18:0-22:1 (622.6133, 604.6027) d18:1-22:0 (622.6133, 604.6027) - 
C41H81NO3 d18:0-23:1 (636.6290, 618.6184) d18:1-23:0 (636.6290, 618.6184) - 
C42H83NO3 d18:0-24:1 (650.6446, 632.6340) d18:1-24:0 (650.6446, 632.6340) - 
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C43H85NO3 d18:0-25:1 (664.6603, 646.6497) d18:1-25:0 (664.6603, 646.6497) - 
C44H87NO3 d18:0-26:1 (678.6759, 660.6653) d18:1-26:0 (678.6759, 660.6653) - 
2    
C32H61NO3 d18:0-14:2 (508.4725, 490.4619) d18:1-14:1 (508.4725, 490.4619) d18:2-14:0 (508.4725, 490.4619) 
C33H63NO3 d18:0-15:2 (522.4881, 504.4775) d18:1-15:1 (522.4881, 504.4775) d18:2-15:0 (522.4881, 504.4775) 
C34H65NO3 d18:0-16:2 (536.5038, 518.4932) d18:1-16:1 (536.5038, 518.4932) d18:2-16:0 (536.5038, 518.4932) 
C35H67NO3 d18:0-17:2 (550.5194, 532.5088) d18:1-17:1 (550.5194, 532.5088) d18:2-17:0 (550.5194, 532.5088) 
C36H69NO3 d18:0-18:2 (564.5351, 546.5245) d18:1-18:1 (564.5351, 546.5245) d18:2-18:0 (564.5351, 546.5245) 
C37H71NO3 d18:0-19:2 (578.5507, 560.5401) d18:1-19:1 (578.5507, 560.5401) d18:2-19:0 (578.5507, 560.5401) 
C38H73NO3 d18:0-20:2 (592.5664, 574.5558) d18:1-20:1 (592.5664, 574.5558) d18:2-20:0 (592.5664, 574.5558) 
C39H75NO3 d18:0-21:2 (606.5820, 588.5714) d18:1-21:1 (606.5820, 588.5714) d18:2-21:0 (606.5820, 588.5714) 
C40H77NO3 d18:0-22:2 (620.5977, 602.5871) d18:1-22:1 (620.5977, 602.5871) d18:2-22:0 (620.5977, 602.5871) 
C41H79NO3 d18:0-23:2 (634.6133, 616.6027) d18:1-23:1 (634.6133, 616.6027) d18:2-23:0 (634.6133, 616.6027) 
C42H81NO3 d18:0-24:2 (648.6290, 630.6184) d18:1-24:1 (648.6290, 630.6184) d18:2-24:0 (648.6290, 630.6184) 
C43H83NO3 d18:0-25:2 (662.6446, 644.6340) d18:1-25:1 (662.6446, 644.6340) d18:2-25:0 (662.6446, 644.6340) 
C44H85NO3 d18:0-26:2 (676.6603, 658.6497) d18:1-26:1 (676.6603, 658.6497) d18:2-26:0 (676.6603, 658.6497) 
3    
C42H79NO3 d18:0-24:3 (646.6133, 628.6027) d18:1-24:2 (646.6133, 628.6027) d18:2-24:1 (646.6133, 628.6027) 
C43H81NO3 d18:0-25:3 (660.6290, 642.6184) d18:1-25:2 (660.6290, 642.6184) d18:2-25:1 (660.6290, 642.6184) 
C44H83NO3 d18:0-26:3 (674.6446, 656.6340) d18:1-26:2 (674.6446, 656.6340) d18:2-26:1 (674.6446, 656.6340) 
4    
C44H81NO3 d18:0-26:4 (672.6290, 654.6184) d18:1-26:3 (672.6290, 654.6184) d18:2-26:2 (672.6290, 654.6184) 
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Table S3: Glucose, fatty acid, and protein oxidation rates and total energy expenditures in low 
(LBW) and normal birth weight (NBW) men during the control (C) and high-fat, high-calorie 
(O) diets. Data are presented as mean values ± standard errors of means (SEM). P-values are 
presented unadjusted for multiple comparisons, and P-values ≤0.05 are considered statistically 
significant. PNBW and PLBW: O vs. C diet within each birth weight group, PC and PO: LBW vs. NBW 
men within each diet, PΔ: LBW vs. NBW men on response values. P-values ≤0.05 are marked in 
bold. Day: 9 am-11 pm, Night: 11 pm-8 am, Sleep: 1 am-6 am, 24 hours: 9 am-9 am. 
Abbreviations: EE: Energy expenditure, FOX: Fatty acid oxidation, GOX: Glucose oxidation, POX: 
Protein oxidation. 
 NBW  
(n = 26) 
LBW  
(C: n = 20, O: n = 18) 
LBW vs. NBW 
(n = 20/n = 18, n = 26) 
 
(kJ/min) 
C 
(Mean ± SEM) 
O 
(Mean ± SEM) 
PNBW C 
(Mean ± SEM) 
O 
(Mean ± SEM) 
PLBW PC PO PΔ 
Calorimetry 24 h          
GOX          
Day 3.85 ± 0.17 3.50 ± 0.08 0.0297 3.69 ± 0.16 3.30 ± 0.14 0.0609 0.52 0.19 0.94 
Night 1.97 ± 0.10 2.07 ± 0.07 0.3126 1.78 ± 0.09 1.84 ± 0.10 0.3391 0.18 0.06 0.97 
Sleep 1.91 ± 0.12 1.89 ± 0.08 0.9131 1.58 ± 0.10 1.77 ± 0.11 0.0836 0.05 0.37 0.21 
24 h 3.10 ± 0.13 2.93 ± 0.07 0.1510 2.92 ± 0.13 2.73 ± 0.09 0.2620 0.34 0.09 0.97 
FOX          
Day 3.34 ± 0.16 4.23 ± 0.14 <0.0001 3.46 ± 0.14 4.52 ± 0.21 <0.0001 0.60 0.23 0.60 
Night 2.34 ± 0.10 2.80 ± 0.10 0.0005 2.60 ± 0.08 3.06 ± 0.12 0.0023 0.07 0.10 0.93 
Sleep 2.14 ± 0.14 2.72 ± 0.12 0.0001 2.50 ± 0.09 2.87 ± 0.13 0.0221 0.05 0.38 0.40 
24 h 2.92 ± 0.12 3.63 ± 0.12 <0.0001 3.11 ± 0.11 3.91 ± 0.14 <0.0001 0.24 0.14 0.76 
POX          
Day 1.13 ± 0.04 0.79 ± 0.03 <0.0001 1.08 ± 0.04 0.74 ± 0.04 <0.0001 0.48 0.32 0.71 
Night 1.13 ± 0.04 0.79 ± 0.03 <0.0001 1.08 ± 0.04 0.74 ± 0.04 <0.0001 0.48 0.32 0.71 
Sleep 1.13 ± 0.04 0.79 ± 0.03 <0.0001 1.08 ± 0.04 0.74 ± 0.04 <0.0001 0.48 0.32 0.71 
24 h 1.13 ± 0.04 0.79 ± 0.03 <0.0001 1.08 ± 0.04 0.74 ± 0.04 <0.0001 0.48 0.32 0.71 
EE          
Day 8.32 ± 0.15 8.52 ± 0.13 0.0142 8.24 ± 0.16 8.56 ± 0.18 0.0021 0.71 0.86 0.39 
Night 5.43 ± 0.09 5.65 ± 0.10 0.0001 5.46 ± 0.11 5.66 ± 0.13 0.0017 0.82 0.97 0.99 
Sleep 5.17 ± 0.09 5.39 ± 0.09 0.0010 5.16 ± 0.11 5.30 ± 0.13 0.0009 0.96 0.93 0.82 
24 h 7.14 ± 0.12 7.36 ± 0.12 0.0005 7.12 ± 0.14 7.38 ± 0.15 0.0008 0.88 0.90 0.55 
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Table S4: Associations between plasma ceramide levels and other lipid levels or physiological 
measures following the control (C) and high-fat, high-calorie (O) diets and between response 
values (Δ). Data are presented as r-values (+/– for positive or negative values, respectively) and P-
values (+/–: P≤0.05, + +/– –: P≤0.01, + + +/– – –: P≤0.001, (+)/(–): P≤0.1 for positive or negative 
associations, respectively). P-values are presented unadjusted for multiple comparisons, and P-
values ≤0.05 are considered statistically significant. Regression analyses were performed on the 
pooled data set of LBW and NBW men and were adjusted for age, BMI, and birth weight group. 
Abbreviations: See Table 1.  
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Lipid profiling                  
P-VLDL-CHOL C + ++  + ++ ++ (+) +  (+)  + ++  +++ ++ 
 O         ++ (+)   ++  +++ + 
 Δ                 
P-LDL-CHOL C +++    ++ + +++      ++ + +++ ++ 
 O  +++ + + +++ +++ + +++ +++ +++ ++ + ++ + ++ +++ 
 Δ  (+)   (+) (+) (+) +  +     (+)  
P-HDL-CHOL C                 
 O              (–)   
 Δ +  (+)  + +  + ++ (+)   ++   + 
P-CHOL C +++    +++ ++ ++      ++ (+) +++ ++ 
 O  +++ ++ ++ +++ +++ + +++ +++ +++ ++ ++ +++ + +++ +++ 
 Δ (+) (+)   + + (+) +  +   +  + (+) 
P-TG C + +++  + ++ ++  (+)  +  + ++  +++ ++ 
 O                                                                                                                                                                                                                                          ++ ++ +++ ++ ++ (+) ++ ++ + +++ + +++ (+) +++ ++ 
 Δ                 
Clamp                  
Basal                  
B-Glucose C + ++   (+)  +   ++   ++  + + 
 O             (+)    
 Δ         +        
S-Insulin C     + (+)    (+)       
 O                 
 Δ (+)                
P-NEFA C  (–)  –        – (–)  (–)  
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 O             +  ++  
 Δ    (+)      (+)       
HGP C  +     +++   +    (+) (+)  
 O                 
 Δ                 
Hepatic IR C   (+)  + (+)  (+)     (+) (+)  + 
 O (+)                
 Δ              (+)   
GOX C  –               
 O     (+)            
 Δ  – (–)            –  
FOX C + + +  + (+)  +  (+)   (+)  + + 
 O  (+)             +  
 Δ (+) (+)           (+)  (+)  
Insulin-stimulated                  
M-value C +                
 O                 
 Δ  (+)      (+)   +  +   + 
IVGTT                  
FPIR C                 
 O              (–)   
 Δ    (–)             
Hepatic DI C       –          
 O   (–)        –   – (–)  
 Δ              (–)   
Peripheral DI C                 
 O  (–)     (–) (–)        (–) 
 Δ                 
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Table S1: Protein, carbohydrate, and fat contents of the control (C) and high-fat, high-calorie (O) diets.  
 C O O/C 
 
 Total 
(Mean) 
Per 100 g 
(Mean) 
Total 
(Mean) 
Per 100 g 
(Mean) 
Total 
(Ratio) 
Per 100 g 
(Ratio) 
Energy (kJ)       
Total 9664 698 14848 1135 1.54 1.63 
Energy (E%)       
Protein 15 15 8 8 0.53 0.53 
Carbohydrate 49 49 33 33 0.67 0.67 
Fat 35 35 60 60 1.71 1.71 
Energy (g)       
Protein 88 6.4 67.1 5.1 0.76 0.80 
Carbohydrate 266.7 19.2 277.6 21.2 1.04 1.10 
Fat 92.1 6.6 239 18.3 2.60 2.77 
Fat (g)       
Saturated fatty 
acids 
35.6 2.6 109.8 8.4 3.08 3.23 
Monounsaturated 
fatty acids 
31.5 2.3 85.4 6.5 2.71 2.83 
Polyunsaturated 
fatty acids 
8.6 0.6 28.5 2.2 3.31 3.67 
n-3 fatty acids 0.9 0.1 5.8 0.4 6.44 4.00 
n-6 fatty acids 7.2 0.5 21.8 1.7 3.03 3.40 
 
Table S2: Acylcarnitine names, molecular formulas, methyl and butyl ester ion mass to charge ratios, and 
internal standards (IS) used for quantifications. 
 Names Formulas Methyl esters 
 
Butyl esters 
 
IS 
   [M+H]+ [M+H]+  
Lipid profiling      
Acylcarnitines      
C2 Ethanoylcarnitine 
(Acetylcarnitine) 
C9H17NO4 218 260 C2-IS 
C2-IS D3-Ethanoylcarnitine C9D3H14NO4 221 263 - 
C3 Propanoylcarnitine 
(Propionylcarnitine) 
C10H19NO4 232 274 C3-IS 
C3-IS D3-Propanoylcarnitine C10D3H16NO4 235 277 - 
C4/ 
Ci4 
Butanoylcarnitine 
(Butyrylcarnitine)/ 
Isobutanoylcarnitine 
(Isobutyrylcarnitine) 
C11H21NO4 246 288 C4-IS 
C4-IS D3-Butanoylcarnitine C11D3H18NO4 249 291 - 
C5:1 Pentenoylcarnitine 
(Tiglylcarnitine) 
C12H21NO4 258 300 C5-IS 
C5's Pentanoylcarnitine 
(Valerylcarnitine)/ 
Isopentanoylcarnitine 
(Isovalerylcarnitine) 
C12H23NO4 260 302 C5-IS 
C4-OH 3-Hydroxybutanoylcarnitine C11H21NO5 262 304 C4-IS 
C5-IS D9-Isopentanoylcarnitine C12D3H20NO4 269 311 - 
C6 Hexanoylcarnitine 
(Caproylcarnitine) 
C13H25NO4 274 316 C8-IS 
C5-OH/ 
C3-DC 
3-Hydroxypentanoylcarnitine/ 
Propanedioylcarnitine 
(Malonylcarnitine) 
C12H23NO5/ 
C10H17NO6 
276/ 
276 
318/ 
360 
C8-IS 
C4-DC/ 
Ci4-DC 
Butanedioylcarnitine 
(Succinylcarnitine)/ 
Isobutanedioylcarnitine 
C11H19NO6 290 374 C4-IS 
C8:1 Octenoylcarnitine C15H27NO4 300 342 C8-IS 
C8 Octanoylcarnitine 
(Capryloylcarnitine) 
C15H29NO4 302 344 C8-IS 
C5-DC Pentanedioylcarnitine 
(Glutarylcarnitine) 
C12H21NO6 304 388 C8-IS 
C8-IS D3-Octanoylcarnitine C15D3H26NO4 305 347 - 
C8:1-OH/ 
C6:1-DC 
3-Hydroxyoctenoylcarnitine/ 
Hexenedioylcarnitine 
C15H27NO5/ 
C13H21NO6 
316/ 
316 
358/ 
400 
C8-IS 
C6-DC Hexanedioylcarnitine 
(Adipoylcarnitine) 
C13H23NO6 318 402 C8-IS 
C10:3 Decatrienoylcarnitine C17H27NO4 324 366 C8-IS 
C10:2 Decadienoylcarnitine C17H29NO4 326 368 C8-IS 
C10:1 Decenoylcarnitine C17H31NO4 328 370 C8-IS 
C10 Decanoylcarnitine 
(Caprylcarnitine) 
C17H33NO4 330 372 C8-IS 
C7-DC Heptanedioylcarnitine 
(Pimeloylcarnitine) 
C14H25NO6 332 416 C8-IS 
C8:1-DC Octenedioylcarnitine C15H25NO6 344 428 C8-IS 
C10-OH/ 
C8-DC 
3-Hydroxydecanoylcarnitine/ 
Octanedioylcarnitine 
(Suberoylcarnitine) 
C17H33NO5/ 
C15H27NO6 
346/ 
346 
388/ 
430 
C8-IS 
C12:1 Dodecenoylcarnitine 
(Lauroleoylcarnitine) 
C19H35NO4 356 398 C8-IS 
C12 Dodecanoylcarnitine 
(Lauroylcarnitine) 
C19H37NO4 358 400 C8-IS 
C12-OH/ 
C10-DC 
3-Hydroxydodecanoylcarnitine/ 
Decanedioylcarnitine 
(Sebacoylcarnitine) 
C19H37NO5/ 
C17H31NO6 
374/ 
374 
416/ 
458 
C16-IS 
C14:2 Tetradecadienoylcarnitine C21H37NO4 382 424 C16-IS 
C14:1 Tetradecenoylcarnitine 
(Myristoleoylcarnitine) 
C21H39NO4 384 426 C16-IS 
C14 Tetradecanoylcarnitine 
(Myristoylcarnitine) 
C21H41NO4 386 428 C16-IS 
C14:1-OH/ 
C12:1-DC 
3-Hydroxytetradecenoylcarnitine/ 
Dodecenedioylcarnitine 
C21H39NO5/ 
C19H33NO6 
400/ 
400 
442/ 
484 
C16-IS 
C14-OH/ 
C12-DC 
3-Hydroxytetradecanoylcarnitine/ 
Dodecanedioylcarnitine 
C21H41NO5/ 
C19H35NO6 
402/ 
402 
444/ 
486 
C16-IS 
C16:2 Hexadecadienoylcarnitine 
(Palmitolinoleoylcarnitine) 
C23H41NO4 410 452 C16-IS 
C16:1 Hexadecenoylcarnitine 
(Palmitoleoylcarnitine) 
C23H43NO4 412 454 C16-IS 
C16 Hexadecanoylcarnitine 
(Palmitoylcarnitine) 
C23H45NO4 414 456 C16-IS 
C16-IS D3-Hexadecanoylcarnitine C23D3H42NO4 417 459 - 
C16:1-OH/ 
C14:1-DC 
3-Hydroxyhexadecenoylcarnitine/ 
Tetradecenedioylcarnitine 
C23H43NO5/ 
C21H37NO6 
428/ 
428 
470/ 
512 
C16-IS 
C16-OH/ 
C14-DC 
3-Hydroxyhexadecanoylcarnitine/ 
Tetradecanedioylcarnitine 
C23H45NO5/ 
C21H39NO6 
430/ 
430 
472/ 
514 
C16-IS 
C18:2 Octadecadienoylcarnitine 
(Linoleoylcarnitine) 
C25H45NO4 438 480 C16-IS 
C18:1 Octadecenoylcarnitine 
(Oleylcarnitine) 
C25H47NO4 440 482 C16-IS 
C18 Octadecanoylcarnitine 
(Stearoylcarnitine) 
C25H49NO4 442 484 C16-IS 
C18:2-OH 3-Hydroxyoctadecadienoylcarnitine C25H45NO5 454 496 C16-IS 
C18:1-OH/ 
C16:1-DC 
3-Hydroxyoctadecenoylcarnitine/ 
Hexadecenedioylcarnitine 
C25H47NO5/ 
C23H41NO6 
456/ 
456 
498/ 
540 
C16-IS 
C18-OH/ 
C16-DC 
3-Hydroxyoctadecanoylcarnitine/ 
Hexadecanedioylcarnitine 
C25H49NO5/ 
C23H43NO6 
458/ 
458 
500/ 
542 
C16-IS 
C20:4 Eicosatetraenoylcarnitine 
(Arachidonoylcarnitine) 
C27H45NO4 462 504 C16-IS 
C20 Eicosanoylcarnitine 
(Arachidoylcarnitine) 
C27H53NO4 470 512 C16-IS 
C20:1-OH/ 
C18:1-DC 
3-Hydroxyeicosenoylcarnitine/ 
Octadecenedioylcarnitine 
C27H51NO5/ 
C25H45NO6 
484/ 
484 
526/ 
568 
C16-IS 
C20-OH/ 
C18-DC 
3-Hydroxyeicosanoylcarnitine/ 
Octadecanedioylcarnitine 
C27H53NO5/ 
C25H47NO6 
486/ 
486 
528/ 
570 
C16-IS 
C22 Docosanoylcarnitine 
(Behenoylcarnitine) 
C29H57NO4 498 540 C16-IS 
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Table S1: Protein, carbohydrate, and fat contents of the control (C) and high-fat, high-calorie (O) diets.  
 C O O/C 
 
 Total 
(Mean) 
Per 100 g 
(Mean) 
Total 
(Mean) 
Per 100 g 
(Mean) 
Total 
(Ratio) 
Per 100 g 
(Ratio) 
Energy (kJ)       
Total 9664 698 14848 1135 1.54 1.63 
Energy (E%)       
Protein 15 15 8 8 0.53 0.53 
Carbohydrate 49 49 33 33 0.67 0.67 
Fat 35 35 60 60 1.71 1.71 
Energy (g)       
Protein 88 6.4 67.1 5.1 0.76 0.80 
Carbohydrate 266.7 19.2 277.6 21.2 1.04 1.10 
Fat 92.1 6.6 239 18.3 2.60 2.77 
Fat (g)       
Saturated fatty 
acids 
35.6 2.6 109.8 8.4 3.08 3.23 
Monounsaturated 
fatty acids 
31.5 2.3 85.4 6.5 2.71 2.83 
Polyunsaturated 
fatty acids 
8.6 0.6 28.5 2.2 3.31 3.67 
n-3 fatty acids 0.9 0.1 5.8 0.4 6.44 4.00 
n-6 fatty acids 7.2 0.5 21.8 1.7 3.03 3.40 
Table S2: Glucose, fatty acid, and protein oxidation rates and total energy expenditures in low (LBW) and 
normal birth weight (NBW) men during the control (C) and high-fat, high-calorie (O) diets. Data are presented as 
mean ± SEM. P-values from Student’s t-tests are presented unadjusted for multiple comparisons, and P-values ≤ 0.05 
are considered statistically significant. PNBW and PLBW: O versus C diet within each birth weight group, PC and PO: 
LBW versus NBW individuals within each diet, PΔ: LBW versus NBW individuals on response values. P-values ≤ 0.05 
are marked in bold. Details on the measurements have been described in previous articles (10; 11). Abbreviations: EE, 
Energy expenditure; FOX, Fatty acid oxidation; GOX, Glucose oxidation; POX, Protein oxidation. 
 NBW  
(n = 26) 
LBW  
(C: n = 20, O: n = 18) 
LBW versus NBW 
(n = 20/n = 18, n = 26) 
 
(kJ/min) 
C 
(Mean ± SEM) 
O 
(Mean ± SEM) 
PNBW C 
(Mean ± SEM) 
O 
(Mean ± SEM) 
PLBW PC PO PΔ 
Calorimetry 24 h          
GOX          
Day 3.85 ± 0.17 3.50 ± 0.08 0.0297 3.69 ± 0.16 3.30 ± 0.14 0.0609 0.52 0.19 0.94 
Night 1.97 ± 0.10 2.07 ± 0.07 0.3126 1.78 ± 0.09 1.84 ± 0.10 0.3391 0.18 0.06 0.97 
Sleep 1.91 ± 0.12 1.89 ± 0.08 0.9131 1.58 ± 0.10 1.77 ± 0.11 0.0836 0.05 0.37 0.21 
24 h 3.10 ± 0.13 2.93 ± 0.07 0.1510 2.92 ± 0.13 2.73 ± 0.09 0.2620 0.34 0.09 0.97 
FOX          
Day 3.34 ± 0.16 4.23 ± 0.14 <0.0001 3.46 ± 0.14 4.52 ± 0.21 <0.0001 0.60 0.23 0.60 
Night 2.34 ± 0.10 2.80 ± 0.10 0.0005 2.60 ± 0.08 3.06 ± 0.12 0.0023 0.07 0.10 0.93 
Sleep 2.14 ± 0.14 2.72 ± 0.12 0.0001 2.50 ± 0.09 2.87 ± 0.13 0.0221 0.05 0.38 0.40 
24 h 2.92 ± 0.12 3.63 ± 0.12 <0.0001 3.11 ± 0.11 3.91 ± 0.14 <0.0001 0.24 0.14 0.76 
POX          
Day 1.13 ± 0.04 0.79 ± 0.03 <0.0001 1.08 ± 0.04 0.74 ± 0.04 <0.0001 0.48 0.32 0.71 
Night 1.13 ± 0.04 0.79 ± 0.03 <0.0001 1.08 ± 0.04 0.74 ± 0.04 <0.0001 0.48 0.32 0.71 
Sleep 1.13 ± 0.04 0.79 ± 0.03 <0.0001 1.08 ± 0.04 0.74 ± 0.04 <0.0001 0.48 0.32 0.71 
24 h 1.13 ± 0.04 0.79 ± 0.03 <0.0001 1.08 ± 0.04 0.74 ± 0.04 <0.0001 0.48 0.32 0.71 
EE          
Day 8.32 ± 0.15 8.52 ± 0.13 0.0142 8.24 ± 0.16 8.56 ± 0.18 0.0021 0.71 0.86 0.39 
Night 5.43 ± 0.09 5.65 ± 0.10 0.0001 5.46 ± 0.11 5.66 ± 0.13 0.0017 0.82 0.97 0.99 
Sleep 5.17 ± 0.09 5.39 ± 0.09 0.0010 5.16 ± 0.11 5.30 ± 0.13 0.0009 0.96 0.93 0.82 
24 h 7.14 ± 0.12 7.36 ± 0.12 0.0005 7.12 ± 0.14 7.38 ± 0.15 0.0008 0.88 0.90 0.55 
 
 
